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ABSTRACT 
Hepatocellular carcinoma (HCC) is the second leading cause of death from cancer 
globally and increasing in prevalence. HCC usually occurs in the context of chronic liver 
damage. The specific genetic alterations promoting HCC have been difficult to identify due 
to the genetic heterogeneity of HCC and the prevalence of large chromosome aberrations. 
To study the pathogenesis of HCC, we used Sleeping Beauty (SB) transposons for both 
a forward genetic screen and reverse genetic studies of genes identified in HCC mouse 
models, altered in human HCC, or components of the Hepatitis B virus, a major HCC risk 
factor. Hepatic steatosis is a common chronic liver disease linked to HCC development. 
We used conditional SB transposon insertional mutagenesis in mice with diet and ethanol 
induced hepatic steatosis to model steatosis-associated HCC and perform a forward 
genetic screen for molecular drivers. We compared the results from this screen to human 
HCC data from multiple sources. We found an increase in HCC in females in both mice 
and humans with hepatic steatosis, reducing the typical male sex bias of HCC. We 
identified over 200 genes candidate steatosis-associated HCC genes in mice, many of 
which are altered in human steatosis and alcohol associated HCC. We identified an 
association between protein kinase A/cyclic AMP signaling pathway alterations and 
steatosis-associated HCC, and NAT10 overexpression and HCC, both of which could 
potentially be targeted therapeutically. We used SB transposon-based gene delivery for 
reverse genetic studies testing candidate oncogenes identified in human HCC, 
complementary mouse models including the steatosis-associated HCC screen, and 
Hepatitis B viral genes for their roles in promoting liver tumorigenesis. These studies 
revealed new oncogenic roles for genes tested in normal livers, in mice of both sexes, in 
steatotic livers, and in fibrotic livers. We generated several new mouse models of HCC 
that could be used for mechanistic studies or therapeutic testing. 
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CHAPTER 1: INTRODUCTION 
 
 
 
Sleeping Beauty transposon-driven models of hepatocellular carcinoma  
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Tschida BR, Largaespada DA, Keng VW. Mouse models of cancer: Sleeping Beauty transposons for 
insertional mutagenesis screens and reverse genetic studies. 
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I. Hepatocellular carcinoma 
1. Hepatocellular carcinoma pathophysiology  
Hepatocellular carcinoma (HCC), the major type of primary malignant liver cancer, is 
composed of cells resembling hepatocytes with abnormal appearance and organization.1 
Studies examining restriction fragment length polymorphisms2 or Hepatitis B virus (HBV) 
genome integration sites3–5 in tumor cells suggest most HCCs are monoclonal. The cell of 
origin can be either a mature hepatocyte or hepatic progenitor cell that accumulates 
genetic mutations leading to dysregulation of proliferation and survival.1 Both hepatocytes 
and hepatic progenitor cells are proliferative cells capable of acquiring these mutations 
and are susceptible to transformation. Although hepatocytes are highly differentiated, they 
can regenerate liver tissue by self-replication in response to most forms of liver damage 
and can give rise to HCC in some instances.1 Hepatic progenitor cells, or oval cells, are 
activated and proliferate in response to extensive liver damage or when liver regeneration 
by hepatocytes is compromised. These give rise to more oval cells, the number of which 
increases with increasing severity of liver injury,6 and to intermediate hepatocytes which 
proliferate and differentiate into hepatocytes.7 Oval cells are believed to be the cell of origin 
for most cases of HCC.1 Hepatic carcinogenesis is a multistep process, most often 
occurring in the setting of chronic liver damage and regeneration.8 Acquisition of mutations 
in proliferating oval cells or hepatocytes gives rise to dysplastic focal lesions which 
develop into HCC after multiple rounds of damage, mutation, and clonal expansion.9 
HCC tumors commonly contain a mixture of cells resembling hepatocytes and oval cells, 
with some organization into plate-like structures around sinusoids.1 The development of 
multiple tumor nodules is common in HCC.10 HCCs are classified as either early HCCs 
which are small, vaguely nodular tumors with poorly defined margins, or progressed 
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HCCs, which vary in size and are moderately differentiated, distinctly nodular, infiltrative, 
and characterized by neovascularization.10 The 4-scale HCC grading system described 
by Edmondson and Steiner in 195411 remains the most commonly used HCC grading 
system.10 This system defines Grade I HCCs as tumors consisting of small cells with 
abundant cytoplasm and a minimal amount of nuclear irregularity that resemble normal 
liver tissue. Grade II HCC tumors have nuclear irregularity and excessive nuclear staining. 
Grade III HCC tumor cells are variable in size and shape and have irregular nuclei of 
variable sizes and shapes. Grade IV HCCs have cells that are highly variable in size and 
shape and often contain giant anaplastic cells.11 HCC tumors are highly heterogeneous; 
one tumor often contains regions that resemble multiple tumor grades.12 
2. Major risk factors for hepatocellular carcinoma 
A. Overview 
HCC is the second leading cause of death from cancer in the world, with a staggering 
mortality to incidence ratio of 0.95.13 Unlike most cancers, it is increasing in prevalence in 
the United States.14–16 The risk for HCC development in men is 2-4 times higher than in 
women, with limited molecular data explaining this sex bias.8,17 HCC almost always 
develops in the context of chronic liver damage and cirrhosis, major causes of which 
include Hepatitis B Virus (HBV) infection, Hepatitis C Virus (HCV) infection, alcoholic liver 
disease, and hepatic steatosis.8 Chronic liver damage leads to excess extracellular matrix 
accumulation, scarring the liver parenchyma and leading to increasing severity of fibrosis. 
With ongoing injury, fibrosis can eventually progress to cirrhosis, which is characterized 
by distortion of the liver parenchyma and vascular structure and by nodules of 
regenerating hepatocytes surrounded by scar tissue.18,19 
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B. Hepatitis B Viral infection 
Viral infection with HBV or HCV accounts for approximately 85% of the world total liver 
cancer cases, 42.5% of the cases in developed countries and 92% of the cases in 
developing countries, with only a small proportion of cases resulting from joint infections.20 
Over half of HCC cases globally are attributable to HBV infection.20 HBV is a partially 
double-stranded DNA virus in the Hepadnaviridae family.21 HBV promotes HCC through 
various indirect and direct mechanisms that are not fully understood. HBV infection causes 
chronic liver inflammation and hepatocyte injury, leading to hepatocyte proliferation. This 
increases the chances for the accumulation of transforming mutations and the 
development of fibrosis and cirrhosis.22 Hepatic cirrhosis often accompanies HBV-
associated HCC development, but HBV can also cause HCC in the absence of cirrhosis.23 
The HBV genome can integrate into the host genome, leading to insertion mutations and 
altered gene expression, such as activation of TERT expression.24,25 The HBV regulatory 
protein, HBx, required for the transcription of the viral genome, can transactivate host 
genes controlling proliferation, survival, and DNA repair,26 altering expression of genes 
that can lead to hepatocarcinogenesis. 
C. Hepatitis C Viral infection 
Approximately one-third of HCC cases worldwide are attributable to HCV infection.20 HCV 
is an RNA virus in the Flaviviridae family that can induce HCC through indirect 
mechanisms.27 HCV infection causes chronic inflammation and hepatocyte injury, leading 
to hepatocyte and proliferation, fibrosis, and cirrhosis.22 The HCV core protein localizes to 
the host cell mitochondrial membrane and endoplasmic reticulum, where it promotes 
oxidative stress.27 The immune response to HCV infection induces insulin resistance, 
increased levels of inflammatory cytokines, and fibrosis.28,29 The relationship between 
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HCV infection, immune response, insulin resistance, inflammation, and HCC has not been 
fully characterized.27 
D. Alcoholic liver disease 
Chronic heavy alcohol intake is one of the most common causes of cirrhosis and an 
established risk factor for HCC development.30,31 Heavy alcohol intake also enhances 
hepatocarcinogenesis due to HBV, HCV, or non-alcoholic fatty liver disease.31 Alcohol can 
promote HCC through DNA damage due to acetaldehyde, oxidative stress, and chronic 
inflammation due to alcoholic steatohepatitis.31 Acetaldehyde is a major metabolite 
produced during ethanol oxidation. It can interfere with DNA synthesis and repair, leading 
to mutations and tumor formation.32 Chronic alcohol consumption increases levels of 
Cytochrome P-4502E1, which creates oxidative stress as it metabolizes ethanol to 
acetaldehyde.31,33 Ethanol is a substantial source of calories (7.1 kcal per gram). It 
comprises, on average, half of an alcoholic’s caloric intake, displacing normal nutrients 
and leading to nutritional deficiencies which can cause liver damage.33 Even in the 
presence of adequate dietary nutrition, ethanol metabolism can induce fatty liver.34 
Ethanol oxidation through the alcohol dehydrogenase pathway produces NADH, 
stimulating fatty acid synthesis.33  Chronic heavy alcohol intake induces fatty liver disease 
in almost all cases, itself risk factor for HCC (reviewed below).31,33,35 Alcoholic fatty liver 
progresses to alcoholic steatohepatitis in approximately 30% of cases and to hepatic 
cirrhosis  in 10-20% of cases.35  
E. Hepatic steatosis 
A strong risk factor for HCC development, hepatic steatosis, or fatty liver disease, is the 
most common chronic liver disease in the United States and becoming increasingly 
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common in the United States and worldwide.36–39  Hepatic steatosis can be induced by 
chronic heavy alcohol intake or due to metabolic syndrome in the absence of chronic 
alcohol use.31,33,35 Metabolic syndrome is characterized by obesity, diabetes, insulin 
resistance, dyslipidemia, and non-alcoholic fatty liver disease.40 Obesity is the biggest risk 
factor for non-alcoholic hepatic steatosis.39 With the rise of obesity, fatty liver disease has 
become the most common chronic liver disease in Western countries,39 partially 
accounting for the increase in HCC. Obese individuals are at a 2-4 fold relative risk for 
HCC and a 5-6 fold relative risk for HCC-related mortality.41  
Fatty liver disease due to alcohol and non-alcoholic steatosis appear similar 
histologically,42 and can develop inflammation, hepatocyte injury, and fibrosis.27 Hepatic 
steatosis progresses to steatohepatitis in approximately 30% of cases, and approximately 
30% of those progress to cirrhosis.40 Cirrhotic livers can have varying degrees of steatosis 
ranging from focal steatosis in regenerative nodules to more substantial steatosis.19 High 
intrahepatic levels of fatty acids creates oxidative stress that can induce DNA damage and 
inflammatory cytokines. This can lead to hepatocyte and oval cell proliferation and 
accumulation of mutations, leading to tumor formation.27 Alcohol consumption further 
increases the risk of HCC development steatotic livers and was found to be among the 
most signiﬁcant factors associated with progression of fatty liver disease to HCC.37 
3. Molecular drivers of hepatocellular carcinoma 
A. Known drivers of hepatocellular carcinoma 
Cancer arises from a series of molecular changes inheritable by progeny cells that confer 
selective advantages by corrupting normal cellular processes including proliferation, 
survival, migration, replicative immortality, angiogenesis, and metabolism.43,44 A small 
number of alterations driving HCC have been identified. These include inactivation of 
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TP53 which confers a survival advantage,43,45,46 Wnt/β-catenin signaling activation through 
CTNNB1 activating mutations and AXIN1 inactivating mutations conferring a proliferation 
and survival advantage,45–47 TERT amplification and promoter mutations which confer 
replicative immortality,43,46 and EGFR amplification and activating mutations conferring a 
proliferative advantage.43,46,48 Pro-angiogenic receptor tyrosine kinases VEGFR2 and 
PDGFRβ are commonly overexpressed in HCC,49,50 and downstream regulators of 
receptor tyrosine kinase signaling like PTEN and RSK2 often have inactivating 
mutations.51,52 Five major molecular subtypes of HCC have been defined by gene 
expression analysis, characterized by Wnt/β-catenin signaling, high proliferation, 
interferon signaling, polysomy of chromosome 7, and an unannotated class. The Wnt/β-
catenin signaling subtype is often driven by CTNNB1 mutations.53 The driving events for 
the other subtypes are not fully understood. The highly proliferative subtype is likely driven 
by receptor tyrosine kinase activation, and the polysomy of chromosome 7 subtype is likely 
driven by overexpression of EGFR along with an unidentified set of other oncogenes on 
chromosome 7.53,54 
B. Molecularly targeted therapies 
Therapeutic options currently available for HCC are insufficient. Only 30-40% of HCC 
cases in Western countries are diagnosed at early stages and suitable for the potentially 
curative locoregional therapies of local ablation, surgical resection, chemoembolization, 
radioembolization, and liver transplantation.55–57 For later stage HCC patients not eligible 
for locoregional therapies, only two systemic treatments have been shown to provide 
improvement in HCC survival, targeted multikinase inhibitors sorafenib and 
regorafenib.56,57 Sorafenib is the only approved molecularly targeted HCC therapy. It 
inhibits the pro-angiogenetic receptor tyrosine kinases VEGFR1, VEGFR2, and VEGFR3 
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and PDGFRβ, as well as serine/threonine kinases RAF1 and BRAF which signal 
downstream of receptor tyrosine kinases.50,57 Sorafenib is approved as a first line 
treatment for HCC and significantly extends median survival by almost 3 months.57 
Regorafenib is another molecularly targeted therapy that, like sorafenib, inhibits pro-
angiogenic kinases VEGFR1, VEGFR2, and VEGFR3 and PDGFRβ, as well as c-KIT, 
RET, BRAF, and a constitutively active mutant form of BRAF.56,58 It has been shown to 
improve lifespan by almost 3 months in patients with HCC disease progression during 
sorafenib treatment.56 Learning more about the molecular alterations driving HCC is 
needed to provide targets for the development of more effective therapies.  
C. Challenges for driver alteration identification 
Genomic and gene expression data has revealed a great amount of heterogeneity in the 
many mutated and misexpressed genes in HCC.59–61 Sequencing of over 500 HCC cases 
revealed only a small number of genes were mutated in more than five percent of cases, 
including TERT, CTNNB1, TP53, and AXIN1, while the vast majority of mutations occurred 
infrequently.46 Chromosome aberrations involving copy number variations or large regions 
and whole chromosomes are highly prevalent in HCC, making the identification of the 
specific tumor-promoting changes difficult as these large regions harbor many genes, 
multiple of which may be involved in tumorigenesis.45,46,53,62 Altered gene expression due 
to epigenetic changes such as hyper- or hypo-methylation is also common in HCC.63 Thus, 
distinguishing molecular drivers of HCC from passenger alterations presents a challenge. 
Complementary experimental methods are needed to identify and validate the molecular 
alterations and processes operative in HCC that could serve as a basis for new targeted 
HCC prevention or treatment strategies. 
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4. Progress and limitations modeling HCC in mice 
A. Genetically modified mouse models 
Genetically modified mouse models can be engineered to express oncogenes in a tissue-
specific manner, often using the Albumin promoter to restrict transgene expression to 
hepatocytes for modeling HCC.64 HBV-driven HCC has been modeled using transgenic 
mice expressing whole fragments of the HBV genome, the surface antigen, or the HBx 
gene.65–67 Mouse models of HCV-induced HCC have been generated expressing the 
complete set of viral proteins,68 the core protein alone,69,70 or the core with envelope 
proteins 1 and 2.71 Transgenic mice expressing well-characterized oncogenes such as 
Myc, Egf, and an activating Ctnnb1 mutation in combination with an HRas mutation have 
also been used to model HCC.72–74 Genetically engineered mice have been generated 
with liver-specific tumor suppressor gene loss, such as liver-specific Pten-deficient mice 
which develop hepatic steatosis and liver tumors.75 Genetically modiﬁed mouse models 
allow tumor development in situ in immunocompetent animals. They can be engineered 
to express multiple oncogenes, facilitating the investigation of cooperation between 
oncogenic alterations. They are, however, slow and costly to generate, so are typically 
used to study known oncogenes and tumor suppressor genes rather than novel genes 
involved in tumor development and maintenance. They do not model the acquisition of 
transforming alterations by individual somatic cells, since the whole liver is typically 
engineered to express the genetic modification, nor do they reflect the heterogeneity of 
tumor cells in which multiple mutations drive tumorigenesis.64 
B. Mosaic mouse models 
To overcome the cost and time obstacles of generating conventional genetically modified 
mouse models, a mosaic mouse model was developed where liver progenitor cells 
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(hepatoblasts) are genetically modified in culture, then transplanted into syngeneic 
recipient mice and assessed for tumor formation.76 Hepatoblasts from Trp53-deficient 
mice modified to express oncogenes like Myc, Ras, or Akt and wildtype hepatoblasts 
engineered to express oncogenes and shRNA knockdown constructs against the tumor 
suppressor Trp53 can form tumors when seeded into recipient mouse livers.76,77 These 
tumors resemble human HCC and can acquire additional spontaneous genetic lesions like 
focal amplifications promoting tumorigenesis, modeling the genetic heterogeneity of 
HCC.77 This model has been used to screen genes by shRNA knockdown for tumor 
suppressor identification and by overexpression of cDNAs for HCC oncogene 
identification.78,79 These models overcome the time and cost associated with the 
generation of genetically engineered mouse models, but do not recapitulate the typical 
development of HCC in context of chronic liver disease. 
C. Xenograft models 
In xenograft models, human HCC cells from a biopsy or cell line are injected into 
immunodeficient mice either ectopically in the flank or orthotopically in the liver. These 
models have the advantages of rapid tumor development and allowing the study of human 
tumor cells in vivo. Xenografts neither model the immune response to tumor cells, nor the 
natural tumor progression in which neoplastic cells interact with the surrounding 
environment as tumors develop.64 This system can be improved by implanting tumor cells 
in an environment with liver damage that more closely resembles the conditions under 
which HCC typically develops. HCC cells have been implanted into livers with fibrosis 
induced by carbon tetrachloride or alcohol. The resulting tumors better model HCC 
development, grow larger than in normal livers, and are capable of metastasizing.80 
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D. Chemically induced models 
Hepatocyte injury by chemical compounds can lead to liver tumor formation, modeling the 
development of liver cancer in context of liver damage typically occurring in humans.64 N-
nitrosodiethylamine (DEN) is a DNA-damaging agent commonly used to induce liver 
tumors in mice. Repeated DEN administration can result in tumor development in 100% 
of male mice and 30% of female mice.81 Carbon tetrachloride (CCl4) is a hepatotoxin that 
induces fibrosis and HCC by repeated cycles of liver injury, inﬂammation, and repair, 
modeling liver disease progression in humans.64 Although choline-deficiency is not a major 
cause of hepatic steatosis in humans, a choline-deficient diet is commonly used to model 
steatosis-associated HCC in rodents; it induces hepatic steatosis with 100% penetrance 
and liver tumors with approximately 20% penetrance.82 The addition of ethionine or 
ethanol to this diet can increase both tumor formation and steatosis severity.83,84 Choline-
deficient diets are a particularly useful model for alcohol-associated hepatic steatosis 
because, like alcohol, choline-deficiency decreases the synthesis of phosphatidylcholine, 
causing fatty acids to accumulate in hepatocytes.33,83 These systems model HCC 
development in context of liver damage, but it can be difficult to determine the mutations 
driving tumor formation using these models. The interaction between tumor-promoting 
mutations and the influence of the environment of liver damage in which tumors arise 
could be addressed by using these liver damaging agents on genetically-driven mouse 
models of HCC, like those listed above. This would be useful to study the influence of 
chronic liver damage on HCC induction driven by known cancer genes, but would be 
inefficient for identifying new HCC oncogenes or tumor suppressors in the context of liver 
damage. 
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II. The Sleeping Beauty (SB) transposon system for cancer studies 
1. SB transposon system overview  
The Sleeping Beauty (SB) transposon system is a useful tool for both forward and reverse 
genetic studies to elucidate cancer genes in vivo. The SB transposable element is a 
synthetic DNA transposon belonging to the Tc1/Mariner family that mobilizes in a cut-and-
paste fashion. It was awakened from millions of years of evolutionary sleep by correcting 
the mutations responsible for its transposase inactivity.85 The current SB transposon 
system consists of two parts: firstly, a transposon vector containing any DNA sequence 
that is flanked by SB inverted repeat/direct terminal repeat (IR/DR) sequences and 
secondly, the SB transposase enzyme that is responsible for excision and reintegration of 
the transposon placed under the control of a promoter. When both these components are 
present in a cell, a cut-and-paste transposition reaction occurs in which the transposon is 
excised from its original location and re-integrated at a new “TA” dinucleotide location 
within the genome. The mobilization process is relatively random, although it has the 
propensity for local hopping, a phenomenon in which a transposon reintegrates in close 
vicinity to the donor locus.86 SB transposition can be active in both transgenic mouse 
germline and somatic cells.86–89 
2. SB transposon insertional mutagenesis for forward genetic cancer screens 
A. Body wide SB insertional mutagenesis 
Comparative analysis of molecular alterations in human tumors to data obtained through 
unbiased transposon-based insertional mutagenesis screens in mice is a method that can 
be used to identify driver genes for a variety of cancer types.90,91 In transposon-based 
mutagenesis screens, the random insertion of mutagenic transposons alters normal 
endogenous genes in mouse cells and induces cancer. The mutagenic transposon called 
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T2/Onc (Figure 1.1A), designed to cause both gene gain- and loss-of-function insertional 
mutations, contains a strong promoter that can induce gene overexpression and stop 
cassettes that can truncate gene expression. Insertion of T2/Onc near or within a gene 
can lead to tumor formation when proto-oncogenes are overexpressed or tumor 
suppressor genes are inactivated. The genetic changes that drive tumor progression can 
then be identified by the locations of transposon insertions in the genome.87,88,92 (Figure 
1.1B-C) T2/Onc combined with transgenes ubiquitously expressing SB transposase in 
wild-type or cancer predisposed mice have induced or accelerated sarcoma and T-cell 
leukemia.87,88 In both cases, the SB initiated or accelerated tumors were characterized by 
somatic, tumor specific transposon insertions that were shown to occur at dozens of 
recurrently mutated known and novel cancer genes.87,88 SB insertion sites are readily 
cloned and can be characterized rapidly to implicate new genes in solid tumor 
development using a forward genetic approach. Next-generation sequencing platforms 
allow rapid and adequate coverage for identifying transposon insertion sites. Sites 
mutated by insertions significantly more frequently in tumors than predicted by random 
chance are called common insertion sites (CIS) and are hypothesized to reveal potential 
driver mutations. These data can be compared to human cancer mutation data to elucidate 
which alterations found in human tumors may be important cancer drivers. (Figure 1.2) 
These transposon-based systems, therefore, provide powerful genetic tools for identifying 
cancer-promoting mutations.  
B. Conditionally expressed SB transposon system 
Tissue specific mutagenesis with SB has developed informative models of various types 
of human solid tumors. In these studies, mice conditionally express the catalytically 
improved SB transposase, SB11,93 from the endogenous Rosa26 locus after Cre 
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recombinase has excised a loxP flanked stop cassette (lsl) separating the SB11 cDNA 
from the Rosa26 promoter. Thus, using these Rosa26-lsl-SB11 mice, SB mutagenesis 
can be restricted to tissues expressing the Cre recombinase from a tissue-specific 
promoter. Conditional SB transposition systems have been used to generate various solid 
tumors and screen for genes associated with these cancer types.48,92,94 In addition to 
tissue-specific promoters driving Cre recombinase, predisposed genetic backgrounds 
have also been incorporated into these screens to elucidate mutations cooperating with 
common cancer initiating mutations.48,95 Variations of this mutagenesis system have been 
used to reveal both known and novel oncogenes as well as tumor suppressors in solid 
tumors and leukemias.48,87,92,94–97  
C. Forward genetic screens for hepatocellular carcinoma drivers 
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality 
worldwide.13  The pathogenic changes underlying the development and progression of 
HCC are complex and incompletely understood. To specifically model HCC in mice and 
identify driver mutations, we previously used the conditional SB transposon system for 
insertional mutagenesis. Mice were generated carrying the conditional Rosa26-lsl-SB11 
transposase transgene, the T2/Onc2 transposon, and the hepatocyte specific Albumin-
Cre to limit transposase expression and subsequent transposon mobilization to 
hepatocytes. In addition, because TP53 is frequently mutated in human HCC, a 
conditional dominant negative Trp53 transgene, p53-lsl-R270H,98 was added along with 
the transposition system. Both the three transgene mutagenesis system and the 
mutagenesis system on the Trp53 mutated background produced tumors in mice that 
modeled all stages of liver cancer progression including neoplastic nodules, adenomas, 
HCC, and lung metastasis.48 These models recapitulated the sex bias seen in humans, 
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with higher tumor burdens occurring in males than females.48,54 This screen uncovered 19 
candidate HCC-associated loci including known oncogenes such as Egfr and Met and 
novel candidate genes associated with HCC including Ube2H and Zbtb20.48 
HCC has also been generated in mice using a modified mutagenic transposon, T2/Onc3, 
in which oncogene overexpression is driven by the CAGGS promoter, which is more active 
in epithelial cells than the murine stem cell virus 5’ long-terminal repeat promoter used in 
T2/Onc2.92 As expected, body wide mobilization of T2/Onc3 produced more carcinomas92 
than T2/Onc2, which induced mainly hematopoietic malignancies.87 Of the tumors 
generated by body wide mobilization of T2/Onc3, liver tumors occurred most frequently.92 
A CIS identified in this screen was the complex Dlk1-Dio3 imprinted domain which 
contains protein-coding genes, long non-coding RNAs, microRNAs, and small nucleolar 
RNAs, and which is aberrantly expressed in human HCC.99 
The MYC oncogene is amplified in 30% and overexpressed in a majority of HCC.63 To 
identify genetic alterations cooperating with MYC overexpression, a transposon based 
mutagenesis screen was performed on a MYC overexpression mouse model of liver 
cancer. Transgenic mice were generated carrying the mutagenic SB transposon T2/Onc2, 
ubiquitously expressed Rosa26-SB11 transposase, tetracycline-repressible MYC, and 
liver specific tet-transactivator transgenes.95 MYC-overexpressing mice undergoing 
transposition had an accelerated rate of tumorigenesis, with 65% of mice developing 
tumors before 16 weeks of age compared to 29% of MYC-overexpressing controls without 
transposition. Fourteen CISs were identified from tumors in the mice undergoing 
transposition. Of these, three were validated as tumor suppressor genes by shRNA 
knockdown in Trp53-null hepatoblasts immortalized by MYC overexpression. 
Hepatoblasts with Ncoa2, Zfx, or Dtnb shRNA knockdown gave rise to tumors when 
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injected into nude mice. Therefore, this study identified 14 candidate MYC-cooperating 
liver cancer driver mutations, three of which were shown to act as tumor suppressors in 
context of MYC overexpression.95 
While these SB mutagenesis studies in context of an otherwise normal liver, in context of 
known HCC-promoting gene expression, and in mice of both sexes provide useful 
information about HCC genetics, HCC most often develops in the context of chronic liver 
damage and cirrhosis. SB mutagenesis in chronically damaged livers could reveal unique 
genetic changes in response to the unique selective pressure nascent HCC cells 
encounter in damaged livers. These specific changes may have relevance for the 
prevention and treatment of HCC in patients.  
In two studies, SB insertional mutagenesis in mouse livers expressing the HBV surface 
antigen (HBsAg) has been used identify genes promoting HCC in the context of HBV 
induced liver inflammation. 100,101 In one of these studies, transgenic mice were generated 
with the mutagenic T2/Onc2 transposon, expression of the conditional Rosa26-lsl-SB11 
transposase transgene restricted to hepatocytes by Albumin-Cre, and hepatic expression 
of HBsAg to induce liver inflammation.100 Transposon mutagenesis in context of HBsAg 
expression in this study revealed over 2,800 candidate liver cancer genes, over 1000 of 
which have altered expression or mutations in human HCC. Well-characterized pathways 
involved in HCC like Wnt/β-catenin, p53, and Ras signaling were altered by transposon 
insertions in most of the tumors. More than 1000 of the candidate cancer genes identified 
in this study were involved in cellular metabolism.100 Another study used the mutagenic 
T2/Onc3 transposon, conditional Rosa26-lsl-SB11 transposase, Albumin-Cre, and 
hepatically expressed HBsAg transgenes to induce HCC and identified over 1000 CIS 
genes, 410 of which were mutated in human HCC.101 Tumor suppressor gene candidates 
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from both screens were tested in vivo by shRNA knockdown in immortalized mouse liver 
cells which were then injected into nude mice for a tumor formation assay. This assay 
validated 27 candidate genes as tumor suppressors.101 These studies demonstrated the 
use of SB mutagenesis to identify mutations promoting HCC in context of liver damage. 
More studies in damaged liver contexts such as hepatic fibrosis and steatosis would be 
highly relevant to human HCC. 
3. SB transposon system for reverse genetic studies of cancer 
A. Selection of candidate genes for study 
Transposon-based forward genetic screens and human HCC mutation and expression 
data have generated a wealth of candidate cancer-promoting alterations with possible 
relevance for human disease. This can make prioritizing these genes for further study 
challenging. To select candidate cancer genes for testing, we propose that SB CIS genes 
found in mouse models should be compared to human cancer genetic data, when 
available, to identify the strongest candidate genes. Transposon insertions in the 5’ region 
of a gene with the promoter in the forward orientation relative to the gene likely drive 
overexpression, while transposon insertions scattered throughout a gene likely disrupt 
expression. (Figure 1.1) This allows CIS genes to be identified as candidate oncogenes 
or tumor suppressors based on insertion site profiles.90 CIS genes without a clear trend of 
alteration in human cancer should be considered weaker candidate cancer genes. CIS 
genes with known roles as human oncogenes or tumor suppressors are not novel, but can 
be useful as controls or for proof-of-principle experiments. CIS genes found as candidate 
oncogenes in SB screens that are amplified, overexpressed, or have activating mutations 
in human cancer can be considered strong candidate oncogenes that should be prioritized 
for study. Likewise, candidate tumor suppressor CIS genes from SB screens that are 
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deleted, under-expressed, or have inactivating mutations in human cancer can be 
considered strong candidate tumor suppressor genes that should be prioritized for further 
study. (Figure 1.2)  
B. SB gene delivery-based reverse genetic cancer models  
The roles of candidate cancer genes selected for study can be tested in vivo using reverse 
genetic models. Transgenic mice provide the advantage of allowing development of 
orthotopic cancer models in immunocompetent mice. Generating transgenic mice, 
however, is costly and slow, making it an impractical method for addressing a large 
number of candidate cancer genes. SB-mediated gene delivery may provide a more 
efficient method to generate reverse genetic cancer models. In addition to its use as a 
mutagen, SB can be used to deliver genes-of-interest or knockdown vectors for stable 
expression within cells in vivo.102–106 SB can excise a cDNA sequence or shRNA sequence 
that is flanked by inverted repeat/direct terminal repeat (IR/DR) sequences from a plasmid 
and reintegrate it at a random “TA” dinucleotide in the genome.106 SB transposon plasmids 
have been delivered to the brain by intracranial injection of DNA-polyethylenimine 
complexes,103,105 lung by intravenous injection of DNA-polyethylenimine complexes,104 
and liver by hydrodynamic injection of plasmid DNA,102,107  while SB has been expressed 
from a transgene48,108 or plasmid,102–104 allowing reverse genetic studies of brain, lung, and 
liver cancer genes. In this way, SB can be used to generate reverse genetic models of 
cancer in tissue types for which efficient methods of plasmid delivery exist. 
C. SB and the selective Fah-deficient mouse model for hepatic gene expression 
A unique mouse model for validating candidate liver cancer genes that uses Fah mutant 
mice expressing SB for gene delivery (Fah-/-/SB11) has been established.48,54,102,108 Fah 
19 
 
mutant mice have a defect in the tyrosine metabolic pathway similar to the human 
hereditary tyrosinemia type I disease and require maintenance on 2-(2-nitro-4-
fluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone) water. While on nitisinone water, 
these animals are physiologically normal. Candidate liver oncogene cDNAs or short-
hairpin RNAs against putative tumor suppressor gene homologues can be introduced into 
the livers of Fah/SB11 mice for validation along with the Fah cDNA on SB transposon 
plasmid vectors flanked by SB IRDRs. The plasmids are introduced into the livers of      
Fah-/-/SB11 mice by hydrodynamic tail vein injection,107 and then nitisinone is removed. 
As hepatocytes lacking Fah die, the livers of the Fah-/-/SB11 mice are repopulated by 
hepatocytes in which transposon vectors are integrated by SB and stably express the Fah 
cDNA and gene-of-interest. This results in generating mice with almost entirely transgenic 
livers in 6–8 weeks. (Figure 1.3A-B) This system can be used to efficiently test the role of 
novel HCC-associated genes identified in insertional mutagenesis screens that are altered 
in human disease to determine their importance as driver mutations. An advantage of 
using this animal model is that the cost and effort associated with the generation of 
germline transgenic animals harboring the genes-of-interest can be avoided. Genes-of-
interest can be cloned into SB transposon vectors and introduced into the livers of Fah-/-
/SB11 animals by a relatively simple technique involving hydrodynamic tail vein injection. 
Live imaging can be used to monitor the pathogenicity of the genes-of-interest by including 
a luciferase reporter on the gene delivery vector and mice are sacrificed when a phenotype 
is observed. Most importantly, this approach allows the rapid generation of liver cancer 
mouse models driven by various genetic alterations. This system has been used to model 
liver cancer driven by known liver oncogenes,102 genes identified in a forward genetic 
screen48 and the HBV viral gene HBx.108 It could prove useful for efficiently testing liver 
20 
 
cancer drivers discovered in other studies, in mice of both sexes, and in context of liver 
steatosis and fibrosis, conditions highly relevant to human HCC. 
III. Hypothesis  
1. SB insertional mutagenesis in steatotic livers will reveal a distinct set of 
steatosis-associated HCC genes. 
2. SB gene delivery can be used to efficiently test candidate HCC genes 
discovered in a variety of disease-relevant contexts. 
IV. Objectives 
1. Use SB insertional mutagenesis to model hepatic steatosis-associated HCC 
and compare to human HCC data to identify steatosis-associated HCC genes. 
(Figure 1.4) 
2. Use SB gene delivery to test a candidate steatosis-associated HCC oncogene 
in steatotic livers in vivo. (Figure 1.4) 
3. Use SB gene delivery to test candidate HCC oncogenes in a variety of disease 
relevant contexts in vivo. (Figure 1.4) 
 
Mutagenic transposon
MSCV 5’ LTRIR/DR IR/DRSA pA SApASD
Proto-oncogene activation
Tumor suppressor gene
A
B
C
Exon 1 Exon 2 Exon 3MSCV 5’ LTR SD
Exon 1 Exon 2 Exon 3
Exon 1 Exon 2 Exon 3
MSCV 5’ LTR SD
MSCV 5’ LTRSD
IR/DR IR/DRSA pA
SApA
IR/DR IR/DRSA pA
SApA
IR/DRIR/DR SApA
SA pA
Exon 1 Exon 3Exon 2  MSCV 5’ LTR SD
Exon 1 Exon 3Exon 2  MSCV 5’ LTRSD
IR/DR IR/DRSA pA
SApA
IR/DRIR/DR SApA
SA pA
Figure 1.1. Mutagenic transposon vector for gain- and loss-of-function screen.
(A) The mutagenic T2/Onc transposon contains splice acceptors (SAs) followed by poly-
adenylation (pA) signals in both orientations, which are designed to elicit premature tran-
script truncation. The 5’- long terminal repeat (LTR) of the murine stem cell virus (MSCV) 
fused with a splice donor (SD) was placed in between the two SAs to drive misexpression 
of genes. This MSCV contains enhancer and strong cis-regulatory elements that have 
been shown to be active and methylation-resistant in pluripotent cells. IR/DR, inverted 
repeat/direct terminal repeat sequences. (B) Gain-of-function screen for proto-oncogenes. 
The mutagenic transposon vector can integrate upstream of a proto-oncogene and cause 
misexpression or create truncated versions by integrating withintronic sequences of the 
endoenous gene. (C) Loss-of-function screen for tumor suppressor genes. The mutagenic 
transposon can integrate within intronic sequences and disrupt expression of tumor 
suppresor genes.
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Figure 1.2. Pipeline for selecting candidate cancer genes from SB screens for 
further study. SB insertion mutations can result in gene overexpression or disruption. 
Human molecular cancer data can likewise reveal potential gain-of-function or loss-of-
function alterations. To determine which common insertion sites (CISs) are most likely 
relevant oncogenes or tumor suppressors in human cancer, human cancer data is 
analyzed for gain- or loss-of-function alterations in CIS genes. Genes overexpressed by 
transposon insertions that have gain-of-function alterations in human cancer are consid-
ered to be strong candidate oncogenes, and genes interrupted by transposon insertions 
that have loss-of-function alterations in human cancer are considered strong candidate 
tumor suppressor genes. These strong candidate cancer genes should be prioritized for 
further study.
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Figure 1.3. Validation of candidate liver cancer genes using the Fah mutant mouse 
model. (A) Schematic of the selective Fah mutant mouse model. (B) Schematic of time-
line for validation of candidate liver cancer genes using the Fah mutant mouse model.
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Figure 1.4. Thesis objectives.
Objective 1: Perform a forward genetic screen using SB insertional mutagenesis in mice 
of both sexes with hepatic steatosis to model hepatic steatosis-associated HCC, then 
compare to human HCC data to identify steatosis-associated HCC genes.
Objective 2: Use SB gene delivery to test a candidate steatosis-associated HCC driver 
gene in steatotic livers in mice of both sexes.
Objective 3: Use SB gene delivery to test candidate HCC driver genes in a variety of 
disease relevant contexts in vivo. 
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CHAPTER 2: 
 
 
 
Sleeping Beauty insertional mutagenesis in mice identifies steatosis-associated 
hepatocellular carcinoma drivers 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The following chapter contains material from a manuscript under review: 
Tschida BR, Keng VW, Temiz NA, Kuka TP, Lee LA, Riordan JD, Tierrablanca CA, Hullsiek R, Wagner S, 
Hudson WA, Linden MA, Amin K, Beckmann PJ, Heuer RA, Yang JD, Roberts LR, Nadeau JH, Dupuy AJ, 
Largaespada DA. Sleeping Beauty insertional mutagenesis in mice identifies steatosis-associated 
hepatocellular carcinoma drivers. Under review. 
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Abstract  
To study the molecular pathology of HCC in the context of hepatic steatosis, we performed 
a forward genetic screen using conditional Sleeping Beauty (SB) transposon insertional 
mutagenesis in mice with diet and ethanol-induced hepatic steatosis and compared the 
results to human HCC data from public databases and clinical samples.  In humans, we 
found the proportion of female patients developing HCC increased in the context of 
steatosis. Experimental steatosis similarly reduced the male liver tumor burden sex bias 
in mice. We identified 203 candidate steatosis-associated HCC genes, many of which are 
altered in human HCC and are members of established HCC-driving signaling pathways.  
In particular, the protein kinase A/cyclic AMP signaling pathway was frequently altered in 
mouse and human steatosis-associated HCC. NAT10, a candidate HCC driver identified 
in mice, was overexpressed in human HCC, was associated with decreased survival, and 
drove liver tumorigenesis in a steatotic mouse model in vivo. 
Statement of significance: Hepatic steatosis, a common chronic liver disease increasing 
in prevalence, is a strong risk factor for hepatocellular carcinoma (HCC). This study 
identifies genes and pathways that promote HCC and may represent novel targets for 
prevention and treatment, particularly in the increasingly relevant context of hepatic 
steatosis.  
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Introduction 
Hepatocellular carcinoma (HCC) is the second leading cause of death from cancer 
worldwide.13  HCC is sex biased, occurring in men 2-4 times more frequently than women.8 
Hepatic steatosis, or fatty liver disease, is an increasingly common and strong risk factor 
for HCC.37 Alcohol consumption further increases the risk of HCC and is among the most 
signiﬁcant factors associated with progression of hepatic steatosis to HCC.37  
There is considerable genetic heterogeneity in HCC.60 The vast majority of mutations 
occur infrequently46 and chromosome aberrations involving large gains and losses are 
prevalent,46,53 making the distinction between molecular drivers of tumorigenesis and 
passenger alterations challenging. In addition, limited data is available on steatosis-
associated HCC; only 12 cases with hepatic steatosis as the sole predisposing condition 
have been characterized by The Cancer Genome Atlas Consortium (TCGA) (TCGA 
Research Network: http://cancergenome.nih.gov/). Comparative methods are needed to 
identify specific genes and processes operative in HCC and provide a basis for new 
prevention and treatment strategies. 
Comparative analysis of molecular alterations in human tumors to data obtained through 
Sleeping Beauty (SB) transposon-based insertional mutagenesis in mice has identified 
HCC drivers in normal livers, in the context of commonly known HCC-promoting 
mutations, and in mice of both sexes.48 Mutagenic transposons contain a strong promoter 
that can induce gene overexpression and stop cassettes that can truncate gene 
expression, leading to tumor formation when proto-oncogenes are overexpressed or 
tumor suppressor genes are inactivated. The locations of these transposon insertions tag 
cancer genes in resulting tumor cells.87 While earlier studies have provided useful 
information about HCC genetics, few recapitulate the environment of chronic liver damage 
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in which human tumors almost always develop, which changes the selective pressures 
that nascent HCC cells encounter.8 SB insertional mutagenesis in mouse livers expressing 
the Hepatitis B virus surface antigen protein to model Hepatitis B-induced liver 
inflammation identified a distinct set of HCC promoting mutations, many of which were 
linked to cellular metabolic processes.100 We expected SB mutagenesis in steatotic livers 
would reveal unique genetic drivers not identified in earlier SB screens for HCC that may 
have relevance for HCC prevention and treatment in patients, particularly those with 
steatosis. 
In this study, we aimed to identify molecular alterations that promote HCC in the context 
of diet and alcohol-associated hepatic steatosis using liver-specific SB insertional 
mutagenesis in mice treated with ethanol and a choline-deficient diet.  Choline-deficient 
diets are an established model for hepatic steatosis, and ethanol treatment acts additively 
to increase steatosis severity and susceptibility to liver tumor formation.83,84 This is a 
particularly useful model for alcohol-associated steatosis because both alcohol ingestion 
and choline-deficiency decrease phosphatidylcholine synthesis, causing fatty acid 
accumulation in hepatocytes.33,83 Using this system, we modeled steatosis-associated 
HCC in mice and found over 200 candidate driving mutations, many of which affected 
genes altered in human steatosis-associated HCC. The protein kinase A/cyclic AMP 
(PKA/cAMP) signaling pathway was altered frequently in mouse and human steatosis-
associated HCC. NAT10, identified as a candidate oncogene in mice, is overexpressed in 
human steatosis-associated HCC and associated with decreased survival, and we 
validated its oncogenic role in steatosis-associated liver cancer in vivo. 
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Results 
A transposon insertional mutagenesis-driven mouse model of hepatic steatosis-
associated liver cancer  
We used a previously described conditional SB transposon-based insertional 
mutagenesis system to induce liver adenomas and HCC, generating a mutagenized 
transgenic mouse cohort with one copy each of Albumin-cre, mutagenic transposon 
(T2/onc), and transposase expressing Rosa26-lsl-SB11 transgenes and a control cohort 
carrying two of the three transgenes (thereby lacking transposition).48 All mutagenized and 
control mice were treated with a diet designed to induce hepatic steatosis (eCDD) 
consisting of 5% ethanol in the drinking water ad libitum for two months after weaning 
followed by untreated drinking water and a modified choline-deficient diet for the 
remainder of the study (Figure 2.1A).  Choline-deficient diet treatment reliably induces 
hepatic steatosis and leads to liver tumor formation in 22% of mice after 19 months.82 The 
addition of 5% ethanol increases steatosis severity and sensitization to ethionine-induced 
tumor formation.83,84 In our study, we used SB transposon insertional mutagenesis in place 
of ethionine to induce tumorigenesis in eCDD-treated mice.  
Mice treated with eCDD developed hepatic steatosis (Figure 2.1E, 2.2A-B). All livers 
examined histopathologically from eCDD-treated mice displayed fatty change (34/34).  We 
measured the lipid droplet percentage of liver tissue from representative eCDD-treated 
and normal diet (ND)-treated control mouse liver sections by quantifying the percent of 
unstained pixels from hematoxylin and eosin (H&E)-stained slides using Aperio Positive 
Pixel Count software. Lipid droplet percentage of liver tissue was approximately 8-fold 
higher in eCDD-treated than ND-treated mice (P = .012, Student’s t test). (Figure 2.2A-B)  
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To determine whether SB insertional mutagenesis drove liver tumor formation, tumor 
penetrance and average tumor burden were compared between eCDD-treated SB- 
mutagenized mice and age-matched control mice. Mutagenized mice had higher tumor 
penetrance than control mice, with 75.5% (n = 49) vs. 21.9% (n = 32) developing tumors 
by 436 days (P < .0001, Chi-square test). (Figure 2.1B) Average tumor burden was also 
higher in mutagenized mice, 4.76 tumors per mouse vs. 0.28 tumors per control mouse 
(P = .002, Student’s t test). (Figure 2.1C)  SB transposase expression was confirmed by 
immunohistochemistry (IHC). (Figure 2.1E) Liver tumors that developed in mutagenized 
mice and were examined histopathologically were classified as well-differentiated 
hepatocellular neoplasms, analogous to adenomas (81%), or as hepatocellular 
carcinomas (19%). (Figure 2.1D-E) Albumin expression was detected in tumors by IHC, 
confirming their hepatocyte origin.48 (Figure 2.1E) Thus, SB transposon insertional 
mutagenesis plus treatment with eCDD induced steatosis-associated liver cancer in our 
mouse model. 
Increased HCC incidence in females with hepatic steatosis 
The sex distribution of a previously described109 cohort of 460 adult patients diagnosed 
with HCC between January 2007 and December 2009 at the Mayo Clinic, Rochester 
followed the typical bias, with 72% (332) males and 28% (128) females. We examined the 
sex distribution among subsets of patients with and without hepatic steatosis as the 
primary predisposing factor. The 397 HCC patients without steatosis were 74.6% (296) 
men and 25.4% (101) women.  The 63 HCC patients with steatosis were 57.1% (36) men 
and 42.9% (27) women, a significantly higher female proportion than the non-steatotic 
subset and the overall cohort (P = .004, and P = .014, respectively, Chi-square test). 
(Figure 2.3A) 
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We previously induced liver tumors in mice fed a normal diet using transgenes for hepatic 
insertional mutagenesis identical to those used in the current study.48,54 (Table 2.1) The 
sex distribution of SB-induced liver tumors in ND-treated mice modeled the typical human 
sex bias, with an average tumor burden of 8.15 tumors per male (n = 27) and 2.27 tumors 
per female (n = 11) (P = .024, Student’s t test). (Figure 2.3B) This sex bias was absent in 
SB-induced liver tumors in eCDD-treated mice, with an average tumor burden for males 
(n = 23) and females (n = 26) of 3.26 and 6.04, respectively (P = .213, Student’s t test). 
(Figure 2.3C) Tumor penetrance in male mice decreased non-significantly from 84.6% 
with ND to 65.2% with eCDD treatment (P = .115, Chi-square test) and increased non-
significantly in female mice from 63.6% with ND to 80.8% with eCDD treatment (P = .267, 
Chi-square test).  Thus, the SB system models the human HCC sex bias, with higher 
prevalence of non-steatosis associated liver cancer in males than females, and a 
reduction of the male sex bias in steatosis-associated liver cancer. 
FoxA1 and FoxA2 are repressed in steatotic liver 
Forkhead box transcription factors FoxA1 and FoxA2 contribute to the liver cancer sex 
bias in mice.110  Their activities are metabolically regulated in human liver, where FOXA1 
transcript is down-regulated with steatosis111 and FOXA2 function is negatively regulated 
by phosphorylation at T156 downstream of the insulin signaling pathway.112 
In our mouse model, FoxA1 expression was reduced and phosphorylated T156 FOXA2 
(p-FOXA2) increased in mice with hepatic steatosis. As detected by qRT-PCR, FoxA1 
transcript levels were lower in eCDD- than ND-treated mouse livers (P = .014, Student’s t 
test). (Figure 2.2F) In humans and mice, hepatic steatosis increases with age113,114 and in 
ND-treated mice, FoxA1 expression significantly decreased with age (Pearson’s 
correlation coefficient, r = -.823, P = .002). (Figure 2.2G). We examined FOXA1 
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expression by IHC and quantified staining using Aperio Positive Pixel Count in serial 
sections from the same liver samples used to quantify lipid droplet percentage of liver 
tissue, finding a non-significant inverse correlation between the two measures. (Pearson’s 
correlation coefficient, r = -.624, P = .261). (Figure 2.2A, C) Serial sections from the same 
samples were stained for p-FOXA2 by IHC, average staining was quantified using ImageJ 
(National Institutes of Health), and the percentage of cells with nuclear p-FOXA2 was 
measured with Aperio Positive Pixel Count. Intensity of p-FOXA2 staining increased 
(Pearson’s correlation coefficient, r = .890, P = .043) and nuclear p-FOXA2 increased non-
significantly (Pearson’s correlation coefficient, r = .775, P = .124) with lipid droplet liver 
tissue percentage. (Figure 2.2A, D-E) We analyzed expression of ApoM, a transcriptional 
target of FOXA1 and FOXA2, by qRT-PCR, finding reduced expression in eCDD- versus 
ND-treated control mouse livers (P = .022, Student’s t test). (Figure 2.2H) Collectively, 
these data suggest FOXA1 and FOXA2 are repressed in steatotic liver. Since loss of 
FoxA1 and FoxA2 eliminates sex bias in chemically-induced HCC in mice,110 repression 
of FOXA1 and FOXA2 may contribute to the reduction in HCC sex bias with steatosis.  
Common transposon insertion sites identify genes relevant to human steatosis-associated 
HCC 
To identify common transposon insertion sites (CIS) harboring liver cancer genes, 
transposon insertions from 159 tumors collected from 36 eCDD-treated transposition mice 
of both sexes (15 males and 21 females) (Table 2.1) were amplified and sequenced on 
the Illumina platform, revealing 7010 non-redundant insertions.  From these, TAPDANCE 
analysis115 identified 67 CIS with 73 associated genes and gene centric CIS (gCIS) 
analysis87 identified 188 CIS genes. 58 CIS genes were identified by both methods, so 
203 candidate steatosis-associated liver cancer genes were identified in total. (Table 2.2)  
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Many steatosis-associated liver cancer CIS genes were altered in human HCC cases 
profiled by TCGA (TCGA Research Network: http://cancergenome.nih.gov/). Of all TCGA 
HCC cases, 68% (139/203) CIS genes were significantly misexpressed (P < .05 by 
Benjamini-Hochberg (BH)-adjusted Student’s t test) in tumors compared to average 
expression in normal livers, 14% (29) were misexpressed in HCC cases with steatosis as 
the sole predisposing condition, and 62% (125) were misexpressed in alcohol-associated 
HCC cases. (Figure 2.4A, Table 2.3) Examining mutation and copy number changes for 
all TCGA HCC cases, 10% of CIS genes (20) were altered in more than 5% of tumors, 
15% (30) were altered in more than 5% of alcohol-associated HCC cases, and 29% (59) 
were altered in more than 5% of steatosis-associated HCC cases. (Figure 2.4B, 2.5-7, 
Table 2.3) This overlap shows the relevance of genes altered in our mouse model to 
human HCC. 
The majority of CIS gene expression changes in human steatosis or alcohol-associated 
TCGA HCC cases were consistent with the gene’s predicted role as an oncogene or tumor 
suppressor, as based on transposon insertion locations and orientations (i.e. predicted 
oncogenes were overexpressed in human HCC and predicted tumor suppressors under-
expressed). Of the 29 significant CIS gene expression changes in steatosis-associated 
HCC, 69% (20) were consistent with the predicted effect of transposon insertions. (Figure 
2.8A) Of the 125 significant CIS gene expression changes in alcohol-associated HCC, 
66% (83) were consistent with the predicted effect of transposon insertions. (Table 2.3) 
Nineteen CIS genes had significant expression changes greater than 2-fold in alcohol-
associated HCC, of which 74% (14) were consistent with the predicted effect of 
transposon insertions. (Figure 2.8B) These genes represent the most promising human 
steatosis-associated HCC driver candidates to be prioritized for further study.  
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Many CIS are enriched in steatosis-associated HCC 
To differentiate CIS specifically relevant to steatosis-associated HCC from those likely to 
drive HCC regardless of steatotic context, we performed an enrichment analysis. We 
compared the prevalence of steatosis-associated liver cancer CIS insertions in tumors 
generated in the eCDD HCC screen and a previously conducted, otherwise identical SB 
screen for HCC drivers in ND-treated mice48 using Fisher’s exact test with Benjamini-
Hochberg correction and a significance threshold of P < .05. We found 49 steatosis-
enriched TAPDANCE CIS genes and 79 steatosis-enriched gCIS with 30 overlapping, for 
a total of 98 steatosis-enriched CIS genes. (Table 2.4) 
Wnt/β-catenin signaling pathway genes altered in steatosis-associated HCC 
Ingenuity Pathway Analysis (IPA) indicated the Wnt/β-catenin signaling pathway was 
significantly associated with the steatosis-associated CIS gene list (P = .001) and the 
steatosis-enriched CIS gene list (P = .007). To assess the generalizability of this finding, 
we analyzed genes with significant expression changes between tumor and adjacent 
tumor-free liver from an independent mouse model of steatosis-associated HCC in which 
wild-type C57BL/6J mice were treated with a diet high in saturated fat and sucrose to 
induce liver cancer. Several Wnt/ β-catenin signaling genes showed significant expression 
changes in tumors from this cohort. We also analyzed human TCGA HCC data by IPA for 
pathways associated with genes with significant expression changes in steatosis-
associated (all differentially expressed genes) alcohol-associated (>2-fold change) HCC. 
Similar to the mouse tumors, we found Wnt/β-catenin signaling was significantly 
associated with genes altered in human alcohol-associated HCC (P = .015) and several 
pathway genes had expression changes in human steatosis-associated HCC. (Figure 2.9, 
Table 2.5) The association of this well-characterized HCC-promoting pathway with the 
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candidate genes identified in our screen highlights the relevance of this mouse model to 
human HCC. 
PKA/cAMP signaling pathway genes altered in steatosis-associated HCC 
IPA indicated the PKA/cAMP signaling pathway was significantly associated with the 
steatosis-associated (P = .003) and the steatosis-enriched (P < .0001) CIS gene lists, and 
several pathway genes had altered expression in wild-type, high-fat diet-fed mouse liver 
tumors. PKA/cAMP signaling was associated with genes with significant expression 
changes in human steatosis-associated (all differentially expressed genes) or alcohol-
associated (>2-fold change) HCC from TCGA (P = .016 and P < .0001, respectively). 
(Figure 2.10, Table 2.6) 
Phosphorylation of the catalytic subunit of PKA at T197 is required for enzyme 
activation.116 Activated PKA phosphorylated at T197 (p-PKA) was examined by IHC 
analysis of a tissue microarray of human HCC cases, and staining intensity was quantified 
using ImageJ. We detected a significant increase in p-PKA in HCC, with 75 of 99 tumors 
displaying stronger p-PKA staining than matched normal liver. (Wilcoxon signed rank test, 
P < .0001). (Figure 2.11A) Five cases on the tissue microarray had steatosis indicated in 
the pathology reports, 3 displaying stronger p-PKA staining than paired tumor-free liver 
(Wilcoxon signed rank test, P =.005) (Figure 2.11A-B), further supporting a role for the 
activation of PKA/cAMP signaling in steatosis-associated HCC. 
PKA activation promotes steatosis-associated hepatocarcinogenesis in vivo 
To test the effects of PKA activation on tumor formation in steatotic livers, we used an in 
vivo model of activated mutant PRKACA overexpression in livers of mice with diet-induced 
hepatic steatosis. A mutation in PRKACA leading to a substitution of leucine at position 
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206 with arginine in the catalytic subunit of PKA (PRKACAL206R) is constitutively active.117 
We used SB transposon-based gene delivery to stably overexpress PRKACAL206R in the 
selective Fah-deﬁcient mouse model as described previously.48,54,108 Fah-deficient male 
mice expressing SB transposase knocked into the Rosa26 locus (Fah/SB11)48 were 
maintained on the protective drug nitisinone until delivery of transposon vectors by 
hydrodynamic tail vein injection107 at 8 weeks and selection of hepatocytes with stable 
Fah-rescue transgene expression by nitisinone withdrawal. Mice were treated with either 
eCDD or ND. For each diet, negative control mice were injected with an SB transposon-
based GFP expression vector co-expressing Fah (pKT2/GD-GFP)108 and short hairpin 
against Trp53 (pT2/shp53)108 (GFP/shp53) and experimental mice were injected with an 
SB transposon-based expression vector for mouse PRKACAL206R cDNA co-expressing 
Fah with a GFP reporter (pT2/GD-PRKACAL206R) plus pT2/shp53 (PKA/shp53). (Figure 
2.12A) As shown previously,108 the use of pT2/shp53 in this model sensitizes to, but is not 
sufficient to induce, tumorigenesis. With eCDD-treatment, the use of pT2/shp53 is still not 
sufficient to induce tumorigenesis. GFP/shp53-injected eCDD-treated mice of both sexes 
develop a mean of 0.73 tumors, and pKT2/GD-GFP-injected eCDD-treated mice develop 
a mean of 0.08 tumors (No significant difference, Student’s t test). (Data not shown) 
Mice were sacrificed between 150 and 180 days post-injection. eCDD-treated PKA/shp53 
mice (n = 13) developed more tumors than eCDD-treated GFP/shp53 mice (n = 20), with 
a mean of 3.85 vs 0.85 tumors per mouse (P = .008, Student’s t test). (Figure 2.12B) In 
ND-treated mice, a mean of 0.64 versus 0.00 tumors per PKA/shp53 (n = 14) and 
GFP/shp53 (n = 18) mouse. (P = .006, Student’s t test) developed. (Figure 2.12B) 
Treatment with eCDD significantly increased tumor formation in PKA/shp53-injected mice 
compared to ND treatment (P = .009, Student’s t test). (Figure 2.12B) 
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NAT10 is over-expressed in human hepatic steatosis-associated HCC 
In eCDD-treated transposition mice, Nat10 was identified as a candidate gene by both 
TAPDANCE and gCIS (P = .049 and P < .0001, respectively) (Table 2.2) for which the 
predicted effect of transposon insertions was to drive overexpression. (Figure 2.13) Nat10 
insertions were enriched in tumors from eCDD-treated versus ND-treated SB-
mutagenized mice (Q = .038, BH corrected Fisher’s exact test). (Table 2.4)  
Nat10 was selected for further study based on alterations in human HCC supporting its 
predicted role as an oncogene. Of 357 human HCC cases on TCGA, 6.72% (24) 
overexpressed NAT10 more than 2-fold, which was associated with decreased survival (P 
= .0124, Log-rank Mantel-Cox test).(Figure 2.14A) Ten cases additionally had copy 
number gains that corresponded with overexpression (P < .0001, One-way ANOVA with 
post-hoc test). (Figure 2.14B) Among steatosis-associated HCC cases on TCGA, NAT10 
transcript was even more significantly overexpressed in tumors (P < .0001, Student’s t-
test). (Figure 2.14C) 
NAT10 protein expression was examined by IHC analysis of a human HCC tissue 
microarray, and staining intensity was quantified using ImageJ. NAT10 was 
overexpressed in a majority of HCC cases, with 82 of 99 HCC cases and 3 of 5 steatosis-
associated cases displaying stronger NAT10 staining than paired tumor-free liver 
(Wilcoxon signed rank test, P < .0001; and P = .003, respectively). (Figure 2.14D-E) 
Nat10 overexpression promotes steatosis-associated hepatocarcinogenesis in vivo 
To test the effects of Nat10 on tumor formation in steatotic livers, we used SB transposon-
based gene delivery to stably overexpress Nat10 in the selective Fah-deﬁcient mouse 
model as described above. Mice were treated with either eCDD or ND. For each diet, 
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negative control mice of both sexes were injected with pKT2/GD-GFP and pT2/shp53 
(GFP/shp53) and experimental mice of both sexes were injected with an SB transposon-
based expression vector for mouse Nat10 cDNA co-expressing Fah with a GFP reporter 
(pT2/GD-Nat10) plus pT2/shp53 (Nat10/shp53). (Figure 2.15A) 
Mice were sacrificed between 150 and 180 days post-injection. Six of 7 eCDD treated- 
and 4 of 10 ND treated- mouse livers examined histopathologically showed fatty change. 
The increased hepatic steatosis in eCDD- compared to ND- treated regenerated Fah-
deficient mouse livers was not statistically significant (P = .060, Chi-square test). 
eCDD-treated Nat10/shp53 mice (n = 24) developed more tumors than eCDD-treated 
GFP/shp53 mice (n = 25), with a mean of 4.42 vs 0.84 tumors per mouse (P = .014, 
Student’s t test). (Figure 2.15B) Similar results were observed in ND-treated mice, with a 
mean of 2.76 versus 0.14 tumors per Nat10/shp53 (n = 25) and GFP/shp53 (n = 29) 
mouse. (P < .0001, Student’s t test). (Figure 2.15B) Treatment with eCDD did not 
significantly increase tumor formation in Nat10/shp53 mice compared to ND treatment (P 
= .267, Student’s t test). 
Nat10/shp53-induced liver tumors were classified as well-differentiated hepatocellular 
neoplasms, analogous to adenomas (57%), or as hepatocellular carcinomas (43%) by 
histopathological analysis. Nat10/shp53-injected mouse livers and liver tumors 
overexpressed Nat10 compared to GFP/shp53 mouse livers (P < .0001 and P = .027, 
respectively, Student’s t test) as measured by qRT-PCR. (Figure 2.15C) Higher NAT10 
IHC staining levels were detected in Nat10/shp53 than GFP/shp53 mouse livers by 
ImageJ quantification (P = .004, Wilcoxon rank sum test). (Figure 2.16A) Both 
Nat10/shp53 and GFP/shp53 mouse livers expressed normal levels of Fah transcript 
(Figure 2.16B) and FAH protein expression was detected by IHC in GFP/shp53 and 
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Nat10/shp53 mouse livers and Nat10/shp53 mouse liver tumors, indicating efficient liver 
repopulation with transfected cells. (Figure 2.15D) Albumin expression was detected in 
Nat10/shp53 mouse liver tumors by IHC, confirming hepatocyte tissue origin of tumors.48 
(Figure 2.15D) 
Discussion 
Hepatic steatosis is a major and increasingly widespread HCC risk factor.37 Here we report 
the results of a forward genetic screen for HCC drivers in mouse livers with diet and 
alcohol-induced steatosis. Because HCC occurs most frequently in men, many mouse 
models of HCC include only males.64 We found, however, that the proportion of women 
developing HCC is higher in the context of hepatic steatosis than in the general population. 
Our steatosis-associated HCC model recapitulated the reduction of male HCC sex bias 
observed in human steatosis-associated HCC. The inclusion of females in studying HCC 
pathogenesis is, therefore, particularly important in this context. We found estrogen and 
androgen receptor pioneer factors FOXA1 and FOXA2 are negatively regulated in 
steatotic livers, which may contribute to the reduction in sex bias. Based on these 
similarities to human disease, HCC genes discovered in this screen may have broader 
relevance to human steatosis-associated HCC than those identified by studies conducted 
exclusively in males. 
The considerable genetic heterogeneity in human HCC necessitates the use of methods 
complementary to direct profiling of patient samples to identify driver alterations, such as 
mouse models.60 Analysis of recurrently mutated genes in liver tumors undergoing 
hepatocyte-specific transposition in steatotic livers identified over 200 candidate steatosis-
associated HCC genes, the majority of which are altered by expression change, copy 
number alteration, or mutation in human HCC. Most expression changes in human 
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steatosis and alcohol-associated HCC were also consistent with predicted roles of CIS 
genes as either oncogenes or tumor suppressors, providing additional evidence that our 
screen identified a subset of alterations in human steatosis and alcohol associated HCC 
that are promising candidate drivers of human hepatocarcinogenesis. 
PKA/cAMP signaling pathway genes were commonly altered in SB-induced steatosis-
associated mouse tumors and human steatosis-associated HCC. Similar disruption of this 
pathway in an independent mouse model of high fat diet-induced steatosis-associated 
HCC further supported its importance and demonstrated the broader relevance of our 
model to hepatocarcinogenesis in steatotic livers. We showed expression of a 
constitutively active PKA catalytic subunit induced tumorigenesis in steatotic livers in vivo. 
The PKA/cAMP signaling pathway regulates glucose and lipid metabolism, proliferation, 
and cell survival in the liver.118–120 Activating mutations in the PKA catalytic subunit, 
PRKACA, are common in adrenocortical tumors,117 and recurrent translocations in 
fibrolamellar HCC lead to DNAJB1-PRKACA chimeric transcripts associated with PKA 
upregulation.117,121 β-adrenergic receptors activate PKA/cAMP signaling in many cell types 
including hepatocytes and regulate many cancer-relevant cellular processes including 
growth, metabolism, DNA damage repair, cell motility, survival, and inflammation.122 
Several retrospective studies have found inhibition of β-adrenergic receptor signaling by 
the non-selective β-blocker, propranolol, in patients with cirrhosis may decrease HCC 
incidence, an effect that might involve PKA/cAMP signaling.123–125 To our knowledge, a 
prospective clinical trial has yet to be completed. Our identification of frequent alterations 
in human and mouse tumors support a role for PKA/cAMP signaling in steatosis-
associated HCC. 
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We identified NAT10 as a steatosis-associated HCC oncogene.  In a study of human HCC, 
NAT10 protein was found to be overexpressed in HCC compared to normal liver, and high 
expression was found to correlate with high TNM classification and poor survival 
outcomes.126 NAT10 expression has been shown to promote invasion and migration of 
HCC cells.127 Our data demonstrates a direct role for Nat10 overexpression in driving liver 
tumorigenesis in vivo in a mouse model with hepatic steatosis. NAT10 is a lysine and RNA 
acetyltransferase that acetylates histones, alpha tubulin, and RNA, thereby regulating 
gene expression, cell division, and precursor rRNA processing.128–130 Normal expression 
is required for the formation of N4-Acetylcytidine, a highly conserved modification of 
eukaryotic 18S rRNAs with an important role in ribosome biogenesis.130  N4-Acetylcytidine 
formation by NAT10 may be a nutrient-responsive RNA modification regulating 
translational output by promoting ribosome biogenesis only in the presence of 
acetylCoA,131 which is highly abundant in steatotic liver.132 In steatotic livers, NAT10 
overexpression may allow cells to respond to the abundance of acetylCoA by promoting 
increased ribosome biosynthesis, potentially bypassing a rate-limiting step in the process 
of hepatocarcinogenesis.  
NAT10 is a candidate for therapeutic targeting in HCC. Our study and other published 
work126 found NAT10 protein overexpression in over 60% of HCC cases, indicating a 
higher rate of NAT10 activation than is indicated by transcript expression levels on TCGA 
(6.7%).  NAT10 knockdown has been demonstrated to decrease growth rates of several 
cancer cell types.130,133 Importantly, a chemical inhibitor of NAT10 acetyltransferase 
activity, Remodelin, has been characterized.134 Our Nat10 overexpression mouse model 
could be used to test the efficacy of Remodelin for preventing or treating NAT10-driven 
HCC. The rate of ribosome biogenesis regulates cell proliferation135 and could be rate 
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limiting in HCC. Inhibition of this process using the RNA polymerase I specific inhibitor, 
CX-5461, reduces proliferation and induces senescence in many cancer cell types in vitro 
and in vivo.135,136 The efficacy of CX-5461 for inhibiting NAT10-overexpressing HCC cell 
proliferation could be evaluated to clarify the mechanism by which NAT10 drives 
tumorigenesis and for potential therapeutic benefit.  
The candidates we identified in this forward genetic screen for HCC drivers in the highly 
relevant context of hepatic steatosis may provide insight into which of the many genes 
altered in human HCC are likely drivers, the pathways promoting HCC in steatotic livers, 
and potential strategies for HCC prevention or treatment to investigate. We identified 
activation of the PKA/cAMP signaling pathway and overexpression of NAT10 as important 
steatosis-associated HCC-promoting events, both of which could potentially be targeted 
therapeutically. 
Methods 
Generation and maintenance of transposition and control transgenic animals 
Animal studies were conducted using procedures approved and monitored by the 
Institutional Animal Care and Use Committee at the University of Minnesota. Transgenic 
mice with Cre-inducible SB transposase and T2/Onc transposon concatemer on 
chromosome 15 (Rosa26-lsl-SB11Tg/Tg; T2/OncTg/Tg) rederived from lines previously 
generated48 were bred to mice with one copy of Cre recombinase expressed from the liver 
specific Albumin promoter (Alb-CreTg/WT) rederived from lines previously generated.48 
These crosses produced SB-mutagenized mice (Alb-CreTg/WT; Rosa26-lsl-SB11Tg/WT; 
T2/OncTg/WT) and control mice lacking transposon mobilization (Rosa26-lsl-SB11Tg/WT; 
T2/OncTg/WT). Genotyping for Alb-Cre, Rosa26-lsl-SB11, and T2/Onc was performed as 
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described previously.48 After weaning at 21 days, mice were placed on 5% v/v ethanol 
drinking water for 2 months, then normal drinking water and a modified choline-deficient 
diet (#0296021050, MP Biomedicals) ad libitum for the remainder of the study. 
Mutagenized mice were sacrificed with age-matched control mice at approximately 60 day 
intervals (to assess tumor formation), when mice became moribund, or by 400-436 days 
and liver tumor analysis was performed as described.48 
Fah-deficient mouse model 
Animal studies were conducted using procedures approved and monitored by the 
Institutional Animal Care and Use Committee at the University of Minnesota. Transgenic 
mice deficient for Fah and expressing SB11 transposase (Fah-/-; Rosa26-SB11Tg/WT) were 
generated and maintained as described.108 Mice were assigned to either a normal diet 
(ND) or ethanol treatment and choline-deficient diet (eCDD). ND mice were maintained on 
nitisinone drinking water until injection with plasmid DNA at 8 weeks of age, then placed 
on normal drinking water and standard diet. After weaning at 21 days of age, eCDD mice 
were placed on 5% v/v ethanol plus nitisinone drinking water. After plasmid injection at 8 
weeks of age, eCDD mice were placed on normal drinking water and a modified choline-
deficient diet (#0296021050, MP Biomedicals) ad libitum for the remainder of the study. 
We generated an SB transposon-based expression vector for Nat10 co-expressing Fah 
with a GFP reporter (pT2/GD-Nat10) as follows. A Nat10 cDNA clone was purchased 
(#MC202909, Origene) and cloned into pENTR entry vector (#A10462, Invitrogen) to get 
pENTR-Nat10.  The Nat10 component from pENTR-Nat10 was cloned into the previously 
generated pT2/GD-IRES-GFP54 Gateway destination SB transposon plasmid co-
expressing Fah and GFP using Gateway LR clonase mix II (#11791-020, Thermo Fisher 
Scientific) according to the manufacturer’s instructions to get pT2/GD-Nat10. The mouse 
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PRKACA transcript variant 1 (Accession # NM008854) open reading frame with 
nucleotides 616 and 617 mutated from TT to CG to generate the L206R mutation flanked 
by Gateway cloning sequences was ordered as a gBlock, cloned into the pENTR entry 
vector (#A10462, Invitrogen), then into the Gateway destination SB transposon plasmid 
co-expressing Fah and GFP using Gateway LR clonase mix II (#11791-020, Thermo 
Fisher Scientific) according to the manufacturer’s instructions to get 
pT2/GD/PRKACAL206R. The pKT2/GD-GFP and pT2/shp53 plasmids were generated 
previously.108 Plasmids used for in vivo studies were prepared using endotoxin-free maxi-
preparation kits (#740424.50, Macherey-Nagel).  Twenty µg of each plasmid was 
delivered by hydrodynamic tail vein injection as described.107 At 150-180 days post-
injection, liver tumor analysis was performed as described.48 Livers were examined using 
GFP goggles (#FHS/EF-2G2, BLS-ltd), and GFP-positive tumors were counted and 
collected.  
Quantitative reverse transcriptase PCR (qRT-PCR) 
RNA was extracted from mouse liver tissue using the TRIzol reagent (#15596026, 
Invitrogen) or the RNeasy kit (#74106, Qiagen) and DNase treated with the DNA-free kit 
(#AM1906, Ambion) using protocols described by the manufacturers. cDNA was 
synthesized using the Transcriptor First Strand cDNA Synthesis Kit (#04379012001, 
Roche) or SuperScript IV VILO Master Mix (#11756050, Invitrogen) according the 
manufacturers’ instructions. Primer sequences are listed in Table 2.7. qPCR was 
performed on a C1000 Touch Thermal Cycler with CFX96 Real-Time System (#1855195, 
Bio Rad) using SYBR Green Master Mix (#4309155, Applied Biosystems) according to 
manufacturer’s instructions. 
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Tissue Microarray Preparation 
A human HCC tissue microarray was procured from the University Of Washington 
Department Of Pathology. HCC and paired tumor-free liver tissue cores from cases with 
etiologies of Hepatitis B (11), Hepatitis C (58), autoimmune hepatitis (3), alcohol (1), a 
combination thereof (9), or unknown (18) collected from surgeries performed between 
1999 and 2007 were formalin fixed, paraffin embedded, sectioned at 5 microns on a 
standard microtome, and heat-fixed onto glass slides. 
Histological Staining 
Formalin fixed, paraffin embedded tissue section slides were either stained with H&E and 
analyzed by color bright-field microscopy by two board-certified pathologists (KA and ML, 
American Board of Pathology) or stained by IHC as described108 using the antibodies listed 
in Table 2.8. Stained tissue section slides were photographed at 10x magnification and 
representative fields are displayed. 
Histological stain quantification with Aperio  
When specified, slides were scanned at 20x magnification with Aperio ScanScope XT 
(Leica) and analyzed using Aperio ImageScope Positive Pixel Count software (Leica). 
Measurements were taken from 5 representative 1000 by 1000 pixel boxes per section 
and averaged. To quantify fat percentage of liver tissue from H&E stained sections, the 
hue value was set to 0.05 and hue width 0.999999 to include all stained pixels. Intensity 
threshold of negative pixels was 255 to include all pixels. The white color of fat droplets 
was defined as weak positive pixels (wpp), with intensity threshold upper limit 255 and 
lower limit 218. Stained tissue was defined as strong positive pixels (spp), with intensity 
threshold lower limit 0. Liver fat percentage was defined as the percentage of spp out of 
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the total positive pixels (wpp plus spp). To quantify positive IHC staining for FOXA1, the 
hue value was set to 0.1 and hue width 0.16. Color saturation threshold was 0.04. Upper 
limit of intensity threshold for positive pixels was 230 and lower limit was 0. Negative pixel 
intensity threshold was 230. The average stained pixel intensity was measured as brown 
stained pixel intensity divided by the number of positive pixels to exclude fat droplets.  
FOXA1 IHC stain level was defined as 1000 divided by the average stained pixel intensity. 
To quantify the percent of p-FoxA2 IHC stained nuclei, OD values for nuclear hematoxylin 
(negative IHC stain) were 0.706 for red, 0.629 for green and 0.33 for blue. OD values for 
nuclear DAB (positive IHC stain) were 0.244583 for red, 0.509334 for green, 0.825081 for 
blue. The cytoplasm intensity threshold value was 230. The upper limit intensity threshold 
was 220 for weak, 188 for medium, and 162 for strong positive nuclei. The lower limit 
intensity threshold for strong positive nuclei was 0. Minimum elongation, compactness, 
and roundness was 0.4. Maximum nuclear size was set to 300 um2 and minimum nuclear 
size 20 um2. The upper limit for intensity thresholding was 164 and lower limit 0. 
Cytoplasmic rejection was the nuclear segmentation type. The percent positive nuclei was 
defined as the percent of positive stained nuclei out of the total nuclei (negative stained 
plus positive stained). 
Histological stain quantification with ImageJ 
When specified, images of IHC stained tissue section slides taken at 10x magnification 
were analyzed using ImageJ software (National Institutes of Health), to measure IHC stain 
level. We used the IHC Image Analysis Toolbox137 (available from 
imagej.nih.gov/ij/plugins/ihc-toolbox/index.html) default H-DAB settings to detect brown 
staining. The brown stain image was then converted to 32-bit grayscale. Lower intensity 
threshold was set to 10, upper threshold 185. Background pixels were set to NaN to 
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exclude fat droplets. Measurements were taken from 3 representative 100 by 100 pixel 
boxes per tissue section and averaged. IHC stain level was defined as 1000 divided by 
the average stained pixel intensity. 
Transposon insertion site analysis 
Transposon-genomic DNA junctions were amplified from genomic DNA isolated from SB-
induced liver tumor samples by linker-mediated PCR as described,138 and sequenced on 
the Illumina MiSeq with 150 cycle paired end reads. Identification of TAPDANCE CIS and 
gene centric CIS was performed as previously described.87,115 To account for T2/Onc 
local-hopping, the donor chromosome 15 was excluded from analysis. Known CIS artifacts 
caused by T2/Onc sequence elements (En2, Foxf2) or amplified regions within the mouse 
genome (Serinc3, Sfi) were excluded.87,115  
CIS enrichment analysis 
For each CIS gene with more than 3 transposon insertions in SB-induced liver tumors in 
eCDD-treated mice, the number of SB-induced liver tumors in eCDD-treated mice with 
and without insertions was compared to the number of SB-induced liver tumors in ND-
treated mice from a previous study48 with and without insertions. Steatosis-enriched CIS 
were defined as CIS with a significantly higher proportion of tumors with insertions in 
eCDD treated than ND treated mice with a Q value < .05 by Benjamini-Hochberg-corrected 
Fisher’s exact test. 
Sex distribution of human HCC cases by presence of steatosis 
Clinical information abstracted from records of 460 HCC patients at the Mayo Clinic, 
Rochester between January 2007 and December 2009 was reported previously.109  The 
number of male and female HCC cases in the overall cohort and in the subset without 
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hepatic steatosis was compared to the subset with non-alcoholic hepatic steatosis as the 
primary HCC etiology by Chi squared test. 
Analysis of genomic data from TCGA   
RNA-seq normalized counts, copy number variation, mutation, and survival data 
generated by TCGA Research Network (http://cancergenome.nih.gov/) were extracted 
from TCGA and cBioportal.139,140 Normalized expression count values under 0.1 were 
adjusted to 0.1 to minimize the effects of low count genes in differential expression 
analysis. Genes with significant expression changes between tumor and normal liver were 
identified by Benjamini-Hochberg adjusted Student’s t test. 
Generation and RNA-sequencing of high fat diet-fed wildtype mouse liver tumors 
Animal studies were conducted using procedures approved and monitored by the 
Institutional Animal Care and Use Committee at the Pacific Northwest Research Institute. 
Starting at five weeks of age, male C57BL/6J mice were fed a high saturated fat and 
sucrose diet for 400 days (#D12331; Research Diets) ad libitum, after which mice were 
euthanized for liver tissue collection. Tumors and adjacent tumor free liver samples were 
frozen in liquid nitrogen and stored at -80˚C. RNA was extracted from liver samples using 
the Direct-zol RNA Miniprep kit (#R2050, Zymo Research). Library preparation was 
performed with the TruSeq Stranded mRNA kit (#RS-122-2101, Illumina) and samples 
were sequenced on the Illumina NextSeq 500 platform with a high output 2x75bp paired-
end kit. Quantification of all RefSeq genes from the GRCm38/mm10 genome assembly 
was performed using the kallisto algorithm.141  
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Ingenuity Pathway Analysis 
Gene lists specified in the results section were subjected to a core analysis including direct 
and indirect relationships using Ingenuity Pathway Analysis (IPA) Software (Ingenuity 
Systems, Redwood City, CA, USA; www.ingenuity.com).  
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Table 2.1: Frequency of liver tumor nodules in experimental mice
Experimental mouse* Sex Age (days) Diet # of visible tumors
ATR M121 Male 82 eCDD 0
ATR M122 Male 154 eCDD 0
ATR M132 Male 189 eCDD 0
ATR M133 Male 189 eCDD 0
ATR M146 Male 213 eCDD 1
ATR M147 Male 213 eCDD 1
ATR M172 Male 260 eCDD 2
ATR M181 Male 300 eCDD 1
ATR M182 Male 340 eCDD 0
ATR M184 Male 340 eCDD 0
ATR M204 Male 377 eCDD 5
ATR M194 Male 380 eCDD 38
ATR M201 Male 381 eCDD 1
ATR M202 Male 381 eCDD 4
ATR M203 Male 381 eCDD 2
ATR M211 Male 400 eCDD 1
ATR M216 Male 400 eCDD 5
ATR M221 Male 400 eCDD 1
ATR M223 Male 400 eCDD 0
ATR M221* Male 429 eCDD 0
ATR M225 Male 434 eCDD 3
ATR M226 Male 434 eCDD 5
ATR M227 Male 434 eCDD 5
ATR F123 Female 82 eCDD 0
ATR F124 Female 154 eCDD 0
ATR F151 Female 359 eCDD 2
ATR F153 Female 359 eCDD 0
ATR F154 Female 359 eCDD 2
ATR F134 Female 375 eCDD 4
ATR F171 Female 380 eCDD 1
ATR F173 Female 380 eCDD 1
ATR F174 Female 380 eCDD 7
ATR F162 Female 381 eCDD 3
ATR F163 Female 381 eCDD 0
ATR F164 Female 382 eCDD 17
ATR F175 Female 400 eCDD 2
ATR F177 Female 400 eCDD 0
ATR F221* Female 429 eCDD 8
ATR F223* Female 429 eCDD 29
ATR F224* Female 430 eCDD 12
ATR F225* Female 431 eCDD 4
ATR F185 Female 431 eCDD 20
ATR F221 Female 434 eCDD 20
ATR F191 Female 434 eCDD 9
ATR F195 Female 434 eCDD 4
ATR F211 Female 435 eCDD 5
ATR F212 Female 435 eCDD 1
ATR F222 Female 436 eCDD 3
ATR F223 Female 436 eCDD 3
ATR M11 Male 105 ND 0
ATR M15 Male 105 ND 0
ATRP M66 Male 160 ND 3 50
ATR M36 Male 215 ND 0
ATRP M134 Male 223 ND 30
ATR M325 Male 231 ND 5
ATR M31 Male 250 ND 3
ATR M41 Male 289 ND 0
ATR M362 Male 317 ND 8
ATRP M51 Male 330 ND 22
ATRP M175 Male 375 ND 1
ATR M71 Male 440 ND 1
ATR M81 Male 460 ND 1
ATR M93 Male 471 ND 17
ATR M341 Male 472 ND 1
ATR M296 Male 492 ND 16
ATR M297 Male 511 ND 13
ATRP M254 Male 528 ND 14
ATRP M292 Male 539 ND 5
ATR M312 Male 600 ND 15
ATR M302 Male 603 ND 13
ATRP M353 Male 611 ND 3
ATR M271 Male 623 ND 17
ATRP M362 Male 652 ND 9
ATR M352 Male 668 ND 18
ATRP M301 Male 700 ND 2
ATR M364 Male 702 ND 3
ATRP F121 Female 178 ND 0
ATR F13 Female 285 ND 0
ATR F1 Female 310 ND 0
ATR F42 Female 342 ND 0
ATR F106 Female 512 ND 5
ATRP F31 Female 575 ND 2
ATR F115 Female 588 ND 6
ATRP F183 Female 596 ND 6
ATRP F143 Female 612 ND 4
ATRP F115 Female 621 ND 1
ATRP F362 Female 652 ND 1
*Experimental mice carrying albumin -Cre (Alb -Cre), T2Onc and Rosa26 -lsl-SB11 
transgenes
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Table 2.4: Steatosis-enriched CIS list
Gene
% eCDD tumors 
with CIS
% ND tumors 
with CIS
BH q 
value
% eCDD tumors 
with CIS
% ND tumors 
with CIS
BH q 
value
Gnai3 9.1 0.0 1.6E-04 9.1 0.0 3.7E-04
Gbe1 9.1 0.0 1.6E-04 9.1 0.0 3.7E-04
Arih1 8.1 0.0 3.1E-04 7.1 0.0 1.9E-03
Atrn 8.1 0.0 3.1E-04 5.1 0.0 9.5E-03
Prr16 8.1 0.0 3.1E-04 - - -
Mtus1 7.1 0.0 7.9E-04 7.1 0.0 1.9E-03
Kynu 7.1 0.0 7.9E-04 5.1 0.0 9.5E-03
Cfh 7.1 0.0 7.9E-04 4.0 0.0 1.4E-02
Suclg2 6.1 0.0 1.5E-03 7.1 0.0 1.9E-03
Chchd3 6.1 0.0 1.5E-03 6.1 0.0 5.1E-03
Mllt10 6.1 0.0 1.5E-03 6.1 0.0 5.1E-03
Rnf111 6.1 0.0 1.5E-03 5.1 0.0 9.5E-03
Gfi1 6.1 0.0 1.5E-03 5.1 0.0 9.5E-03
Acbd5 6.1 0.0 1.5E-03 4.0 0.0 1.4E-02
Bmpr2 6.1 0.0 1.5E-03 - - -
Gigyf2 6.1 0.0 1.5E-03 - - -
Rundc3b 6.1 0.0 1.5E-03 - - -
Ppm1b 5.1 0.0 3.1E-03 5.1 0.0 9.5E-03
Hipk3 5.1 0.0 3.1E-03 5.1 0.0 9.5E-03
Usp47 5.1 0.0 3.1E-03 5.1 0.0 9.5E-03
Grb14 5.1 0.0 3.1E-03 5.1 0.0 9.5E-03
20-E4.10.00.43parhT
Sh3d21 - - -
Atp2a2 5.1 0.0 3.1E-03 4.0 0.0 1.4E-02
Sfpq 5.1 0.0 3.1E-03 4.0 0.0 1.4E-02
Yeats2 5.1 0.0 3.1E-03 - - -
Trip11 5.1 0.0 3.1E-03 - - -
Gopc 5.1 0.0 3.1E-03 - - -
Ppp2r2a 5.1 0.0 3.1E-03 - - -
Cacul1 5.1 0.0 3.1E-03 - - -
Rhobtb1 5.1 0.0 3.1E-03 - - -
Pafah1b1 5.1 0.0 3.1E-03 - - -
Zeb1 4.0 0.0 7.8E-03 5.1 0.0 9.5E-03
Dhx9 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
Nrip1 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
Sec63 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
Ubl3 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
Sucla2 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
Scyl2 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
Palmd 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
Rnf169 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
Tax1bp1 4.0 0.0 7.8E-03 4.0 0.0 1.4E-02
---01taN
Caprin1 - - -
Ctif 4.0 0.0 7.8E-03 - - -
Notch2 4.0 0.0 7.8E-03 - - -
Stag2 4.0 0.0 7.8E-03 - - -
Mkln1 4.0 0.0 7.8E-03 - - -
Ahr 4.0 0.0 7.8E-03 - - -
4933406I18Rik - - - 16.2 0.0 9.3E-08
Ptprd - - - 12.1 0.0 1.2E-05
Nckap1 - - - 8.1 0.0 1.1E-03
Fgf2 - - - 7.1 0.0 1.9E-03
Tcf12 - - - 7.1 0.0 1.9E-03
Thrb - - - 7.1 0.0 1.9E-03
Wdfy3 - - - 6.1 0.0 5.1E-03
Tmem135 - - - 6.1 0.0 5.1E-03
4.0 0.0 7.8E-03
tnemhcirne SICgtnemhcirne SIC ECNADPAT
5.1 0.0 3.1E-03
65
Gnaq - - - 6.1 0.0 5.1E-03
Stard4 - - - 5.1 0.0 9.5E-03
Prpf6 - - - 5.1 0.0 9.5E-03
Rab2a - - - 5.1 0.0 9.5E-03
Bcar3 - - - 5.1 0.0 9.5E-03
Ncor1 - - - 5.1 0.0 9.5E-03
Pde3b - - - 5.1 0.0 9.5E-03
Lcorl - - - 5.1 0.0 9.5E-03
Acadm - - - 4.0 0.0 1.4E-02
Xylb - - - 4.0 0.0 1.4E-02
Paip1 - - - 4.0 0.0 1.4E-02
Ube2d3 - - - 4.0 0.0 1.4E-02
Abhd2 - - - 4.0 0.0 1.4E-02
Celf1 - - - 4.0 0.0 1.4E-02
Prkd3 - - - 4.0 0.0 1.4E-02
Larp4b - - - 4.0 0.0 1.4E-02
Vps54 - - - 4.0 0.0 1.4E-02
Pex14 - - - 4.0 0.0 1.4E-02
Rreb1 - - - 4.0 0.0 1.4E-02
Bmpr1a - - - 4.0 0.0 1.4E-02
Btbd7 - - - 4.0 0.0 1.4E-02
D330022K07Rik - - - 4.0 0.0 1.4E-02
Dennd4c - - - 4.0 0.0 1.4E-02
Nsd1 - - - 4.0 0.0 1.4E-02
Rock2 - - - 4.0 0.0 1.4E-02
Cdk13 - - - 4.0 0.0 1.4E-02
Adcy9 - - - 4.0 0.0 1.4E-02
Mtmr3 - - - 4.0 0.0 1.4E-02
Cnot2 - - - 4.0 0.0 1.4E-02
Lnpep - - - 4.0 0.0 1.4E-02
Fam193a - - - 4.0 0.0 1.4E-02
Chd2 - - - 4.0 0.0 1.4E-02
Pan3 - - - 4.0 0.0 1.4E-02
Snx13 - - - 4.0 0.0 1.4E-02
Kcnn2 - - - 4.0 0.0 1.4E-02
Stim2 - - - 4.0 0.0 1.4E-02
Tek - - - 4.0 0.0 1.4E-02
Slc22a23 - - - 4.0 0.0 1.4E-02
Ablim1 - - - 4.0 0.0 1.4E-02
Tcf7l2 - - - 4.0 0.0 1.4E-02
Mkl2 - - - 4.0 0.0 1.4E-02
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Table 2.7: Primer sequneces for RT-PCR
Transcript Primer sequences Amplicon size Annealing temperature (°C)
5′-TCCAGCCTTCCTTCTTGGGTATGGA-3′
5’-CGCAGCTCAGTAACAGTCCGCC-3’
5’-GGATGGTTGTGTCGGCCGGG-3’
5’-AGGAGTAGGCCTCCTGCGTGT-3’
5’- ACTGCAGAGCACCAACTCTC-3’
5’-GGGTGTGGTGACCGATTGTA-3’
5’-GGCCTTGCTGTCATACCAGT-3’
5’- TTCCCAAGAGAAGAGCCGAC-3’
 5’-TTACTCCCACAGCTCCTGG-3’
5’-TGGCTTTGGGTTGCTTTGAG-3’
PCR was performed with an initial denaturing step of 95°C for 15 min; 40-cycles of denaturing at 94°C for 
15 sec, annealing at above specified temperatures, and extension at 72°C for 30 sec with optics on. 
75pb 294MopA
55pb 572haF
75pb 18201taN
β 75pb 563nitca-
06pb3111AxoF
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Table 2.8: Antibodies for IHC
noituliDydobitnAnietorP
SB R&D Systems MAB2798 1:100
ALB Novus Biologicals NBP132458 1:200
FOXA1 Abcam AB23738 1:200
phospho T156 FOXA2 Abgent AP13206C 1:100
NAT10 Abcam AB194297 1:250
 FAH AbboMax 602-910 1:250
phospho T197 PKA Abcam AB59218 1:1000
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Figure 2.1. SB transposition and eCDD treatment in mice promotes steatosis-asso-
ciated liver tumorigenesis. (A) Mouse genotype and treatment model. EtOH, 5% etha-
nol drinking water. CDD, choline-deficient diet. RLS, Rosa26-Lsl-SB11. Alb-cre, Albu-
min-cre. (B) Tumor penetrance and (C) average tumor burden in control (n = 32) and 
SB-mutagenized mice (n = 49) treated with eCDD. (D) Gross livers from SB-mutagenized 
and control mice treated with eCDD. Arrows, tumors. Gross liver scalebars, 0.5 cm. (E) 
H&E and IHC for SB and ALB stained mouse liver sections. Liver section scale bars, 100 
µm. T, tumor. N, non-tumor tissue. **P < .01. ****P < .0001. Error bars represent SEM. M, 
male mouse. F, female mouse. 79
Figure 2.2. FOXA1 and FOXA2 repressed in steatotic liver. (A) Hematoxylin and eosin 
(H&E) and IHC for FOXA1 (FOXA1) and phosphorylated T156 FOXA2 (p-FOXA2) 
stained liver sections from control mice treated with ND, ages 105, 343, 471 days (top 
three rows) or eCDD, ages 375, 260 days (bottom two rows). Scalebars, 100µm. (B) Lipid 
droplet percent of liver tissue from the H&E stained liver slides from mice on ND vs eCDD 
pictured in panel A. (C) FOXA1 IHC stain level vs lipid droplet percent of liver tissue mea-
sured from the mouse liver slides pictured in panel A. (D) p-FOXA2 IHC stain level vs lipid 
droplet % of liver tissue from the mouse liver slides pictured in panel A. (E) Percent of 
cells with p-FOXA2 stained nuclei vs lipid droplet % of liver tissue from the mouse liver 
slides pictured in panel A. (F) qRT-PCR of control liver tissue from mice treated with ND 
vs eCDD for FoxA1, normalized to Actb and average ND level. (G) qRT-PCR of control 
mouse liver tissue from mice treated with ND for FoxA1, normalized to Actb average ND 
level, vs mouse age. (H) qRT-PCR of control mouse liver tissue from mice treated with 
ND vs eCDD for ApoM, normalized to Actb and average ND level. r, Pearson’s correlation 
coefficient. #P > .05. *P < .05. **P < .01. Error bars represent SEM.
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Figure 2.3. Reduced male HCC sex bias in fatty liver. (A) Male and female proportions 
of human HCC cases by steatosis status. (B) Average tumor burden per ND treated, 
SB-mutagenized male (n = 27) and female (n = 11) mouse. (C) Average tumor burden per 
eCDD treated, SB-mutagenized male (n = 23) and female (n = 26) mouse. #P > .05. *P < 
.05. **P < .01. Error bars represent SEM.
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Figure 2.4. Steatosis-associated liver cancer CIS genes altered in human HCC. (A) 
Representation of the 203 CIS genes and subsets with significant expression changes in 
and (B) subsets altered in more than 5% of tumors by amplification, mutation, or deletion 
in all TCGA HCC cases, steatosis- associated HCC, and alcohol-associated HCC.
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Figure 2.5. Oncoprint showing steatosis-associated CIS gene amplifications, deep 
deletions, and mutations occurring in at least 5% of all TCGA HCC cases. Amplifica-
tion, high copy number change. Mutation, any frame shift, stop, or amino acid change.
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Figure 2.6. Oncoprint showing steatosis-associated CIS gene amplifications, deep 
deletions, and mutations occurring in at least 5% of steatosis-associated TCGA 
HCC cases. Amplification, high copy number change. Mutation, any frame shift, stop, or 
amino acid change.
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Figure 2.7. Oncoprint showing steatosis-associated CIS gene amplifications, deep 
deletions, and mutations occurring in at least 5% of alcohol-associated TCGA HCC 
cases. Amplification, high copy number change. Mutation, any frame shift, stop, or amino 
acid change.
85
C
ntf
P
rr16
Txnrd1
Lgi2
A
nkrd36
Idua
R
hobtb1
Y
eats2
C
ntd1
C
ited2
A
dk
A
cadm
Tek
N
r1i2
Scp2
Slc35d1
N
at2
A
adat
K
cnn2
0.00001
0.0001
0.001
0.01
0.1
1
10
100
Expression in human alcohol-associated HCC
Fo
ld
 c
ha
ng
e 
in
 tu
m
or
 v
s 
no
rm
al
 li
ve
r
0.0001
0.001
0.01
0.1
1
10
Expression in human steatosis-associated HCC
Slc22a23
C
aprin1
Larp4b
Atp2a2
D
hx9
N
ploc4
E
if4enif1
N
at10
N
ckap1
W
ac
M
llt10
U
be2d3
M
gat1
E
sd
Kbtbd3
Xbp1
Ahr
P
ex14
Abcd3
Adk
Shb
U
gt1a6a
Slc35d1
Acadm
Scp2
N
r1i2
N
at2
Aadat
Kcnn2
Fo
ld
 c
ha
ng
e 
in
 tu
m
or
 v
s 
no
rm
al
 li
ve
r
B
A
Direction indicates predicated effect of transposon insertions:
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Arrows
Disrupts
Human expression change in direction of prediction
Human expression change opposite of prediction
Drives expression/ Drives N terminal truncation
Figure 2.8. Transposon insertions in CIS genes predict expression changes in 
human HCC. RNA expression fold change in tumor vs normal liver of the steatosis asso-
ciated CIS genes with (A) significant expression changes in TCGA steatosis-associated 
HCC cases or (B) significant expression changes more than 2 fold in TCGA alcohol-asso-
ciated HCC cases.
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Figure 2.9. Wnt/β-catenin signaling alterations in steatosis-associated liver cancer. 
Schematic of the Wnt/β-catenin signaling pathway with protein families represented as 
circles. Proteins or families for which genes are altered in steatosis HCC mouse models 
or human HCC indicated by colored quadrants. HFD C57BL/6J, high fat diet-fed wildtype 
C57BL/6J mouse strain. 87
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Figure 2.10. PKA/cAMP signaling alterations in steatosis-associated liver cancer. 
Schematic of the PKA/cAMP signaling pathway with protein families represented as 
circles. Proteins or families for which genes are altered in steatosis HCC mouse models 
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C57BL/6J mouse strain.
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Figure 2.11. PKA is activated in HCC. (A) Phospho T197 PKA (p-PKA) IHC stain inten-
sity of tumor and matched non-tumor liver samples on a tissue microarray (TMA) of 
human HCC cases stratified by mention of steatosis in pathology report. Yes, steatosis 
reported. No, no mention of steatosis or steatosis reported absent. Unknown, pathology 
report not available. (B) Representative IHC for p-PKA stained sections of human HCC 
(top) or matched normal liver (bottom) from TMA cases with hepatic steatosis indicated in 
pathology report. Scalebars, 100µm. T, tumor. N, non-tumor liver tissue. **P > .01. ****P 
< .0001. 
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Figure 2.12. PRKACA L206R overexpression drives tumorigenesis in steatotic 
mouse livers. (A) Transposons for tumor induction and treatment plan. EtOH, 5% etha-
nol CDD, choline-deficient diet.  Red triangles, SB inverted repeat/ direct repeat 
sequences. Caggs, Caggs promoter. PRKACA L206R, mouse PKA cDNA sequence with 
L206R mutation. IRES, internal ribosomal entry site. F. luc, firefly luciferase gene 
sequence. pA, polyadenylation signal. PGK, PGK promoter. Fah, mouse Fah cDNA. 
GFP, GFP cDNA sequence. d, days. mo, months. (B) Average tumors per PKA/shp53-in-
jected mouse treated with eCDD (n = 13) or ND (n = 14) or GFP/shp53-injected mouse 
treated with eCDD (n = 20) or ND (n = 18). **P < .01. Error bars represent SEM.
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Figure 2.13. Nat10 is a candidate oncogene in a mouse model of steatosis-associat-
ed HCC. Schematic of Nat10 gene with transposon insertions eCDD treated SB mutagen-
ized mice.
91
AC
B
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
R
el
at
iv
e 
ex
pr
es
si
on
NAT10
****
****
No risk
HCC
Overall survival (months)
Pe
rc
en
t s
ur
vi
va
l
Cases with alteration of NAT10
Cases without alteration of NAT10
8
9
10
11
12
Shallow
 deletion Diploid Gain
****
Lo
g2
 (R
SE
M
)
*P = 0.0124
0 20 40 60 80 100 120 140
0
25
50
75
100
E
D
Normal
Tumor
Yes No Unknown
6
7
8
9
N
A
T1
0 
IH
C
 s
ta
in
 in
te
ns
ity
TMA cases
Steatosis
reported
****
Case 56 Case 36
T
N
NAT10
**
Normal
liver
Steatosis 
associated 
HCC
NAT10
Figure 2.14. NAT10 is altered in human steatosis-associated HCC. (A) Overall 
survival for TCGA HCC cases with and without NAT10 overexpression or copy number 
gain alteration. (B) NAT10 gene expression by copy number for TCGA HCC cases. (C) 
NAT10 expression in TCGA no risk HCC and steatosis-associated HCC cases compared 
to normal liver. D) Representative IHC for NAT10 stained sections of human HCC (top) 
or matched normal liver (bottom) from TMA cases with hepatic steatosis indicated in 
pathology report. Scalebars, 100µm. T, tumor. N, non-tumor liver tissue. E) NAT10 IHC 
stain intensity of tumor and matched normal liver samples on TMA of human HCC cases 
stratified by mention of steatosis on pathology  report. Yes,  steatosis  reported.  No, no 
mention  of steatosis  or steatosis  reported absent. Unknown, pathology report not avail-
able. *P < .05. **P < .01. ****P < .0001. 92
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Figure 2.15. Nat10 overexpression drives tumorigenesis in steatotic mouse livers. 
(A) Transposons for tumor induction plus treatment plan. EtOH, 5% ethanol CDD, 
choline-deficient diet.  Red triangles, SB inverted repeat/ direct repeat recognition 
sequences. Caggs, Caggs promoter. Nat10, mouse Nat10 cDNA sequence. IRES, inter-
nal ribosomal entry site. F. luc, firefly luciferase gene sequence. pA, polyadenylation 
signal. PGK, PGK promoter. Fah, mouse Fah cDNA. GFP, Green fluorescent protein 
gene sequence. (B) Average tumors per Nat10/shp53 injected mouse treated with eCDD 
(n = 24) or ND (n = 25) or GFP/shp53 injected mouse treated with eCDD (n = 25) or ND 
(n = 29). (C) Nat10 RNA expression from non-tumor liver tissue (L) or liver tumor (T) from 
Nat10/shp53 or GFP/shp53 injected eCDD treated mice, normalized to Actb and to wild 
type mouse liver Nat10 (n = 5 each). (D) Immunohistochemistry for NAT10, FAH, and ALB 
stained liver sections from eCDD treated mice injected with GFP/shp53 showing non-tu-
mor liver tissue (top), or injected with Nat10/shp53 showing tumor plus adjacent non-tu-
mor liver (middle and bottom). Scalebars, 100µm. T, tumor. N, non-tumor liver tissue. *P 
< .05. ****P < .0001. Error bars represent SEM. 93
Figure 2.16. Transgenes are expressed in livers of Fah deficient mice after hydro-
dynamic injection (A) NAT10 IHC stain level in mouse livers from injected with 
Nat10/shp53 or GFP/shp53 from both diets combined. (B) Fah transcript expression from 
liver tissue from mice treated with eCDD injected with Nat10/shp53 or GFP/shp53, 
normalized to Actb and to wild type mouse liver Fah. #P > .05. **P < .01. 
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CHAPTER 3: 
 
 
 
Sleeping Beauty transposon-based gene delivery for reverse genetic liver cancer 
models 
 
 
 
 
 
 
 
*The following chapter contains material from previously published work and 
manuscripts in preparation: 
Riordan JD, Keng VW, Tschida BR, Scheetz TE, Bell JB, Podetz-Pedersen KM, Moser CD, Copeland NG, 
Jenkins NA, Roberts LR, Largaespada DA, Dupuy AJ. Identification of rtl1, a retrotransposon-derived 
imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet 2013;9:e1003441. 
Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Solé M, Lee WL, Kuka TP, Moriarity BS, 
Villanueva A, Dupuy AJ, Riordan JD, Bell JB, Silverstein KA, Llovet JM, Largaespada DA. Sex bias 
occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 
2013;57:120–30. 
Jesse D. Riordan JD, Feddersen CR, Tschida BR, Beckmann PJ, Keng VW, Largaespada DA, Dupuy AJ. 
Liver fibrosis alters driver mutation profile in transposon-induced hepatocellular carcinoma. Under review. 
Conboy CB, Tschida BR, Hu H, Alsinet C, Cornellà H, Pinyol R, Burns MB, Rathe SK, Abrahante J, Temiz 
NA, Linden MA, Amin K, Kuka T, Vélez Reyes GL, Keng VW, Harris RS, Llovet J, Starr TK, Largaespada 
DA. R-spondin 2 drives Wnt signaling and tumorigenesis in multiple tissues. In preparation. 
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Abstract 
Hepatocellular carcinoma (HCC) is the second most common cancer-related cause of 
death globally and is occurring with increasingly frequency. To better understand the 
pathogenesis of HCC, candidate oncogenes identified in human HCC, complementary 
mouse models, and tumor-promoting viruses need to be functionally tested to determine 
their roles in driving liver tumorigenesis. New models need to be generated to study 
disease mechanisms and test prevention and treatment strategies in context of the 
relevant tumor-promoting molecular alterations.  Sleeping Beauty transposon-based gene 
delivery to hepatocytes using the selective Fah-mutant mouse model allows rapid 
generation of mice with livers expressing transgenes of interest. We used this model to 
study the roles of candidate oncogenes identified by forward genetic screens, genes and 
pathways altered in human HCC, or components of a known oncogenic virus in promoting 
HCC in several different contexts relevant to the human disease. We showed the Dlk1-
Dio3 domain gene Rtl1 can drive hepatocarcinogenesis in otherwise normal male mouse 
livers, partially explaining the link between aberrant Dlk1-Dio3 domain gene expression 
and HCC. We showed EGFR, which is amplified and overexpressed in the male sex 
biased Poly7 molecular subclass of HCC, promotes hepatocarcinogenesis more efficiently 
in males than females. In contrast, both CTNNB1 and RSPO2, which promote Wnt/β-
catenin signaling, induced HCC without sex bias. We functionally validated the role of Gli2 
in promoting fibrosis-associated HCC in vivo. We also evaluated the oncogenic potential 
of a mutant variant of the Hepatitis B Virus HBx gene and found it to be more oncogenic 
than the wildtype gene. This selective mouse model allowed us to test several candidate 
oncogenes in otherwise normal livers, in both male and female mice, and in fibrotic livers, 
making this a versatile as well as efficient mouse model of HCC.  
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Introduction 
Hepatocellular carcinoma (HCC) is a deadly disease with a 95% case fatality rate.13 It is 
the second most common cause death from cancer worldwide, and is one of few cancer 
types that is becoming more prevalent in the United States.14–16 HCC develops more 
frequently in males than females, although the molecular data explaining this sex bias is 
limited.8,17 Chronic liver disease and cirrhosis usually precede HCC development. 
Common causes of liver damage include Hepatitis B Virus (HBV) infection, Hepatitis C 
Virus (HCV) infection, alcoholic liver disease, and non-alcoholic fatty liver disease.8  
The high genetic complexity of liver tumors is being revealed by large-scale sequencing 
projects by The Cancer Genome Atlas Consortium (TCGA) and other groups which have 
identified a great number of genes mutated or with altered expression levels in a small 
proportion of HCC cases,59–61 making the distinction between cancer-promoting events 
and passenger alterations challenging. It can be difficult to determine the specific driving 
alterations with gain or loss of large regions or whole chromosomes, a common 
occurrence in HCC.45,46,53,62 Gene expression profiling of HCC has facilitated the 
identification of 5 major molecular subtypes, but the tumor promoting alterations have not 
been defined for each subtype.  The Wnt/β-catenin signaling subtype is often driven by 
CTNNB1 mutation, the proliferative subtype is likely driven by tyrosine kinase activation, 
and the polysomy of chromosome 7 subtype is likely driven by overexpression of EGFR 
and a set of other unknown oncogenes on chromosome 7. Drivers of the interferon 
signaling and unannotated classes are unknown.53,54 
Comparative analysis of molecular data from human tumors and Sleeping Beauty (SB) 
transposon insertional mutagenesis-based animal models is useful for identifying cancer 
promoting alterations for many types of cancer.90,91 Mutagenic transposons can cause 
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gain- or loss-of-function, depending on the location and orientation of transposon insertion 
relative to a gene, and can tag cancer genes within tumor cells. Genes associated with 
common insertion sites (CISs), representing regions of the genome with higher frequency 
of transposon integration than would be expected by random chance, may confer a 
proliferative advantage leading to tumor formation.87,88,92,142  Forward genetic screens 
using SB insertional mutagenesis have revealed many candidate liver cancer drivers. 
These have been conducted in context of an otherwise normal liver, predisposing known 
HCC-promoting mutations, liver fibrosis (manuscript under review), hepatic steatosis 
(manuscript in preparation), and with HBV-induced liver inflammation.48,92,95,100,101  
One such SB transposon-based mutagenesis screen, in which a mutagenic transposon 
was mobilized by ubiquitously expressed SBase, generating HCC in mice, identified the 
Dlk1-Dio3 imprinted domain as a site commonly mutated by transposon insertions.92 This 
domain contains genes encoding protein-coding transcripts, long non-coding RNAs 
(lncRNAs), microRNAs, and small nucleolar RNAs.143 Gene expression profiling of the SB-
induced HCCs revealed that transposon insertions in the Dlk1-Dio3 domain consistently 
drove overexpression of one poorly characterized gene, Retrotransposon-like 1 (Rtl1), that 
is predicted to encode a transmembrane protein with protease activity. RTL1 transcript 
was also found to be overexpressed in 30% of human HCC samples.99 Correlative studies 
have shown a link between aberrant Dlk1-Dio3 domain gene expression and HCC, but 
few functional studies have addressed the tumorigenic role of these changes.144–147  
A conditional forward genetic screen for HCC identified CIS genes in liver tumors isolated 
from both sexes of mice. In accordance with the pattern seen in humans, tumor incidence 
was higher in males than females. Egfr was identified as a CIS gene that was enriched for 
insertions in tumors from male compared to female mice.54  The Poly7 molecular subclass 
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of HCC, which occurs more frequently in men than women, is associated with EGFR copy 
number gains and increased EGFR mRNA expression.53,54 Studies functionally evaluating 
the differential hepatocarcinogenic effects of Egfr in males and females are lacking. 
The Wnt/β-catenin signaling is an important HCC-promoting pathway. Gene expression 
profiles of approximately half of HCC cases reflect activation of the Wnt/β-catenin 
signaling pathway, and approximately one third have activating mutations in 
CTNNB1.148,149 R-spondins are secreted proteins that can activate Wnt/β-catenin signaling 
in vitro.150 Rspo2 was identified as CIS genes in gastrointestinal tract cancer and breast 
cancer insertional mutagenesis screens.94,151–153 There is evidence that RSPO2 is involved 
in HCC. Copy number analysis of 231 human HCC samples revealed recurrent high copy 
amplifications of RSPO2 in 3% of cases.154 Analysis of over 450 HCC samples and 90 
non-tumor liver tissue samples revealed RSPO2 overexpression in HCC samples and 
associated expression of Wnt/β-catenin signaling target genes (manuscript in 
preparation). We sought to determine if Rspo2 overexpression could induce liver 
tumorigenesis in vivo. 
Approximately 90% of HCC cases develop in context of liver fibrosis, a condition caused 
by chronic liver damage leading to excessive extracellular matrix accumulation and 
scarring of the liver parenchyma.18,19,31  While HCC is clearly associated with fibrosis, the 
direct contribution of fibrosis to HCC development is unclear. To address this and identify 
genetic drivers of HCC in the relevant context of hepatic fibrosis, a liver specific conditional 
forward genetic SB mutagenesis screen was conducted in the presence or absence of 
carbon tetrachloride (CCl4)-induced hepatic fibrosis (manuscript under review). Gli2 was 
identified as a candidate oncogene enriched for mutations in the CCl4-treated compared 
to the untreated mouse cohort. There is evidence that Hedgehog (Hh) signaling and GLI2 
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expression are involved in HCC. GLI2 protein is overexpressed in HCC and associated 
with poor survival155,156 and Hh signaling inhibition can inhibit HCC cell growth,157,158 but 
the role of GLI2 overexpression in promoting hepatic tumorigenesis has not been 
established. Based on transposon insertion data, we hypothesized that Gli2 
overexpression in vivo in context of hepatic fibrosis would induce HCC formation.  
Approximately 50% of HCC cases worldwide are attributable to HBV infection.14,20,159,160 
There is evidence that HBV viral gene expression, mutations resulting from integration of 
the viral genome, and chronic inflammation in response to viral infection all contribute to 
hepatocarcinogenesis, although the mechanisms by which HBV infection promotes HCC 
are not fully understood.24–26 The HBV regulatory gene X (HBx) encodes a protein that is 
needed for HBV replication and can induce proliferation and transformation of 
hepatocytes.23 We have shown HBx overexpression can promote tumorigenesis in the 
mouse liver.108 A mutant form of HBx with 2 point mutations resulting in 2 amino acid 
substitutions in the C-terminal transactivation domain of the protein is associated with 
increased liver damage and HCC.161 Whether this variant is more oncogenic than wildtype 
HBx has yet to be determined.   
While comparative genomic approaches help to distinguish driver from passenger genetic 
alterations in HCC, reverse genetic approaches are still needed to validate and study the 
oncogenic roles of the candidate drivers identified by forward genetic studies and to study 
the roles of specific components from cancer-promoting viruses. Germline transgenic 
mouse models are powerful tools for studying cancer genes in an orthotopic setting and 
in immunocompetent animals. They are, however, expensive and slow to generate, and 
do not reflect the acquisition of transforming alterations by individual somatic cells.64 
Mosaic mouse models in which genetically modified liver progenitor cells are transplanted 
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into the livers of syngeneic recipient mice help to overcome the time and cost associated 
with generation of genetically engineered mouse models but do not recapitulate the typical 
development of HCC in context of chronic liver disease.76,77 
SB-mediated gene delivery provides an efficient method useful for studying candidate 
cancer genes in vivo.102,103,106 SB can be used to excise transposon-based expression 
vectors for genes of interest or shRNA sequences for gene knockdown from plasmids and 
integrate them randomly at TA dinucleotides in the genome for stable expression.106 SB-
mediated gene delivery to hepatocytes of fumaryl acetoacetate hydrolase (Fah) mutant 
mice is a useful model for studying liver cancer genes.48,102,108 Fah mutant mice have a 
defect in the tyrosine metabolic pathway and die from liver failure unless maintained on 
nitisinone. Plasmids with expression cassettes for genes of interest and an Fah rescue 
cDNA within SB transposons are delivered to hepatocytes by hydrodynamic tail vein 
injection.107 Withdrawal of nitisinone treatment causes the death of hepatocytes lacking 
Fah and subsequent regeneration of the liver with cells stably expressing the Fah rescue 
cDNA plus the gene of interest in approximately 2 months.102 This selective model allows 
the relatively rapid and inexpensive generation of mice with livers expressing a transgene 
of interest. 
In this study, we used SB-mediated gene transfer into the livers of Fah mutant mice to 
study the roles of candidate HCC driving oncogenes either identified by forward genetic 
screens and altered in human cancer and or identified as variants of known HCC-
promoting HBV viral genes. We did so in context of otherwise normal livers, in male and 
female animals to study the HCC sex bias, and in context of hepatic fibrosis, improving 
our understanding of the molecular drivers of HCC in various relevant contexts. 
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Results 
Dlk1-Dio3 domain gene Rtl1 drives hepatocarcinogenesis in vivo 
Because Rtl1 was identified as a candidate oncogene in SB-induced HCCs92 and RTL1 
was overexpressed in human HCC samples,99  we sought to determine if hepatic Rtl1 
overexpression was sufficient to induce liver tumor formation in vivo. Transposon-based 
expression vectors for Rtl1 and Fah48 (Rtl1 only), Rtl1, Fah, and a short hairpin directed 
against Trp53 (Rtl1/shp53),108 or mCherry and Fah (mCherry only) were delivered by 
hydrodynamic tail vein injection to the livers of Fah mutant male mice expressing SB 
transposase.48,107 Nitisinone treatment was withdrawn, inducing the death of Fah-null 
hepatocytes and thereby allowing selective liver repopulation by stably transfected 
cells.102 
Mice were sacrificed approximately 9 months after hydrodynamic injection and examined 
for tumor formation. Rtl1 expression induced liver tumorigenesis, with 85.7% of Rtl1 only-
injected mice (12 of 14) developing tumors versus 23.1% of mCherry only-injected control 
mice (3 of 13) (P = .002, Fisher’s exact test). (Figure 3.1A-B, Table 3.1) Rtl1 only-injected 
mice developed an average of 2.86 tumors, while mCherry only-injected mice developed 
0.23 tumors per mouse (P < .0001, Student’s t test). (Figure 3.1C, Table 3.1)  Loss of p53 
function is one of the most common molecular alterations in HCC.46 Trp53 knockdown 
increased tumorigenesis in Rtl1-expressing animals. Rtl1/shp53-injected mice that were 
aged for approximately 9 months developed 6.67 tumors per mouse, a higher tumor 
burden than in mice injected with Rtl1-only (P = .027, Student’s t test) and had a similar 
tumor penetrance, with 83% of mice (5 of 6) developing tumors. (Figure 3.1B-C, Table 
3.1) 
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Egfr promotes male sex biased liver tumorigenesis 
Since Egfr was identified as a male specific liver tumor CIS gene and EGFR gains and 
overexpression are associated with a subclass of HCC which occurs more frequently in 
men than women,53,54 we tested the sex biased hepatocarcinogenic effects of EGFR in 
vivo. SB transposon-based expression vectors for truncated EGFR and full-length EGFR 
were coadministered with SB transposon-based expression vectors for Fah and a short 
hairpin directed against Trp53 (shp53) by hydrodynamic tail vein injection to Fah mutant 
mice of both sexes expressing SB transposase. Nitisinone was withdrawn to select for 
cells with stable transgene expression.48,107 Mice were sacrificed and examined for tumor 
formation at approximately 130 days post-hydrodynamic injection.  
For both truncated and full-length EGFR, male injected mice developed more HCC than 
female mice. One hundred percent of male mice (9 of 9) and 25% of female mice (1 of 4) 
injected with truncated EGFR, Fah, and shp53 developed tumors (P =.014, Fisher’s exact 
test). (Figure 3.2A-B, Table 3.1) Male and female mice had a mean tumor burden of 5.33 
and 1.00 tumors per mouse, respectively (P = .033, Student’s t test). (Figure 3.2C, Table 
3.1) One hundred percent of male mice (3 of 3) and 33% of female mice (1 of 3) injected 
with full length EGFR, Fah, and shp53 developed tumors (no significant difference in tumor 
penetrance). (Figure 3.2B, Table 3.1) Male and female mice had a mean tumor burden of 
5.67 and 0.67 tumors per mouse, respectively (P = .003). (Figure 3.2C, Table 3.1) Liver 
tumors from both sexes were classified as HCCs by histopathological analysis. 
In contrast to EGFR, CTNNB1 activation is associated with a subclass of HCC with 
relatively low sex bias.53 As a control, we tested the hepatocarcinogenic effects of a 
constitutively active CTNNB1 mutation (CTNNB1S33Y) in mice of both sexes. SB 
transposon expression vectors for CTNNB1S33Y and shp53 were coadministered to Fah 
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mutant mice and hepatocytes with stable transgene expression were selected as 
described above. Mice were sacrificed and examined for tumor formation at approximately 
80 days post-hydrodynamic injection.  
Expression of CTNNB1S33Y induced HCC without strong sex bias. Male and female mice 
had comparable numbers of liver tumors, with a mean of 18.13 tumors per male and 26.50 
tumors per female mouse (P = .195, Student’s t test). (Figure 3.3A-B, Table 3.1) Tumor 
penetrance was 100% in both male and female mice (8 of 8 and 10 of 10, respectively). 
(Table 3.1) Liver tumors from both sexes were classified as HCCs by histopathological 
analysis. 
Rspo2 promotes hepatomegaly and tumorigenesis in the mouse liver 
Rspo2 is a gene involved in Wnt/β-catenin signaling that is altered in mouse 
gastrointestinal tract and breast cancers and amplified and overexpressed in human HCC 
(manuscript in preparation).94,151–154 To study the effects of Rspo2 in the mouse liver, we 
used hydrodynamic injection and Fah selection as described above to generate mice of 
both sexes expressing RSPO2 alone (RSPO2 only) and with shp53 (RSPO2/shp53) along 
with negative controls expressing GFP alone (GFP only) and with shp53 (GFP/shp53). 
Mice were sacrificed at approximately 30 day intervals between 60 and 150 days post 
hydrodynamic injection to examine liver mass and tumor formation. (Table 3.1) Hepatic 
GFP expression was assessed by visualization with GFP goggles at necropsy for all mice. 
Mouse livers injected with RSPO2 only and RSPO2/shp53 displayed hepatomegaly. The 
liver mass as a percent of the total body mass of RSPO2 only-injected mice was 1.6 fold 
higher than GFP only controls at all time points tested (P < .05 for all time points. P < 
.0001 at 150 days). The liver body mass percent of RSPO2/shp53 injected mice was 1.7 
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to 1.9 fold higher than GFP/shp53 controls (P < .05 for all time points. P < .0001 at 150 
days). (Figure 3.4A-B) 
At 150 days post hydrodynamic injection, the rate of background tumor formation in GFP 
only and GFP/shp53 injected mice was low, with 4.3% to 5.0% penetrance and average 
tumor burden of 0.05 to 0.09. (Figure 3.4D-E) Mice injected with RSPO2 only had a non-
significant increase in tumor formation, with 18.2% penetrance and a mean of 0.27 tumors 
per mouse (no significant difference in tumor penetrance or burden). (Figure 3.4D-E) 
RSPO2/shp53 injected mice had significantly increased tumor formation compared to 
GFP/shp53. Sixty-five percent of RSPO2/shp53 injected mice developed tumors vs 4.3% 
of GFP/shp53 control mice (P < .0001, Fisher’s exact test). (Figure 3.4C-D) RSPO2/shp53 
injected mice developed an average of 1.15 tumor per mouse, significantly more than 0.09 
tumors per GFP/shp53 injected moue (P = .001, Student’s t test). (Figure 3.4E) Similarly 
to what was observed for CTNNB1S33Y induced tumors, there was no significant difference 
in tumor penetrance or burden between male and female RSPO2/shp53 injected mice. 
Seventy percent of male and 60% of female mice developed tumors (P = 1.000, Fisher’s 
exact test). (Figure 3.4F) Male mice had an average tumor burden of 1.60 tumors per 
mouse and females 0.70 tumors per mouse (P = .127, Student’s t test). (Figure 3.4G) 
Tumors were classified as HCCs upon histologic examination.  
Gli2 overexpression induces tumor formation in fibrotic liver  
We aimed to test if Gli2 overexpression in fibrotic livers induces HCC, because Gli2 was 
identified as a candidate fibrosis-associated liver oncogene in an SB screen (manuscript 
under review), and GLI2 protein overexpression is associated with poor survival in human 
HCC.155,156 Mice with stable Gli2 expression and control mice expressing mCherry in 
hepatocytes were generated using SB-mediated gene delivery of a Gli2 or mCherry 
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expression vector and Fah rescue transgene to Fah-mutant male mice as described 
above.  
Approximately 90% of the Gli2 injected mice died within 75 days of hydrodynamic 
injection. (Table 3.2)  The morbidity of this cohort was likely not due to technical failure in 
delivery of the Fah rescue transgene, as transgene delivery was verified in a subset of 7 
animals by imaging for a luciferase reporter included in the Fah rescue transgene cassette 
and, of these animals, 100% died within 30 days of hydrodynamic injection. Morbidity was 
also likely not due to tumor formation, since none of these animals showed evidence of 
tumor formation upon examination at time of death. (Data not shown) We attribute the 
lethality, therefore, to a possible interference of Gli2 overexpression with liver repopulation 
or function.  
Of the remaining seven Gli2 injected mice, 3 were treated with CCl4 to induce liver fibrosis 
and 4 were left untreated. Half of the control mCherry injected mice were treated with CCl4 
and the other half untreated. (Table 3.1) These were all aged for 150 days post-
hydrodynamic injection. Gli2 expression induced more tumors in mouse livers than 
mCherry (Figure 3.5A-B). All untreated Gli2 expressing mice had developed tumors by 
150 days, with an average of 39.5 per mouse (P < 0.0001, Gli2 vs. mCherry ANOVA). 
(Figure 3.5B) As expected, the addition of CCl4 treatment increased tumor burden to 57.0 
tumors per mouse (P = .006, Gli2 CCl4 vs. Gli2 untreated Tukey post-hoc test). (Figure 
3.5B) Our model showed Gli2 expression can promote tumor formation in vivo with 
increased multiplicity in context of hepatic fibrosis. 
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Mutant HBx has higher oncogenic potential than wildtype HBx 
Two point mutations in HBx resulting 2 amino acid substitutions (150M to K and 151 V to 
I) (HBxM) is associated with liver damage and HCC more strongly than wildtype HBx.161 
To determine the relative oncogenic potential of HBxM and HBx, we generated male and 
female mice with hepatic HBxM and HBx expression along with a short hairpin directed 
against Trp53 (HBxM/shp53 and HBx/shp53) and control mice expressing GFP and shp53 
(GFP/shp53) using the Fah-mutant mouse model as described above.  
HBxM induced hepatomegaly. Both HBx/shp53 and HBxM /shp53 injected male mice had 
higher liver body mass percent than GFP/shp53 injected mice (7.8 and 7.7 vs 6.2, 
respectively; P = .001 and .0003, respectively, Student’s t test). (Figure 3.6B) HBxM 
injected female mice also had a significant increase in liver body mass percent compared 
to GFP/shp53 injected mice (6.2 vs 5.5, respectively; P = .029, Student’s t test). (Figure 
3.6B) 
HBxM induced more tumors than HBx. Both HBxM and HBx induced tumor formation in 
Fah mutant male mice by approximately 180 days post-injection. Tumor penetrance was 
80% and 100% in HBxM/shp53- and HBx/shp53-injected mice and 0% in GFP/shp53-
injected mice (P = .007 and P = .001, respectively, Fisher’s exact test). (Figure 3.6A, 3.6C, 
Table 3.1) No significant increase in tumor penetrance was seen in female mice, although 
57.1% of HBxM/shp53-injected female mice developed tumors vs 12.5% of GFP/shp53-
injected control mice (P = .119, Fisher’s exact test). (Figure 3.6A, 3.6C) Male mice injected 
with HBxM/shp53 developed a mean of 7.6 tumors per mouse, significantly more than mice 
injected with HBx/shp53, which developed a mean of 3.1 tumors (P = .032, Student’s t 
test) and than mice injected with GFP/shp53, with 0 tumors per mouse (P = .006, Student’s 
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t test). No significant differences in tumor burden were observed in female mice. (Figure 
3.6D) 
Methods 
Generation and maintenance of Fah-deficient mice 
All animal studies were conducted using procedures approved and monitored by the 
Institutional Animal Care and Use Committee at the University of Minnesota. Doubly 
transgenic mice deficient for Fah and expressing the SB11 transposase (Fah-/-; Rosa26-
SB11Tg/WT)88,162  were generated and maintained as described.108 Mice were maintained 
on 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone) drinking water 
until hydrodynamic injection with plasmid DNA at 6-8 weeks of age, then maintained on 
normal drinking water. Injected animals were observed for weight changes. At 150-180 
days post-injection, liver tumor analysis was performed as described below. 
Hydrodynamic injection of plasmid DNA into Fah-deficient mice 
The following plasmids have been described previously: a plasmid expressing mouse Rtl1 
from the human EF-1α promoter,99 a plasmid with an expression cassette for mCherry 
driven by the human EF-1α promoter (manuscript under review), a plasmid containing an 
SB IR/DR flanked expression cassette for mouse Fah and firefly luciferase under the 
control of the phosphoglycerate kinase (PGK) promoter,102 a plasmid containing an 
expression cassette for GFP and a short hairpin RNA directed against Trp53,108 full length 
human EGFR complementary DNA (cDNA) driven by the PGK promoter,54 human 
truncated EGFR (exon 1 to exon 24) cDNA driven by the PGK promoter,54 a plasmid 
expressing mouse Fah and GFP from the PGK promoter and human CTNNB1S33Y and 
firefly luciferase from the Caggs promoter,54 a plasmid with an EF-1α promoter driven 
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expression cassette for mouse Gli2 (manuscript under review), a plasmid expressing 
mouse Fah and GFP from the PGK promoter and human RSPO2 and firefly luciferase 
from the Caggs promoter (manuscript in preparation), a plasmid expressing GFP driven 
by the PGK promoter and mouse Fah and firefly luciferase from the Caggs promoter108 
and a plasmid expressing D genotype HBx from the PGK promoter and mouse Fah and 
firefly luciferase from the Caggs promoter (pKT2/GD-HBx),108 all flanked by SB transposon 
inverted repeat/direct repeats. A plasmid with an SB transposon inverted repeat/direct 
repeat flanked cassette for mutant D genotype HBx with 2 nucleotide substitutions at 389 
and 391 of HBx coding sequence (A389 to T and G391 to A) under control of the PGK 
promoter and mouse Fah and firefly luciferase under control of the Caggs promoter was 
generated as follows: Two fragments containing HBx coding sequence and flanking 
plasmid backbone sequences were PCR amplified from pKT2/GD-HBx with primers 
encoding the point mutations using ReddyMix PCR Master Mix (ThermoFisher Scientific) 
according to the manufacturer’s instructions with an initial denaturing step of 94°C for 5 
min; 35-cycles of denaturing at 94°C for 30 sec, annealing at 56° C (fragment 1) or 52° C 
(fragment 2) for 1 min, and extension at 72°C for 1.5 min; and a final extension at 72°C 
for 5 min. Primers were 5’-TGTTCATGATGCAACTGGATCCAG-3’ and 5’-
AGGTTAATGATCTTTGTACTAGGAGGCTGTAG-3’ for fragment 1 and 5’-
CTAGTACAAAGATCATTAACCTAATCTCC-3’ and 5’-TCGAGACCATGGCTGCTAG-3’ 
for fragment 2.  These fragments were joined by PCR amplification using HotStar 
HiFidelity Polymerase (Qiagen) according to the manufacturer’s instructions with an initial 
denaturing step of 95°C for 5 min; 40-cycles of denaturing at 94°C for 15 sec, annealing 
at 47° C for 1 min, and extension at 72°C for 1.5 min; and a final extension at 72°C for 10 
min. Primers used were 5’-GTTGGAGTCATTAAAACTCG-3’ and 5’- 
CGTCCTTTGTTTACGTCC-3’. This sequence was cloned into the pKT2/GD-HBx vector, 
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replacing the corresponding wildtype HBx sequence using standard cloning techniques. 
All plasmids used for hydrodynamic tail vein injections were prepared using NucleoBond 
Xtra Maxi EF DNA Maxi-preparation kits (Macherey-Nagel) following the manufacturer’s 
instructions.  Twenty µg of each plasmid was delivered by hydrodynamic tail vein injection 
as described.107  
CCl4 treatment for fibrosis induction 
Starting at 6 weeks post-hydrodynamic injection, half of the surviving mice injected with 
Gli2 or mCherry were given 2.5 μl per gram body weight of a 10% CCl4 solution in mineral 
oil by intraperitoneal injections twice weekly for a total of 12 weeks to induce hepatic 
inflammation and fibrosis. 
Liver tumor analysis 
After euthanasia by CO2, the whole mouse was weighed. The liver was removed, 
weighed, and placed in cold phosphate buffered saline. Macroscopic hyperplastic liver 
nodules were counted. When applicable, livers were examined using GFP goggles (BLS-
ltd), and GFP-positive tumors were counted and collected. Tumors greater than 1mm in 
diameter were collected and processed for histological examination. Tissues for 
histological examination were fixed in 10% formalin, paraffin-embedded, sectioned at 5 
microns on a standard microtome (Leica), mounted, and heat-fixed onto glass slides. 
Slides were dewaxed, rehydrated through a gradual decrease in ethanol concentration, 
stained with hematoxylin and eosin (H&E) following a standard protocol, and analyzed by 
color brightfield microscopy by two board-certified pathologists (KA and ML, American 
Board of Pathology). 
 
111 
 
Discussion  
Molecular characterization of HCC has revealed a great amount of genetic complexity, 
making the identification of cancer drivers difficult. Comparative studies using forward 
genetic screening in mice have identified large numbers of candidate driver alterations in 
human HCC, but establishing their roles as HCC drivers requires functional validation. 
HBV is a known HCC-promoting virus, but the roles of individual HBV genetic components 
in promoting HCC are not fully understood.  The SB transposon system can be used not 
only for forward genetic screening for HCC drivers, but also for reverse genetic studies 
testing candidate HCC drivers in vivo. In this study, we used SB based gene delivery to 
hepatocytes of Fah-deficient mice to rapidly generate mice with hepatic expression of 
several candidate oncogenes.  
A SB transposon-based forward genetic screen identified the Dlk-Dio3 domain gene Rtl1 
as a candidate hepatic oncogene. Several studies have correlated Dlk-Dio3 domain 
alterations with HCC,144–147 and through SB-mediated gene delivery, we directly showed 
Rtl1 overexpression results in liver tumor formation in mice. Thus, the role of Dlk-Dio3 
domain alterations in promoting HCC may be explained, at least in part, by the oncogenic 
role of Rtl1 validated in our mouse model. 
Many mouse models of HCC include only males because HCC occurs most commonly in 
men.64 Sex distributions vary in different subclasses of HCC,53 however, making the 
inclusion of both males and females relevant in HCC studies. Males are highly enriched 
in a subclass of HCC with chromosome 7 polysomy and EGFR overexpression,53 and SB 
transposon mutations in EGFR in a forward genetic screen for HCC drivers were enriched 
in male mice.54 Using an SB gene delivery mouse model of HCC, we showed EGFR 
overexpression promotes HCC in a male sex biased manner. In contrast, activated 
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CTNNB1 and RSPO2 both drove HCC in both sexes of mice with similar frequencies, 
confirming the non-sex biased role of Wnt/β-catenin signaling in HCC development. 
The HBV HBx gene has been shown to promote liver cancer.108 We functionally validated 
the role of a mutant HBx variant associated with increased liver damage and HCC,161 
showing it to have stronger oncogenic potential than wildtype HBx. Interestingly, another 
HBx variant with a truncation of the same region of C-terminal transactivation domain 
altered by the mutations we studied is also associated with increased liver damage and 
HCC.163 This suggests the C-terminal transactivation domain of HBx may have an 
important role in tumorigenesis.  
HCC almost always develops in context of chronic liver damage and fibrosis.18,19,31  The 
selective Fah mutant mouse model can be used with CCl4-induced hepatic fibrosis to 
model the conditions under which HCC most commonly occurs. We showed Gli2 
expression can induce liver tumors in a mouse model with hepatic fibrosis, confirming its 
predicted role as a fibrosis-associated oncogene based on mutations in fibrosis-
associated SB-induced mouse liver tumors and on its overexpression in human HCC 
(manuscript under review).155,156  This is the first direct evidence, to our knowledge, that 
Gli2 overexpression can drives liver tumor formation in vivo. 
By performing reverse genetic studies using SB transposon- based gene delivery to Fah 
deficient mouse livers, we modeled HCC induced by a variety of genes discovered in 
forward genetic screens or as variants of oncogenic viral genes. We used this method to 
study HCC in both males and females, and in the highly relevant context of hepatic fibrosis. 
This method has also been used to study drivers of fatty liver associated HCC, another 
highly relevant context (manuscript in preparation). This is a versatile mouse model that 
can be used to study HCC drivers in a variety of highly relevant contexts.
Table 3.1: Liver tumors in hydrodynamically injected mice
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
M1381 Male Rtl1 None 240 4
M1382 Male Rtl1 None 240 1
M1383 Male Rtl1 None 240 0
M1384 Male Rtl1 None 240 6
M1375 Male Rtl1 None 251 1
M1376 Male Rtl1 None 251 3
M1482 Male Rtl1 None 251 5
M1483 Male Rtl1 None 251 1
M1484 Male Rtl1 None 251 4
M1485 Male Rtl1 None 251 3
M1491 Male Rtl1 None 251 5
M1492 Male Rtl1 None 251 4
M1501 Male Rtl1 None 251 0
M1502 Male Rtl1 None 251 3
Mean 2.86
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
M1391 Male Rtl1 /shp53 None 251 5
M1392 Male Rtl1 /shp53 None 251 0
M1394 Male Rtl1 /shp53 None 251 6
M1451 Male Rtl1 /shp53 None 254 5
M1454 Male Rtl1 /shp53 None 254 16
M1455 Male Rtl1 /shp53 None 254 8
Mean 6.67
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
M3062 Male mCherry None 198 0
M3063 Male mCherry None 198 0
M3065 Male mCherry None 200 0
M3066 Male mCherry None 200 0
M3067 Male mCherry None 200 0
M4181 Male mCherry None 201 0
M4182 Male mCherry None 201 1
M4183 Male mCherry None 201 1
M4391 Male mCherry None 201 1
M4402 Male mCherry None 201 0
M4403 Male mCherry None 201 0
M4404 Male mCherry None 201 0
M4406 Male mCherry None 201 0
Mean 0.23
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
M2683 Male mCherry CCl4 202 2
M2686 Male mCherry CCl4 203 0
M2687 Male mCherry CCl4 203 0
M2693 Male mCherry CCl4 205 0
M2701 Male mCherry CCl4 204 0
M2702 Male mCherry CCl4 204 0
M2703 Male mCherry CCl4 206 0
M3132 Male mCherry CCl4 192 0
M3136 Male mCherry CCl4 202 0
M3138 Male mCherry CCl4 202 1
Mean 0.30
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules 113
M3854 Male Gli2 None 157 27
M4022 Male Gli2 None 152 30
M4041 Male Gli2 None 152 52
M4042 Male Gli2 None 152 49
Mean 39.5
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
M3743 Male Gli2 CCl4 153 41
M3761 Male Gli2 CCl4 157 65
M3762 Male Gli2 CCl4 161 65
Mean 57
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
F1141 Female Trunc EGFR/shp53 None 129 0
F1142 Female Trunc EGFR/shp53 None 129 0
F1143 Female Trunc EGFR/shp53 None 129 4
F1144 Female Trunc EGFR/shp53 None 129 0
Mean 1.00
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
M1131 Male Trunc EGFR/shp53 None 129 3
M1132 Male Trunc EGFR/shp53 None 129 3
M1133 Male Trunc EGFR/shp53 None 129 6
M1141 Male Trunc EGFR/shp53 None 132 6
M932 Male Trunc EGFR/shp53 None 134 4
M933 Male Trunc EGFR/shp53 None 134 5
M961 Male Trunc EGFR/shp53 None 134 1
M962 Male Trunc EGFR/shp53 None 137 12
M963 Male Trunc EGFR/shp53 None 137 8
Mean 5.33
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
F1195 Female WT EGFR/shp53 None 128 0
F1181 Female WT EGFR/shp53 None 133 2
F1183 Female WT EGFR/shp53 None 133 0
Mean 0.67
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
M1201 Male WT EGFR/shp53 None 133 6
M1202 Male WT EGFR/shp53 None 133 5
M1212 Male WT EGFR/shp53 None 133 6
Mean 5.67
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
F1351 Female CTNNB1 S33Y/shp53 None 80 15
F1353 Female CTNNB1 S33Y/shp53 None 80 11
F1471 Female CTNNB1 S33Y/shp53 None 80 50
F1472 Female CTNNB1 S33Y/shp53 None 80 50
F1473 Female CTNNB1 S33Y/shp53 None 80 30
F1491 Female CTNNB1 S33Y/shp53 None 80 12
F1493 Female CTNNB1 S33Y/shp53 None 80 50
F1543 Female CTNNB1 S33Y/shp53 None 80 12
F1311 Female CTNNB1 S33Y/shp53 None 83 20
F1312 Female CTNNB1 S33Y/shp53 None 83 15
Mean 26.50
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
M1341 Male CTNNB1 S33Y/shp53 None 80 16
M1343 Male CTNNB1 S33Y/shp53 None 80 18 114
M1541 Male CTNNB1 S33Y/shp53 None 80 15
M1551 Male CTNNB1 S33Y/shp53 None 80 20
M1552 Male CTNNB1 S33Y/shp53 None 80 15
M1553 Male CTNNB1 S33Y/shp53 None 80 15
M1331 Male CTNNB1 S33Y/shp53 None 83 24
M1332 Male CTNNB1 S33Y/shp53 None 83 22
Mean 18.13
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2051 Female RSPO2 None 79 0 8.4%
M2053 Male RSPO2 None 79 0 10.1%
Mean 0.00 9.3%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2052 Female RSPO2 None 120 1 8.7%
F2053 Female RSPO2 None 120 2 8.7%
M3331 Male RSPO2 None 128 0 8.8%
M3332 Male RSPO2 None 128 0 11.5%
Mean 0.75 9.4%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2054 Female RSPO2 None 149 0 9.4%
F2055 Female RSPO2 None 149 0 9.1%
M2871 Male RSPO2 None 150 0 7.9%
M2872 Male RSPO2 None 150 0 7.2%
M2873 Male RSPO2 None 150 1 8.0%
M3054 Male RSPO2 None 155 0 8.7%
M3055 Male RSPO2 None 155 0 8.6%
F2861 Female RSPO2 None 156 0 9.6%
F2863 Female RSPO2 None 156 0 10.4%
F2883 Female RSPO2 None 156 0 10.1%
F2884 Female RSPO2 None 156 0 10.8%
F3382 Female RSPO2 None 156 1 11.0%
F3383 Female RSPO2 None 156 0 9.9%
M3402 Male RSPO2 None 156 1 11.5%
F3052 Female RSPO2 None 158 3 13.3%
F3053 Female RSPO2 None 158 0 10.6%
F2182 Female RSPO2 None 159 0 8.5%
F2183 Female RSPO2 None 159 0 8.1%
M2191 Male RSPO2 None 159 0 10.2%
M2192 Male RSPO2 None 159 0 10.0%
M2182 Male RSPO2 None 160 0 8.8%
M2185 Male RSPO2 None 160 0 10.6%
Mean 0.27 9.7%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2131 Female RSPO2 /shp53 None 59 0 10.0%
M2131 Male RSPO2 /shp53 None 59 0 10.2%
Mean 0.00 10.1%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2864 Female RSPO2 /shp53 None 77 0 9.6%
F3331 Female RSPO2 /shp53 None 80 0 11.4%
M3391 Male RSPO2 /shp53 None 80 0 9.8%
Mean 0.00 10.3%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2132 Female RSPO2 /shp53 None 120 0 8.5%
M2134 Male RSPO2 /shp53 None 120 4 9.9%
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Mean 2.00 9.2%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
M2201 Male RSPO2 /shp53 None 152 1 13.6%
M2204 Male RSPO2 /shp53 None 152 5 10.3%
F2191 Female RSPO2 /shp53 None 153 0 8.0%
F2192 Female RSPO2 /shp53 None 153 0 7.4%
F2193 Female RSPO2 /shp53 None 153 0 9.0%
F2201 Female RSPO2 /shp53 None 153 1 9.4%
M2202 Male RSPO2 /shp53 None 153 1 11.8%
M2203 Male RSPO2 /shp53 None 153 1 11.2%
M3041 Male RSPO2 /shp53 None 153 0 9.7%
M3043 Male RSPO2 /shp53 None 153 2 9.6%
F3041 Female RSPO2 /shp53 None 154 1 11.0%
F2133 Female RSPO2 /shp53 None 155 1 9.0%
F2865 Female RSPO2 /shp53 None 155 1 9.7%
F3043 Female RSPO2 /shp53 None 155 0 11.1%
M2133 Male RSPO2 /shp53 None 155 3 9.0%
M3392 Male RSPO2 /shp53 None 155 3 18.5%
M2135 Male RSPO2 /shp53 None 156 0 9.3%
M2136 Male RSPO2 /shp53 None 156 0 9.2%
F2101 Female RSPO2 /shp53 None 160 2 8.4%
F2102 Female RSPO2 /shp53 None 160 1 8.5%
Mean 1.15 10.2%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2271 Female GFP None 63 0 5.2%
F2272 Female GFP None 63 0 5.0%
M2271 Male GFP None 63 0 6.0%
M2272 Male GFP None 63 0 5.5%
M2273 Male GFP None 63 0 5.4%
Mean 0.00 5.4%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
M271 Male GFP None 82 0 5.2%
M272 Male GFP None 82 0 5.9%
M2883 Male GFP None 106 0 6.4%
Mean 0.00 5.8%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F3401 Female GFP None 127 0 5.8%
F3402 Female GFP None 127 0 6.3%
Mean 0.00 6.0%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2641 Female GFP None 153 0 5.7%
F2642 Female GFP None 153 1 5.8%
F2643 Female GFP None 153 0 not meaured; appeared normal
F2644 Female GFP None 154 0 5.9%
M2643 Male GFP None 154 0 6.1%
F2691 Female GFP None 155 0 5.3%
F2692 Female GFP None 155 0 5.6%
F2693 Female GFP None 155 0 5.3%
F3072 Female GFP None 155 0 6.3%
M2661 Male GFP None 155 0 6.5%
M2672 Male GFP None 155 0 6.3%
F3403 Female GFP None 156 0 7.2%
M2884 Male GFP None 156 0 5.5%
M3384 Male GFP None 156 0 6.1%
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M3094 Male GFP None 157 0 5.6%
M2621 Male GFP None 158 0 6.2%
M2622 Male GFP None 158 0 5.4%
M3095 Male GFP None 158 0 6.7%
F2701 Female GFP None 161 0 5.3%
F2702 Female GFP None 161 0 not meaured; appeared normal
Mean 0.05 5.9%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
M702 Male GFP /shp53 None 70 0 6.3%
M721 Male GFP /shp53 None 70 0 6.3%
Mean 0.00 6.3%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
M701 Male GFP /shp53 None 80 0 5.8%
M703 Male GFP /shp53 None 80 0 6.1%
F3391 Female GFP /shp53 None 81 0 5.4%
F3392 Female GFP /shp53 None 81 0 5.1%
Mean 0.00 5.6%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F3393 Female GFP /shp53 None 127 0 5.1%
F3394 Female GFP /shp53 None 127 0 6.0%
Mean 0.00 5.5%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2651 Female GFP /shp53 None 151 0 6.4%
F2652 Female GFP /shp53 None 151 0 5.6%
F2653 Female GFP /shp53 None 151 0 6.1%
F2662 Female GFP /shp53 None 151 0 5.7%
F2663 Female GFP /shp53 None 151 0 5.6%
F2664 Female GFP /shp53 None 151 0 4.8%
F2665 Female GFP /shp53 None 151 2 5.4%
F2666 Female GFP /shp53 None 151 0 6.0%
M2291 Male GFP /shp53 None 154 0 5.5%
M2292 Male GFP /shp53 None 154 0 4.5%
M2293 Male GFP /shp53 None 154 0 4.1%
M2294 Male GFP /shp53 None 154 0 4.7%
F3395 Female GFP /shp53 None 156 0 6.5%
M3111 Male GFP /shp53 None 156 0 5.4%
M3404 Male GFP /shp53 None 156 0 5.9%
M3405 Male GFP /shp53 None 156 0 5.9%
M1991 Male GFP /shp53 None 157 0 5.6%
M1992 Male GFP /shp53 None 157 0 4.9%
M3112 Male GFP /shp53 None 157 0 5.8%
F3111 Female GFP /shp53 None 158 0 5.5%
F3112 Female GFP /shp53 None 158 0 5.2%
M1993 Male GFP /shp53 None 160 0 5.5%
F2671 Female GFP /shp53 None 161 0 8.3%
Mean 0.09 5.6%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
M1991 Male GFP /shp53 None 157 0 5.6%
M1992 Male GFP /shp53 None 157 0 4.9%
M1993 Male GFP /shp53 None 160 0 5.5%
M2481 Male GFP /shp53 None 169 0 5.6%
M2482 Male GFP /shp53 None 169 0 5.7%
Mean 0.00 5.5%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
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F1992 Female GFP /shp53 None 175 0 5.7%
F1993 Female GFP /shp53 None 176 0 5.9%
F1994 Female GFP /shp53 None 176 1 5.2%
F2461 Female GFP /shp53 None 170 0 not meaured; appeared normal
F2482 Female GFP /shp53 None 171 0 5.8%
F2483 Female GFP /shp53 None 171 0 5.6%
F2484 Female GFP /shp53 None 171 0 5.6%
F2485 Female GFP /shp53 None 171 0 4.9%
Mean 0.13 5.5%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
M2522 Male HBx M/shp53 None 168 8 7.9%
M2523 Male HBx M/shp53 None 168 15 9.2%
M2571 Male HBx M/shp53 None 174 11 6.9%
M2572 Male HBx M/shp53 None 175 13 8.0%
M2573 Male HBx M/shp53 None 175 4 8.0%
M3251 Male HBx M/shp53 None 168 0 6.1%
M3252 Male HBx M/shp53 None 169 0 7.7%
M3253 Male HBx M/shp53 None 169 9 7.4%
M3281 Male HBx M/shp53 None 172 6 6.8%
M3282 Male HBx M/shp53 None 174 10 9.1%
Mean 7.60 7.7%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2521 Female HBx M/shp53 None 169 0 6.5%
F2522 Female HBx M/shp53 None 169 1 6.2%
F2531 Female HBx M/shp53 None 171 0 5.3%
F2533 Female HBx M/shp53 None 171 0 5.6%
F2571 Female HBx M/shp53 None 175 1 6.3%
F2572 Female HBx M/shp53 None 177 1 6.5%
F2573 Female HBx M/shp53 None 177 2 7.4%
Mean 0.71 6.2%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
M2711 Male HBx /shp53 None 167 3 8.2%
M2712 Male HBx /shp53 None 167 4 7.0%
M3214 Male HBx /shp53 None 169 1 6.4%
M3216 Male HBx /shp53 None 169 2 7.1%
M3222 Male HBx /shp53 None 170 3 6.6%
M3223 Male HBx /shp53 None 170 2 9.5%
M3231 Male HBx /shp53 None 168 2 9.2%
M3291 Male HBx /shp53 None 170 1 7.6%
M3292 Male HBx /shp53 None 170 10 8.6%
Mean 3.11 7.9%
Mouse ID Sex Experimental Group Treatment
Days post-
injection
Liver 
Nodules
Liver mass % of body weight
F2711 Female HBx /shp53 None 166 0 6.0%
F2713 Female HBx /shp53 None 166 0 6.1%
F3191 Female HBx /shp53 None 168 0 5.4%
F3192 Female HBx /shp53 None 168 0 5.5%
F3193 Female HBx /shp53 None 168 0 5.4%
F3194 Female HBx /shp53 None 168 0 5.2%
F3195 Female HBx /shp53 None 168 0 5.8%
F3211 Female HBx /shp53 None 170 0 5.4%
F3212 Female HBx /shp53 None 170 1 6.1%
F3231 Female HBx /shp53 None 171 0 5.5%
F3232 Female HBx /shp53 None 171 0 5.4%
F3233 Female HBx /shp53 None 171 2 5.8%
Mean 0.25 5.6%
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Table 3.2: Gli2 -injected mice
Mouse
Died 
prematurely?a
Day PHI of 
premature death
Luciferase confirmed 
by imaging
M3711 Yes 40 N/A
M3712 Yes 37 N/A
M3713 Yes 71 N/A
M3732 Yes 31 N/A
M3733 Yes 28 N/A
M3734 Yes 33 N/A
M3742 Yes 67 N/A
M3743 No N/A N/A
M3761 No N/A N/A
M3762 No N/A N/A
M3851 Yes 38 N/A
M3852 Yes 38 N/A
M3853 Yes 38 N/A
M3854 No N/A N/A
M3862 Yes 24 N/A
M3863 Yes 24 N/A
M3871 Yes 38 N/A
M3872 Yes 37 N/A
M3873 Yes 37 N/A
M3901 Yes 26 N/A
M3902 Yes 26 N/A
M3903 Yes 26 N/A
M3904 Yes 26 N/A
M3973 Yes 35 N/A
M3974 Yes 35 N/A
M3992 Yes 33 N/A
M3993 Yes 33 N/A
M3994 Yes 33 N/A
M4012 Yes 29 N/A
M4013 Yes 29 N/A
M4014 Yes 23 N/A
M4015 Yes 6 N/A
M4021 Yes 41 N/A
M4022 No N/A N/A
M4023 Yes 41 N/A
M4024 Yes 29 N/A
M4032 Yes 6 N/A
M4033 Yes 9 N/A
M4034 Yes 27 N/A
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M4041 No N/A N/A
M4042 No N/A N/A
M4061 Yes 42 N/A
M4062 Yes 28 N/A
M4063 Yes 38 N/A
M4064 Yes 42 N/A
M4071 Yes 30 N/A
M4072 Yes 30 N/A
M4073 Yes 31 N/A
M4075 Yes 36 N/A
M4076 Yes 35 N/A
M4091 Yes 39 N/A
M4092 Yes 33 N/A
M4101 Yes 27 N/A
M4102 Yes 29 N/A
M4103 Yes 29 N/A
M4111 Yes 31 N/A
M4112 Yes 36 N/A
M4113 Yes 38 N/A
M4114 Yes 30 N/A
M4291 Yes 25 Yes
M4292 Yes 26 Yes
M4293 Yes 26 Yes
M4301 Yes 27 Yes
M4302 Yes 27 Yes
M4303 Yes 27 Yes
M4304 Yes 27 Yes
a Died prematurely deﬁned as dying before experiment endpoint
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Figure 3.1. In vivo hepatic Rtl1 expression of drives tumor formation. (A) Macro-
scopic images of representative tumor-containing whole livers from mice injected with 
Rtl1 and control expression SB transposon constructs via hydrodynamic tail vein injec-
tion. Scale bars, 1 cm. (B) Tumor penetrance and (C) mean tumor burden in mice injected 
with mCherry only, Rtl1 only, or Rtl1/shp53 expression SB transposon constructs. *P < 
.05. **P < .01. ****P < .0001. Error bars represent SEM.
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Figure 3.2. Validating the sex biased oncogenic potential of EGFR in vivo. (A) Rep-
resentative images of gross liver from male and female Fah mutant mice injected with 
truncated EGFR and shp53. Scale bars, 0.5 cm. (B) Tumor penetrance and (C) mean 
tumor burden in male and female mice injected with full length EGFR and shp53 (WT 
EGFR/shp53) or truncated EGFR and shp53 (Trunc EGFR/shp53). #P > .05. *P < .05. **P 
< .01. Error bars represent SEM.
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Figure 3.3. Oncogenic potential of CTNNB1S33Y in male and female mice in vivo. (A) 
Representative images of gross livers from male and female Fah mutant mice injected 
with CTNNB1S33Y and shp53. Scale bars, 0.5 cm. (B) Mean tumor burden in male and 
female mice injected with CTNNB1S33Y and shp53 (CTNNB1S33Y/shp53). #P > .05. Error 
bars represent SEM.
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Figure 3.4. RSPO2 promotes hepatomegaly and HCC. (A) Liver mass percent of body 
mass for RSPO2, RSPO2/shp53, and control injected mice. (B) Representative gross 
images of livers in situ from RSPO2/shp53 and GFP/shp53 injected mice at 150 days 
post-hydrodynamic injection. (C) Representative gross images of livers isolated from 
RSPO2/shp53 injected mice at 150 days post-hydrodynamic injection. Tumors are 
indicated by black arrowheads. Scale bars, 1cm. (D) Tumor penetrance and (E) mean 
tumor burden in RSPO2, RSPO2/shp53, and control injected mouse livers at 150 days 
post-hydrodynamic injection. (F) Tumor penetrance and (G) mean tumor burden in male 
RSPO2/shp53 injected mouse livers at 150 days post-hydrodynamic injection by sex. #P 
> .05. *P < .05. ***P < .001. ****P < .0001. Error bars represent SEM.
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Figure 3.5. Gli2 overexpression induces tumor formation. (A) Representative gross 
livers from Gli2 and mCherry injected mice treated with CCl4 or no treatment. Black 
arrowheads indicate tumors. Scale bars, 0.5 cm. (B) Mean tumor burden in Gli2 or 
mCherry injected mice treated with CCl4 or no treatment. **P < .01. ****P < .0001. Error 
bars represent SEM.
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Figure 3.6. Mutant HBx is more oncogenic than HBx in the mouse liver. (A) Repre-
sentative gross liver images from male and female mice injected with HBxM/shp53, HBX-
/shp53, or GFP/shp53. Scalebars, 0.5 cm. (B) Liver mass percent of body mass from 
HBxM/shp53, HBX/shp53, or GFP/shp53 injected mice.  (C) Tumor penetrance and (D) 
mean tumor burden in HBxM/shp53, HBX/shp53, or GFP/shp53 injected mice. #P > .05. 
*P < .05. **P < .01. ****P < .001. Error bars represent SEM.
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CHAPTER 4: SUMMARY 
 
 
Significance of Sleeping Beauty transposon-based forward and reverse genetic 
liver cancer studies and potential future advancements  
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Distinct applications of the Sleeping Beauty transposon system for forward and 
reverse genetic studies of liver cancer in contexts relevant to the human disease are 
described in the preceding chapters. SB transposon insertional mutagenesis and SB 
transposon-based gene delivery are useful tools for modeling HCC. Applying these 
technologies to study liver cancer drivers in a variety of contexts can advance our 
understanding of the molecular pathogenesis of this disease. Since HCC does not usually 
arise in normal livers,8 the relevance of these models is increased dramatically by applying 
these technologies in relevant conditions, by including both male and female animals, and 
modeling liver damage due to hepatic steatosis and fibrosis.  
SB insertional mutagenesis has been established as a method to discover HCC 
associated genes in otherwise normal livers or in context of tumor-predisposing 
mutations.48,54,92,95 HCC, however, almost always develops in context of chronic liver 
damage.8 We used SB insertional mutagenesis to model HCC in context of diet and 
alcohol- induced hepatic steatosis, since steatosis is one of the most common risk factors 
for HCC and this risk is further increased with alcohol consumption.36–39 This SB 
mutagenesis-driven model HCC is likely more relevant to the human disease than 
previous models. One particularly interesting finding of this study was the increase in 
tumor burden observed in female mice with hepatic steatosis, which modeled the higher 
representation of females we found in human steatosis-associated HCC cases than in the 
overall cohort examined. This finding highlights the importance of including both sexes of 
animals when modeling HCC, particularly in context of steatosis.  
In this study, we found a distinct set of mutations from previous SB screens for 
liver cancer drivers,48,54,92,95 which could lead to the development of new targeted 
therapies. The PKA/cAMP signaling pathway was specifically associated with the 
steatosis-associated CIS genes and with genes with expression changes in human 
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steatosis and alcohol-associated HCC. This pathway is activated in other cancers 
including fibrolamellar hepatocellular carcinoma, where a DNAJB1-PRKACA fusion 
leading to PRKACA upregulation may be the sole driver.117,121,164 Inhibition of downsteam 
targets of PKA/cAMP signaling could be investigated for efficacy in inhibiting HCC growth. 
This pathway is also commonly activated by upstream signaling through β-adrenergic 
receptors,122 leading to augmented lipid accumulation in hepatocytes165 and alterations in 
hepatic autophagy, which is involved in non-alcoholic fatty liver disease and HCC.166 Non-
selective beta-blocker (NSBB) use in patients with cirrhosis has been linked to reduced 
HCC incidence in retrospective studies, but, to our knowledge, the effect of NSBB use of 
HCC development has not been functionally evaluated.123–125 Both upstream and 
downstream inhibition of PKA/cAMP signaling could be tested in steatotic livers in vivo 
using the types mouse models described in the preceding chapters. Adrenergic signaling 
activates hepatic stem cells to proliferate in response to liver damage.167 If the pathway is 
activated upstream in tumor cells in response to liver damage from steatosis, blocking 
activation of this pathway upstream by NSBBs could inhibit tumor formation in steatotic 
livers. If genetic or epigenetic alterations downstream of adrenergic receptor activation 
allows steatotic liver tumor cells to sustain signaling through this pathway in the absence 
of adrenergic receptor stimulation, the NSBBs would be ineffective, but expression of a 
dominant negative PKA mutation, Prkar1a glycine to aspartate substitution at position 
325168 would still inhibit tumor formation. Similarly, if this pathway is activated upstream in 
tumor cells in response to liver damage, then reversal of steatosis by diet alteration169–171 
could inhibit tumor progression. 
We also identified Nat10 as a HCC oncogene in our hepatic steatosis mouse 
model. NAT10 protein was found in both our study and another published study126 to be 
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overexpressed in more than half of human HCC cases examined, and NAT10 knockdown 
has been demonstrated to inhibit growth of several cancer cell types.130,133 NAT10 
acetyltransferase activity can be inhibited by a chemical compound, Remodelin.134  
Ribosome biogenesis, a process affected by NAT10 activity, can be inhibited using the 
RNA polymerase I specific inhibitor, CX-5461.135,136 NAT10, therefore, provides another 
potential drug target for HCC treatment or prevention.  
In addition to Nat10, we found 203 candidate liver cancer driving mutations, many 
of which are altered in human steatosis and alcohol associated HCC. Almost half of the 
steatosis-associated candidate liver cancer genes we found were enriched for mutations 
in mice with diet and alcohol-induced hepatic steatosis compared to mice on a normal 
diet.48 This distinct set of mutations in the context of steatosis shows the interactions 
between the tumor predisposing environment of liver damage and the mutations 
promoting cancer are complex, and may alter the target cell for transformation. It has been 
suggested that the mechanism by which predisposing liver damage may increase cancer 
risk is by increasing the frequency of target cells for transformation.172 If this were the case, 
the same liver cancer-promoting mutations would be found regardless of the predisposing 
conditions. We observed, however, a distinct set of mutations driving liver cancer in 
context of hepatic steatosis. One steatosis-enriched cancer gene, Nat10, was validated 
as an oncogene in a mouse model of hepatic steatosis. Other candidate oncogenes could 
be tested using the same method. Candidate tumor suppressors could be tested in 
steatotic Fah-deficient mouse livers using shRNA knockdown or CRISPR/CAS mutation, 
which has been used to edit Fah-deficient hepatocytes in vivo.173  
Forward genetic screens and human mutational data are revealing a large number 
of liver cancer-associated genes. Reverse genetic models can be used to test the roles of 
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these genes in tumorigenesis and study the mechanisms by which these genes drive 
tumorigenesis, which may inform the development of novel therapies. In general, reverse 
genetic models driven by known agents may be more useful for testing therapeutic agents 
than non-specific models, which may not contain the molecular alteration targeted by the 
therapeutic agent. We used SB gene delivery and the selective Fah mutant mouse model 
to test candidate drivers and model HCC in otherwise normal livers, in mice of both sexes, 
in context of hepatic fibrosis, and in context of hepatic steatosis. Here, we described the 
use of SB gene delivery for the generation of 12 different HCC models driven by the 
expression of 7 different oncogenes and mutant oncogene variants, alone, in combination 
with knockdown of tumor suppressor gene Trp53, in fibrotic livers, in steatotic livers, and 
in otherwise normal livers. These represent different molecular subclasses of HCC 
including two models each of the previously described Wnt/β-catenin subclass and the 
Poly7 subclass.53 Drivers of the proliferation, interferon, and unannotated subclasses53  
could be tested using similar methods to generate models of those subclasses of HCC. 
These findings have furthered our understanding of HCC pathogenesis in these various 
contexts. The HCC models we generated and this method of modeling HCC in disease-
relevant contexts of chronic liver damage could be used to study the mechanisms of 
disease progression and could also provide useful preclinical models for therapeutic 
testing.  
We modeled Nat10-induced liver cancer in context of hepatic steatosis, for 
example, validating the oncogenic role of Nat10 in steatotic liver. NAT10 acetylates 
multiple cellular targets, and our SB reverse genetic model of Nat10-induced liver 
tumorigenesis could prove useful for further studies addressing the mechanisms by which 
Nat10 drives liver cancer. NAT10 is required for a highly conserved modification of 18S 
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rRNAs with an important role in ribosome biogenesis.130  NAT10 could allow cells to 
regulate translation in a nutrient-responsive manner, responding to the abundance of 
acetylCoA in steatotic livers132 by promoting ribosome biosynthesis, which may be rate 
limiting for HCC, only in the presence of acetylCoA.131 Treating mice with hepatic Nat10 
overexpression with either Remodelin,134 an inhibitor of NAT10 acetyltransferase activity, 
or CX-5461,135,136 an RNA polymerase I specific inhibitor, could address the role of 
ribosome biogenesis in Nat10-driven liver tumor formation. If CX-5461 treatment inhibits 
Nat10-driven liver tumor formation, this would reveal ribosome biogenesis is a function of 
Nat10 with an important role in tumorigenesis, whereas if Remodelin but not CX-5461 
inhibits liver tumor formation, this would reveal a different Nat10 function is involved in 
tumor formation. At the same time, this could act as a preclinical model to test the efficacy 
of these drugs in inhibiting Nat10-driven liver tumorigenesis. 
Drivers of HCC developing in chronic liver damage contexts can be addressed with 
the SB gene delivery system and the selective Fah mutant mouse model. We modeled 
fibrosis, alcohol-associated steatosis, and Hepatitis B Virus (HBV)-associated liver 
cancer.  Other dietary models of hepatic steatosis could be used to test drivers of 
steatosis-associated HCC. Several different dietary models of non-alcoholic fatty liver 
disease have been described, including high fat diets, which induce obesity, hepatic 
steatosis and fibrosis, and high fat-high fructose and/or sucrose diets, which induces a 
similar degree obesity and hepatic steatosis as high fat diets but with more severe fibrosis 
and HCC.174,175 Expression vectors for HBV or Hepatitis C Virus (HCV) viral proteins could 
be co-administered with candidate oncogenes to evaluate host genetic alterations 
promoting HCC in context of viral infection. This model could also be improved using 
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conditional expression vectors to investigate the role of candidate oncogenes in tumor 
initiation versus maintenance.  
The mosaic mouse model of HCC in which liver progenitor cells are genetically 
modified in culture and transplanted into syngeneic recipient mice livers76 could also be 
used to test candidate HCC genes in disease-relevant liver damage contexts like fibrosis 
and steatosis. This would allow candidate HCC genes to be expressed in a smaller 
population of hepatocytes in livers that have not undergone full regeneration. Livers of 
Fah-deficient, immunodeﬁcient mice have been repopulated with human hepatocytes, 
generating mice with humanized livers.176 This model could also be used in conjunction 
with liver damage to model HCC developing in relevant disease conditions, with the major 
advantage of testing candidate cancer drivers in human hepatocytes in vivo. Since the 
humanized mouse liver model lacks a functioning immune system but allows the study of 
tumor development in human hepatocytes in vivo,176 it would be a useful complementary 
approach to SB gene delivery to Fah-deficient mouse livers or mosaic mouse livers with 
genetically modified which liver progenitor cells, both of which are purely mouse models, 
but allow the study of liver tumor progression in context of a functioning immune 
system.76,102 
The application of SB to generate forward and reverse genetic models of cancer 
in context of disease-relevant damaged tissue, while especially important in the liver given 
the close connection between chronic liver damage and HCC, is not exclusively relevant 
to the study of liver cancer. Obesity is a risk factor for many cancer types including liver, 
colorectal, pancreatic, kidney, esophageal, thyroid, melanoma, leukemia, breast, 
endometrial, cervical, ovarian, and prostate cancers.177 Genetic studies could be 
conducted in these tissue types using SB for insertional mutagenesis or delivery of 
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oncogenes in context of diet-induced obesity to study the interaction between molecular 
cancer drivers and the selective pressures caused by obesity-induced changes in 
cytokines, adipokines, insulin resistance, hormones, and inflammation.177 Certain 
infectious agents are also linked to cancer risk, including HBV and HCV increasing the 
risk for liver cancer, human papillomavirus for cervical and oropharanx cancer, Epstein-
Barr virus for Hodgkin’s and Burkitt’s lymphomas, and Helicobacter pylori for gastric 
cancer.159 SB genetic studies of these cancers could be conducted in the presence of viral 
components or bacterial infection to identify or study the genetic drivers of these cancers 
in context of a relevant infection. The studies we conducted have improved our 
understanding of the molecular drivers of HCC in relevant liver environments, and could 
provide new models for preclinical therapeutic testing. Similar methods might be employed 
to study other cancer types in relevant environments. 
135 
 
BIBLIOGRAPHY 
1.  Alison MR. Liver Stem Cells: Implications for Hepatocarcinogenesis. Stem Cell 
Rev 2005;1:253–260. 
2.  Zhang S-H, Cong W-M, Wu M-C. Focal nodular hyperplasia with concomitant 
hepatocellular carcinoma: a case report and clonal analysis. J Clin Pathol 
2004;57:556–9. 
3.  Govindarajan S, Craig J, Valinluck B. Clonal origin of hepatitis B virus-associated 
hepatocellular carcinoma. Hum Pathol 1988;19:403–5. 
4.  Yamamoto T, Kajino K, Kudo M, et al. Determination of the clonal origin of 
multiple human hepatocellular carcinomas by cloning and polymerase chain 
reaction of the integrated hepatitis B virus DNA. Hepatology 1999;29:1446–52. 
5.  Ng IO, Guan XY, Poon RT, et al. Determination of the molecular relationship 
between multiple tumour nodules in hepatocellular carcinoma differentiates 
multicentric origin from intrahepatic metastasis. J Pathol 2003;199:345–53. 
6.  Lowes KN, Brennan BA, Yeoh GC, et al. Oval cell numbers in human chronic liver 
diseases are directly related to disease severity. Am J Pathol 1999;154:537–41. 
7.  Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. 
Semin Liver Dis 2003;23:385–96. 
8.  El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118–27. 
9.  Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human 
hepatocarcinogenesis. Liver Int 2005;25:16–27. 
10.  Schlageter M, Terracciano LM, D’Angelo S, et al. Histopathology of hepatocellular 
carcinoma. World J Gastroenterol 2014;20:15955–15964. 
11.  Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases 
among 48,900 necropsies. Cancer 1954;7:462–503. 
12.  Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of 
hepatocellular carcinoma tumor grade using needle biopsy: implications for 
transplant eligibility. Ann Surg 2007;245:435–42. 
13.  Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer 
Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, Fr 
Int Agency Res Cancer 2013. Available at: http://globocan.iarc.fr [Accessed 
February 27, 2017]. 
14.  Torre LA, Bray F, Siegel RL, et al. Global Cancer Statistics, 2012. CA A cancer J 
Clin 2015;65:87–108. 
15.  Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-
2011, National Cancer Institute. Bethesda, MD 2014:based on November 2013 
SEER data submission, poste. 
 
136 
 
16.  White DL, Thrift AP, Kanwal F, et al. Incidence of Hepatocellular Carcinoma in all 
50 United States, From 2000 Through 2012. Gastroenterology 2016:pii: S0016-
5085(16)35389-6. 
17.  Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex 
differences in MyD88-dependent IL-6 production. Science (80- ) 2007;317:121–4. 
18.  Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pr Res Clin 
Gastroenterol 2011;25:195–206. 
19.  Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical 
characterization and risk factors for underlying disease. Hepatology 1999;29:664–
669. 
20.  Parkin DM. The global health burden of infection-associated cancers in the year 
2002. Int J Cancer 2006;118:3030–3044. 
21.  Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in 
chronic hepatitis B. Gastroenterology 2007;132:1574–85. 
22.  But DYK, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular 
carcinoma. World J Gastroenterol 2008;14:1652–1656. 
23.  El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. 
Gastroenterology 2012;142:1264–1273. 
24.  Kawai-Kitahata F, Asahina Y, Tanaka S, et al. Comprehensive analyses of 
mutations and hepatitis B virus integration in hepatocellular carcinoma with 
clinicopathological features. J Gastroenterol 2016;51:473–486. 
25.  Sung W-K, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration 
in hepatocellular carcinoma. Nat Genet 2012;44:765–9. 
26.  Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular 
carcinoma. J Hepatol 2016;64:S84–S101. 
27.  Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and 
consequences for treatment. Oncologist 2010;15:14–22. 
28.  Lonardo A, Adinolfi LE, Petta S, et al. Hepatitis C and diabetes: the inevitable 
coincidence? Expert Rev Anti Infect Ther 2009;7:293–308. 
29.  Cua IHY, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C 
is not associated with virus-specific changes in adipocytokines. Hepatology 
2007;46:66–73. 
30.  Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis 
and evaluation. Am Fam Physician 2006;74:756–62. 
31.  Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with 
special emphasis on alcohol and oxidative stress. Biol Chem 2006;387:349–360. 
32.  IARC. Acetaldehyde IARC monographs on the evaluation of the carcinogenic risk 
to humans. Reevaluation of some organic chemicals, hydrazine and hydrogen 
peroxides. Lyon Int Agency Res Cancer 1999;71:319–335. 
137 
 
33.  Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to 
inflammation and fibrosis. Alcohol 2004;34:9–19. 
34.  Lieber CS, Jones DP, DeCarli LM. Effects of Prolonged Ethanol Intake: 
Production of Fatty Liver Despite Adequate Diets. J Clin Invest 1965;44:1009–
1021. 
35.  Becker U, Deis A, Sørensen T, et al. Prediction of risk of liver disease by alcohol 
intake, sex, and age: a prospective population study. Hepatology 1996;23:1025–
9. 
36.  Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. 
Clin Liver Dis 2007;11:1–16. 
37.  Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of 
hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 
2010;51:1972–1978. 
38.  Pekow JR, Bhan AK, Zheng H, et al. Hepatic steatosis is associated with 
increased frequency of hepatocellular carcinoma in patients with hepatitis C-
related cirrhosis. Cancer 2007;109:2490–2496. 
39.  Lazo M, Clark JM. The Epidemiology of Nonalcoholic Fatty Liver Disease : A 
Global Perspective. Semin Liver Dis 2008;28:339–50. 
40.  Yu J, Shen J, Sun TT, et al. Obesity, insulin resistance, NASH and hepatocellular 
carcinoma. Semin Cancer Biol 2013;E pub ahea. 
41.  Calle EE, Thun MJ. Obesity and cancer. Oncogene 2004;23:6365–78. 
42.  Falck-Ytter Y, Younossi ZM, Marchesini G, et al. Clinical features and natural 
history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17–26. 
43.  Hanahan D, Weinberg RA, Francisco S. The hallmarks of cancer [Review]. Cell 
2000;100:57–70. 
44.  Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 
2011;144:646–74. 
45.  Boyault S, Rickman DS, Reynies A de, et al. Transcriptome classification of HCC 
is related to gene alterations and to new therapeutic targets. Hepatology 
2007;45:42–52. 
46.  Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of 
hepatocellular carcinoma genomes. Nat Genet 2014;46:1267–73. 
47.  Polakis P. Wnt Signaling in Cancer. Cold Spring Harb Perspect Biol 
2012;4:a008052. 
48.  Keng VW, Villanueva A, Chiang DY, et al. A conditional transposon-based 
insertional mutagenesis screen for hepatocellular carcinoma-associated genes in 
mice. Nat Biotechnol 2009;27:264–274. 
 
138 
 
49.  Chu JS, Ge FJ, Zhang B, et al. Expression and prognostic value of VEGFR-2, 
PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer 
Res 2013;3:16. 
50.  Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a 
multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine 
kinase signaling. Mol Cancer Ther 2008;7:3129–3140. 
51.  Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic Landscape and 
Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015;149:1226–1239. 
52.  Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 
2000;10:185–200. 
53.  Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular 
classification of hepatocellular carcinoma. Cancer Res 2008;68:6779–88. 
54.  Keng VW, Sia D, Sarver AL, et al. Sex bias occurrence of hepatocellular 
carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 
2013;57:120–30. 
55.  Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and 
evidence-based medicine. World J Gastroenterol 2014;20:4115–4127. 
56.  Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular 
carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, 
double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56–66. 
57.  Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in Advanced Hepatocellular 
Carcinoma. N Engl J Med 2008;359:378–90. 
58.  Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): A new oral 
multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine 
kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245–255. 
59.  Ho DWH, Kai AKL, Ng IOL. TCGA whole-transcriptome sequencing data reveals 
significantly dysregulated genes and signaling pathways in hepatocellular 
carcinoma. Front Med 2015;9:322–330. 
60.  Woo HG, Park ES, Thorgeirsson SS, et al. Exploring Genomic Profiles of 
Hepatocellular Carcinoma. Mol Carcinog 2011;50:235–243. 
61.  Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular 
carcinomas identifies new mutational signatures and potential therapeutic targets. 
Nat Genet 2015;47:505–511. 
62.  Zimmermann U, Feneux D, Mathey G, et al. Chromosomal aberrations in 
hepatocellular carcinomas: relationship with pathological features. Hepatology 
1997;26:1492–8. 
63.  Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular 
carcinoma. Nat Genet 2002;31:339–46. 
 
139 
 
64.  Heindryckx F, Colle I, Vlierberghe H Van. Experimental mouse models for 
hepatocellular carcinoma research. Int J Exp Pathol 2009;90:367–386. 
65.  Araki K, Miyazaki J, Hino O, et al. Expression and replication of hepatitis B virus 
genome in transgenic mice. Proc Natl Acad Sci U S A 1989;86:207–11. 
66.  Babinet C, Farza H, Morello D, et al. Speciﬁc expression of hepatitis-B surface-
antigen (Hbsag) in transgenic mice. Science (80- ) 1985;230:1160–3. 
67.  Xiong J, Yao YC, Zi XY, et al. Expression of hepatitis B virus X protein in 
transgenic mice. World J Gastroenterol 2003;9:112–6. 
68.  Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice 
expressing the structural and nonstructural proteins of hepatitis C virus. 
Gastroenterology 2002;122:352–65. 
69.  Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces 
hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065–7. 
70.  Tanaka N, Moriya K, Kiyosawa K, et al. Hepatitis C virus core protein induces 
spontaneous and persistent activation of peroxisome proliferator-activated 
receptor alpha in transgenic mice: implications for HCV-associated 
hepatocarcinogenesis. Int J Cancer 2008;122:124–31. 
71.  Naas T, Ghorbani M, Alvarez-Maya I, et al. Characterization of liver 
histopathology in a transgenic mouse model expressing genotype 1a hepatitis C 
virus core and envelope proteins 1 and 2. J Gen Virol 2005;86:2185–96. 
72.  Lee JS, Chu IS, Mikaelyan A, et al. Application of comparative functional 
genomics to identify best-fit mouse models to study human cancer. Nat Genet 
2004;36:1306–11. 
73.  Harada N, Oshima H, Katoh M, et al. Hepatocarcinogenesis in mice with beta-
catenin and Ha-ras gene mutations. Cancer Res 2004;64:48–54. 
74.  Borlak J, Meier T, Halter R, et al. Oncogene. 2005 Mar 10;24(11):1809-19. 
Epidermal growth factor-induced hepatocellular carcinoma: gene expression 
profiles in precursor lesions, early stage and solitary tumours. Oncogene 
2005;24:1809–19. 
75.  Watanabe S, Horie Y, Kataoka E, et al. Non-alcoholic steatohepatitis and 
hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and 
tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol 2007;22:S96–
S100. 
76.  Zender L, Xue W, Cordon-Cardo C, et al. Generation and Analysis of Genetically 
Defined Liver Carcinomas Derived from Bipotential Liver Progenitors. Cold Spring 
Harb Symp Quant Biol 2005;70:251–261. 
77.  Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in 
liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253–67. 
78.  Zender L, Xue W, Zuber J, et al. An oncogenomics-based in vivo RNAi screen 
identifies tumor suppressors in liver cancer. Cell 2008;135:852–864. 
140 
 
79.  Sawey ET, Chanrion M, Cai C, et al. Identification of a Therapeutic Strategy 
Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening. Cancer 
Cell 2011;19:347–358. 
80.  Kornek M, Raskopf E, Tolba R, et al. Accelerated orthotopic hepatocellular 
carcinomas growth is linked to increased expression of pro-angiogenic and 
prometastatic factors in murine liver fibrosis. Liver Int 2008;28:509–18. 
81.  Nakatani T, Roy G, Fujimoto N, et al. Sex hormone dependency of 
diethylnitrosamine-induced liver tumors in mice and chemoprevention by 
leuprorelin. Japanese J cancer Res 2001;92:249–56. 
82.  Yoshida LS, Miyazawa T, Hatayama I, et al. Phosphatidylcholine peroxidation and 
liver cancer in mice fed a choline-deficient diet with ethionine. Free Radic Biol 
Med 1993;14:191–199. 
83.  Gyamfi MA, Damjanov I, French S, et al. The pathogenesis of ethanol versus 
methionine and choline deficient diet-induced liver injury. Biochem Pharmacol 
2008;75:981–95. 
84.  Croager EJ, Smith PGJ, Yeoh GCT. Ethanol interactions with a choline-deficient, 
ethionine-supplemented feeding regime potentiate pre-neoplastic cellular 
alterations in rat liver. Carcinogenesis 2002;23:1685–93. 
85.  Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of Sleeping 
Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 
1997;91:501–10. 
86.  Keng VW, Yae K, Hayakawa T, et al. Region-specific saturation germline 
mutagenesis in mice using the Sleeping Beauty transposon system. Nat Methods 
2005;2:763–769. 
87.  Collier LS, Carlson CM, Ravimohan S, et al. Cancer gene discovery in solid 
tumours using transposon-based somatic mutagenesis in the mouse. Nature 
2005;436:272–6. 
88.  Dupuy AJ, Akagi K, Largaespada DA, et al. Mammalian mutagenesis using a 
highly mobile somatic Sleeping Beauty transposon system. Nature 2005;436:221–
226. 
89.  Dupuy AJ, Fritz S, Largaespada DA. Transposition and Gene Disruption in the 
Male Germline of the Mouse. Genesis 2001;30:82–88. 
90.  Copeland NG, Jenkins NA. Harnessing transposons for cancer gene discovery. 
Nat Rev Cancer 2010;10:696–706. 
91.  Howell VM. Sleeping Beauty - A mouse model for all cancers? Cancer Lett 
2012;317:1–8. 
92.  Dupuy AJ, Rogers LM, Kim J, et al. A modified sleeping beauty transposon 
system that can be used to model a wide variety of human cancers in mice. 
Cancer Res 2009;69:8150–6. 
 
141 
 
93.  Geurts A. Gene transfer into genomes of human cells by the sleeping beauty 
transposon system. Mol Ther 2003;8:108–117. 
94.  Starr TK, Allaei R, Silverstein KAT, et al. A Transposon-Based Genetic Screen in 
Mice Identifies Genes Altered in Colorectal Cancer. Science (80- ) 
2009;323:1747–1750. 
95.  O’Donnell KA, Keng VW, York B, et al. A Sleeping Beauty mutagenesis screen 
reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad 
Sci U S A 2012;109:E1377-86. 
96.  Rahrmann EP, Collier LS, Knutson TP, et al. Identification of PDE4D as a 
proliferation promoting factor in prostate cancer using a Sleeping Beauty 
transposon-based somatic mutagenesis screen. Cancer Res 2009;69:4388–97. 
97.  Rahrmann EP, Watson AL, Keng VW, et al. Forward genetic screen for malignant 
peripheral nerve sheath tumor formation identifies new genes and pathways 
driving tumorigenesis. Nat Genet 2013;45:756–66. 
98.  Vries A de, Flores ER, Miranda B, et al. Targeted point mutations of p53 lead to 
dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A 
2002;99:2948–53. 
99.  Riordan JD, Keng VW, Tschida BR, et al. Identification of rtl1, a retrotransposon-
derived imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet 
2013;9:e1003441. 
100.  Bard-Chapeau EA, Nguyen A-T, Rust AG, et al. Transposon mutagenesis 
identifies genes driving hepatocellular carcinoma in a chronic Hepatitis B mouse 
model. Nat Genet 2014;46:24–32. 
101.  Kodama T, Bard-Chapeau EA, Newberg JY, et al. Two-Step Forward Genetic 
Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of 
Hepatocellular Carcinoma. Gastroenterology 2016;151:324–337.e12. 
102.  Wangensteen KJ, Wilber A, Keng VW, et al. A facile method for somatic, lifelong 
manipulation of multiple genes in the mouse liver. Hepatology 2008;47:1714–24. 
103.  Wiesner SM, Decker S a, Larson JD, et al. De novo induction of genetically 
engineered brain tumors in mice using plasmid DNA. Cancer Res 2009;69:431–9. 
104.  Belur L. Gene insertion and long-term expression in lung mediated by the 
sleeping beauty transposon system. Mol Ther 2003;8:501–507. 
105.  Ohlfest JR, Demorest ZL, Motooka Y, et al. Combinatorial antiangiogenic gene 
therapy by nonviral gene transfer using the sleeping beauty transposon causes 
tumor regression and improves survival in mice bearing intracranial human 
glioblastoma. Mol Ther 2005;12:778–88. 
106.  Ivics Z, Kaufman CD, Zayed H, et al. The Sleeping Beauty transposable element: 
evolution, regulation and genetic applications. Curr Issues Mol Biol 2004;6:43–56. 
 
142 
 
107.  Bell JB, Podetz-Pedersen KM, Aronovich EL, et al. Preferential delivery of the 
Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. 
Nat Protoc 2007;2:3153–3165. 
108.  Keng VW, Tschida BR, Bell JB, et al. Modeling hepatitis B virus X-induced 
hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. 
Hepatology 2011;53:781–90. 
109.  Yang JD, Harmsen WS, Slettedahl SW, et al. Factors That Affect Risk for 
Hepatocellular Carcinoma and Effects of Surveillance. Clin Gastroenterol Hepatol 
2011;9:617–623. 
110.  Li Z, Tuteja G, Schug J, et al. Foxa1 and Foxa2 are essential for sexual 
dimorphism in liver cancer. Cell 2012;148:72–83. 
111.  Moya M, Benet M, Guzmán C, et al. Foxa1 reduces lipid accumulation in human 
hepatocytes and is down-regulated in nonalcoholic fatty liver. PLoS One 2012;7. 
112.  Howell JJ, Stoffel M. Nuclear export-independent inhibition of Foxa2 by insulin. J 
Biol Chem 2009;284:24816–24824. 
113.  Gan L, Chitturi S, Farrell GC. Mechanisms and implications of age-related 
changes in the liver: Nonalcoholic fatty liver disease in the elderly. Curr Gerontol 
Geriatr Res 2011;2011. 
114.  Honma T, Yanaka M, Tsuduki T, et al. Increased Lipid Accumulation in Liver and 
White Adipose Tissue in Aging in the SAMP10 Mouse. J Nutr Sci Vitaminol 
(Tokyo) 2011;57:123–129. 
115.  Sarver A, Erdman J, Starr T, et al. TAPDANCE: An Automated tool to identify and 
annotate Transposon insertion CISs and associations between CISs from next 
generation sequence data. BMC Bioinformatics 2012;13:154. 
116.  Cauthron RD, Carter KB, Liauw S, et al. Physiological Phosphorylation of Protein 
Kinase A at Thr-197 Is by a Protein Kinase A Kinase. Mol Cell Biol 1998;18:1416–
1423. 
117.  Cheung J, Ginter C, Cassidy M, et al. Structural insights into mis-regulation of 
protein kinase A in human tumors. Proc Natl Acad Sci U S A 2015;112:1374–9. 
118.  Yang H, Yang L. Targeting cAMP/PKA pathway for glycemic control and type 2 
diabetes therapy. J Mol Endocrinol 2016;57:R93–R108. 
119.  Woo CWH, Siow YL, Karmin O. Homocysteine activates cAMP-response element 
binding protein in HepG2 through cAMP/PKA signaling pathway. Arterioscler 
Thromb Vasc Biol 2006;26:1043–1050. 
120.  Ji H, Shen X, Zhang Y, et al. Activation of cyclic adenosine monophosphate-
dependent protein kinase a signaling prevents liver ischemia/reperfusion injury in 
mice. Liver Transplant 2012;18:659–670. 
121.  Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-
PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 
(80- ) 2014;343:1010–4. 
143 
 
122.  Cole SW, Sood AK. Molecular pathways: Beta-adrenergic signaling in cancer. Clin 
Cancer Res 2012;18:1201–1206. 
123.  Thiele M, Albillos A, Abazi R, et al. Non-selective beta-blockers may reduce risk of 
hepatocellular carcinoma: A meta-analysis of randomized trials. Liver Int 
2015;35:2009–2016. 
124.  Patel H, Kumar A, Shah N, et al. Role of Non-Selective Beta Blockers in 
Hepatocellular Carcinoma: An Analysis in Patients with Cirrhosis and Portal 
Hypertenrion. North Am J Med Sci 2015;8:105–108. 
125.  Nkontchou G, Aout M, Mahmoudi A, et al. Effect of long-term propranolol 
treatment on hepatocellular carcinoma incidence in patients with HCV-associated 
cirrhosis. Cancer Prev Res 2012;5:1007–1014. 
126.  Zhang X, Liu J, Yan S, et al. High expression of N-acetyltransferase 10: a novel 
independent prognostic marker of worse outcome in patients with hepatocellular 
carcinoma. Int J Clin Exp Pathol 2015;8:14765–71. 
127.  Ma R, Chen J, Jiang S, et al. Up regulation of NAT10 promotes metastasis of 
hepatocellular carcinoma cells through epithelial-to-mesenchymal transition. Am J 
Transl Re 2016;8:4215–4223. 
128.  Lv J, Liu H, Wang Q, et al. Molecular cloning of a novel human gene encoding 
histone acetyltransferase-like protein involved in transcriptional activation of 
hTERT. Biochem Biophys Res Commun 2003;311:506–513. 
129.  Shen Q, Zheng X, McNutt MA, et al. NAT10, a nucleolar protein, localizes to the 
midbody and regulates cytokinesis and acetylation of microtubules. Exp Cell Res 
2009;315:1653–1667. 
130.  Ito S, Horikawa S, Suzuki T, et al. Human NAT10 is an ATP-dependent rna 
acetyltransferase responsible for N4-acetylcytidine formation in 18 S ribosomal 
RNA (rRNA). J Biol Chem 2014;289:35724–35730. 
131.  Lee C-D, Tu BP. Metabolic influences on RNA biology and translation. Crit Rev 
Biochem Mol Biol 2017;Feb:1–9. 
132.  Gusdon AM, Song K-X, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and 
therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 
2014;2014:637027. 
133.  Tan TZ, Miow QH, Huang RYJ, et al. Functional genomics identifies five distinct 
molecular subtypes with clinical relevance and pathways for growth control in 
epithelial ovarian cancer. EMBO Mol Med 2013;5:1051–66. 
134.  Larrieu D, Britton S, Demir M, et al. Chemical inhibition of NAT10 corrects defects 
of laminopathic cells. Science (80- ) 2014;344:527–32. 
135.  Drygin D, Lin A, Bliesath J, et al. Targeting RNA polymerase I with an oral small 
molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. 
Cancer Res 2011;71:1418–1430. 
 
144 
 
136.  Haddach M, Schwaebe MK, Michaux J, et al. Discovery of CX-5461, the first 
direct and selective inhibitor of RNA polymerase I, for cancer therapeutics. ACS 
Med Chem Lett 2012;3:602–606. 
137.  Shu J, Dolman GE, Duan J, et al. Statistical colour models: an automated digital 
image analysis method for quantification of histological biomarkers. Biomed Eng 
Online 2016;15. 
138.  Janik C, Starr T. Identification of Sleeping Beauty transposon insertions in solid 
tumors using linker-mediated PCR. J Vis Exp 2013;72:e5015. 
139.  Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer 
genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1. 
140.  Cerami E, Gao J, Dogrusoz U, et al. The cBio Cancer Genomics Portal: An open 
platform for exploring multidimensional cancer genomics data. Cancer Discov 
2012;2:401–404. 
141.  Bray, Nicolas L Pimentel, Harold Melsted P, Pachter L. Near-optimal probabilistic 
RNA-seq quantification. Nat Biotechnol 2016;34:525–7. 
142.  Tschida BR, Largaespada DA, Keng VW. Mouse models of cancer: Sleeping 
Beauty transposons for insertional mutagenesis screens and reverse genetic 
studies. Semin Cell Dev Biol 2014;27:86–95. 
143.  Rocha ST da, Edwards CA, Ito M, et al. Genomic imprinting at the mammalian 
Dlk1-Dio3 domain. Trends Genet 2008;24:306–316. 
144.  Braconi C, Kogure T, Valeri N, et al. microRNA-29 can regulate expression of the 
long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 
2011;30:4750–6. 
145.  Huang J, Zhang X, Zhang M, et al. Up-regulation of DLK1 as an imprinted gene 
could contribute to human hepatocellular carcinoma. Carcinogenesis 
2007;28:1094–1103. 
146.  Luk JM, Burchard J, Zhang C, et al. DLK1-DIO3 genomic imprinted microRNA 
cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma 
associated with poor survival. J Biol Chem 2011;286:30706–30713. 
147.  Yu F, Hao X, Zhao H, et al. Delta-like 1 contributes to cell growth by increasing 
the interferon-inducible protein 16 expression in hepatocellular carcinoma. Liver 
Int 2010;30:703–714. 
148.  Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two 
molecular classes of hepatocellular carcinoma and experimental modulation by 
sorafenib. Clin Cancer Res 2012;18:4997–5007. 
149.  Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic 
mutations and focal copy-number changes identifies key genes and pathways in 
hepatocellular carcinoma. Nat Genet 2012;44:694–698. 
150.  Lau WB de, Snel B, Clevers HC. The R-spondin protein family. Genome Biol 
2012;13:242. 
145 
 
151.  Takeda H, Wei Z, Koso H, et al. Transposon mutagenesis identifies genes and 
evolutionary forces driving gastrointestinal tract tumor progression. Nat Genet 
2015;47:142–150. 
152.  Lowther W, Wiley K, Smith GH, et al. A new common integration site, Int7, for the 
mouse mammary tumor virus in mouse mammary tumors identifies a gene whose 
product has furin-like and thrombospondin-like sequences. J Virol 
2005;79:10093–6. 
153.  Theodorou V, Kimm MA, Boer M, et al. MMTV insertional mutagenesis identifies 
genes, gene families and pathways involved in mammary cancer. Nat Genet 
2007;39:759–769. 
154.  Ahn S-M, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular 
carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. 
Hepatology 2014;60:1972–1982. 
155.  Shi C, Huang D, Lu N, et al. Aberrantly activated Gli2-KIF20A axis is crucial for 
growth of hepatocellular carcinoma and predicts poor prognosis. Oncotarget 
2016;7:26206–19. 
156.  Zhang D, Cao L, Li Y, et al. Expression of glioma-associated oncogene 2 (Gli 2) is 
correlated with poor prognosis in patients with hepatocellular carcinoma 
undergoing hepatectomy. World J Surg Oncol 2013;11:25. 
157.  Huang S, He J, Zhang X, et al. Activation of the hedgehog pathway in human 
hepatocellular carcinomas. Carcinogenesis 2006;27:1334–1340. 
158.  Sicklick JK, Li Y-X, Jayaraman A, et al. Dysregulation of the Hedgehog pathway in 
human hepatocarcinogenesis. Carcinogenesis 2006;27:748–757. 
159.  Plummer M, Martel C de, Vignat J, et al. Global burden of cancers attributable to 
infections in 2012: a synthetic analysis. Lancet Glob Heal 2016;4:e609–e616. 
160.  Bisceglie AM Di. Hepatitis B And Hepatocellular Carcinoma. Hepatology 
2009;49:S56-60. 
161.  Lindh M, Gustavson C, Mårdberg K, et al. Mutation of nucleotide 1,762 in the core 
promoter region during hepatitis B e seroconversion and its relation to liver 
damage in hepatitis B e antigen carriers. J Med Virol 1998;55:185–90. 
162.  Grompe M, Al-Dhalimy M, Finegold M, et al. Loss of fumarylacetoacetate 
hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal 
albino mice. Genes Dev 1993;7:2298–2307. 
163.  Sze KMF, Chu GKY, Lee JMF, et al. C-terminal truncated hepatitis B virus x 
protein is associated with metastasis and enhances invasiveness by C-Jun/matrix 
metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology 
2013;57:131–9. 
164.  Cornella H, Alsinet C, Sayols S, et al. Unique genomic profile of fibrolamellar 
hepatocellular carcinoma. Gastroenterology 2016;148:806–18. 
 
146 
 
165.  Ghosh PM, Shu Z-J, Zhu B, et al. Role of β-adrenergic receptors in regulation of 
hepatic fat accumulation during aging. J Endocrinol 2012;213:251–61. 
166.  Farah BL, Sinha R a., Wu Y, et al. β-adrenergic agonist and antagonist regulation 
of autophagy in HepG2 cells, primary mouse hepatocytes, and mouse liver. PLoS 
One 2014;9. 
167.  Mizuno K, Ueno Y. Hepatol Res. 2016 Jun 7. doi: 10.1111/hepr.12760. [Epub 
ahead of print] Autonomic Nervous System and the Liver. Hepatol Res 2016;Jun 
7:[Epub ahead of print]. 
168.  Niswender CM, Willis BS, Wallen A, et al. Cre recombinase-dependent 
expression of a constitutively active mutant allele of the catalytic subunit of Protein 
Kinase A. Genesis 2005;43:109–119. 
169.  Mu Y, Ogawa T, Kawada N. Reversibility of fibrosis, inflammation, and 
endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient 
diet. Lab Invest 2010;90:245–256. 
170.  Buchman A, Ament M, Sohel M, et al. Choline deficiency causes reversible 
hepatic abnormalities in patients receiving parenteral nutrition: proof of a human 
choline requirement: a placebo-controlled trial. JPEN J Parenter Enter Nutr 
2001;25:260–268. 
171.  Costa K da, Garner S, Chang J, et al. Effects of prolonged (1 year) choline 
deficiency and subsequent re-feeding of choline on 1,2-sn-diradylglycerol, fatty 
acids and protein kinase C in rat liver. Carcinogenesis 1995;16:327–334. 
172.  Zhu L, Finkelstein D, Gao C, et al. Multi-organ Mapping of Cancer Risk. Cell 
2016;166:1132–1146.e7. 
173.  Pankowicz FP, Barzi M, Legras X, et al. Reprogramming metabolic pathways in 
vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat 
Commun 2016;30:12642. 
174.  Lau JKC, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: 
current perspectives and recent advances. J Pathol 2017;241:36–44. 
175.  Dowman JK, Hopkins LJ, Reynolds GM, et al. Development of hepatocellular 
carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a 
high-fat/fructose diet and sedentary lifestyle. Am J Pathol 2014;184:1550–61. 
176.  Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in 
Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007;25:903–10. 
177.  Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer 
and Cancer-Related Mortality. Physiol Rev 2015;95:727–748. 
 
  
147 
 
APPENDIX 
Permission letters 
 
 
Excerpts of text and figures from the following publications were re-printed in this work. 
 
1. Tschida BR, Largaespada DA, Keng VW. Mouse models of cancer: Sleeping Beauty 
transposons for insertional mutagenesis screens and reverse genetic studies. Semin 
Cell Dev Biol 2014;27:86–95. 
(http://www.sciencedirect.com.ezp2.lib.umn.edu/science/article/pii/S1084952114
00007X) 
 
2. Riordan JD, Keng VW, Tschida BR, Scheetz TE, Bell JB, Podetz-Pedersen KM, 
Moser CD, Copeland NG, Jenkins NA, Roberts LR, Largaespada DA, Dupuy AJ. 
Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of 
hepatocarcinogenesis. PLoS Genet 2013;9:e1003441. 
Open access publication. 
(http://journals.plos.org.ezp2.lib.umn.edu/plosgenetics/article/related?id=10.1371/
journal.pgen.1003441) 
 
3. Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Solé M, Lee WL, Kuka 
TP, Moriarity BS, Villanueva A, Dupuy AJ, Riordan JD, Bell JB, Silverstein KA, Llovet 
JM, Largaespada DA. Sex bias occurrence of hepatocellular carcinoma in Poly7 
molecular subclass is associated with EGFR. Hepatology 2013;57:120–30. 
(http://onlinelibrary.wiley.com.ezp2.lib.umn.edu/doi/10.1002/hep.26004/full) 
ELSEVIER LICENSE
TERMS AND CONDITIONS
Mar 16, 2017
This Agreement between Barbara R Tschida ("You") and Elsevier ("Elsevier") consists of
your license details and the terms and conditions provided by Elsevier and Copyright
Clearance Center.
License Number 4071000945057
License date Mar 16, 2017
Licensed Content Publisher Elsevier
Licensed Content Publication Seminars in Cell & Developmental Biology
Licensed Content Title Mouse models of cancer: Sleeping Beauty transposons for
insertional mutagenesis screens and reverse genetic studies
Licensed Content Author Barbara R. Tschida,David A. Largaespada,Vincent W. Keng
Licensed Content Date March 2014
Licensed Content Volume 27
Licensed Content Issue n/a
Licensed Content Pages 10
Start Page 86
End Page 95
Type of Use reuse in a thesis/dissertation
Portion excerpt
Number of excerpts 13
Format both print and electronic
Are you the author of this
Elsevier article?
Yes
Will you be translating? No
Order reference number
Title of your
thesis/dissertation
THE SLEEPING BEAUTY TRANSPOSON SYSTEM FOR FORWARD AND
REVERSE GENETIC STUDIES OF LIVER CANCER
Expected completion date Apr 2017
Estimated size (number of
pages)
140
Elsevier VAT number GB 494 6272 12
Requestor Location Barbara R Tschida
1527 Sargent Ave
SAINT PAUL, MN 55105
United States
Attn: Barbara R Tschida
Publisher Tax ID 98-0397604
Total 0.00 USD
Terms and Conditions
INTRODUCTION
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in
connection with completing this licensing transaction, you agree that the following terms
and conditions apply to this transaction (along with the Billing and Payment terms and
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you
opened your Rightslink account and that are available at any time at
http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
1 of 5 3/16/2017 5:16 PM
148
the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source.  If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made
to any Lancet figures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is finally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If
full payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted.  Further, in the event
that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted.  Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective officers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as specifically authorized
pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in a writing
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions.  These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction.  In the event of
any conflict between your obligations established by these terms and conditions and those
established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
2 of 5 3/16/2017 5:16 PM
149
to you.  Notice of such denial will be made using the contact information provided by you. 
Failure to receive such notice will not alter or invalidate the denial.  In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to specific license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
bona fide students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been
peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the final versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to find, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes author-
incorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
After the embargo period
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
3 of 5 3/16/2017 5:16 PM
150
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement
In all cases accepted manuscripts should:
link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.
Published journal article (JPA): A published journal article (PJA) is the definitive final
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to find, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are affiliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above:
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is defined by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modified in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, figures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
4 of 5 3/16/2017 5:16 PM
151
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons
Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
v1.9
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
5 of 5 3/16/2017 5:16 PM
152
ELSEVIER LICENSE
TERMS AND CONDITIONS
Mar 16, 2017
This Agreement between Barbara R Tschida ("You") and Elsevier ("Elsevier") consists of
your license details and the terms and conditions provided by Elsevier and Copyright
Clearance Center.
License Number 4071001169479
License date Mar 16, 2017
Licensed Content Publisher Elsevier
Licensed Content Publication Seminars in Cell & Developmental Biology
Licensed Content Title Mouse models of cancer: Sleeping Beauty transposons for
insertional mutagenesis screens and reverse genetic studies
Licensed Content Author Barbara R. Tschida,David A. Largaespada,Vincent W. Keng
Licensed Content Date March 2014
Licensed Content Volume 27
Licensed Content Issue n/a
Licensed Content Pages 10
Start Page 86
End Page 95
Type of Use reuse in a thesis/dissertation
Intended publisher of new
work
other
Portion figures/tables/illustrations
Number of figures/tables
/illustrations
2
Format both print and electronic
Are you the author of this
Elsevier article?
Yes
Will you be translating? No
Order reference number
Original figure numbers figures 1 and 2
Title of your
thesis/dissertation
THE SLEEPING BEAUTY TRANSPOSON SYSTEM FOR FORWARD AND
REVERSE GENETIC STUDIES OF LIVER CANCER
Expected completion date Apr 2017
Estimated size (number of
pages)
140
Elsevier VAT number GB 494 6272 12
Requestor Location Barbara R Tschida
1527 Sargent Ave
SAINT PAUL, MN 55105
United States
Attn: Barbara R Tschida
Publisher Tax ID 98-0397604
Total 0.00 USD
Terms and Conditions
INTRODUCTION
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in
connection with completing this licensing transaction, you agree that the following terms
and conditions apply to this transaction (along with the Billing and Payment terms and
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
1 of 5 3/16/2017 5:20 PM
153
opened your Rightslink account and that are available at any time at
http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to
the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source.  If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made
to any Lancet figures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is finally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If
full payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted.  Further, in the event
that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted.  Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective officers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as specifically authorized
pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in a writing
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions.  These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction.  In the event of
any conflict between your obligations established by these terms and conditions and those
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
2 of 5 3/16/2017 5:20 PM
154
established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you.  Notice of such denial will be made using the contact information provided by you. 
Failure to receive such notice will not alter or invalidate the denial.  In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to specific license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
bona fide students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been
peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the final versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to find, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes author-
incorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
3 of 5 3/16/2017 5:20 PM
155
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
After the embargo period
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement
In all cases accepted manuscripts should:
link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.
Published journal article (JPA): A published journal article (PJA) is the definitive final
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to find, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are affiliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above:
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is defined by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modified in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
4 of 5 3/16/2017 5:20 PM
156
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, figures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons
Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
v1.9
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
nirP/ppA/moc.thgirypoc.001s//:sptthesneciL elbatnirP kniLsthgiR tableLicenseFrame.jsp?publisherID...
5 of 5 3/16/2017 5:20 PM
157
Identication of Rtl1 , a Retrotransposon-Derived
Imprinted Gene, as a Novel Driver of
Hepatocarcinogenesis
Jesse D. Riordan 1, Vincent W. Keng 2¤ , Barbara R. Tschida 2, Todd E. Scheetz 3, Jason B. Bell 4,
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States of America, 3 Center for Bioinformatics and Computational Biology, Department of Opthalmology and Visual Sciences, Roy J. and Lucille A. Carver College of
Medicine, University of Iowa, Iowa City, Iowa, United States of America, 4 Department of Genetics, Cell Biology and Development and Center for Genome Engineering,
University of Minnesota, Minneapolis, Minnesota, United States of America, 5 Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic and Mayo
Clinic Cancer Center, Rochester, Minnesota, United States of America, 6 Cancer Research Program, The Methodist Hospital Research Institute, Houston, Texas, United
States of America
Abstract
We previously utilized a Sleeping Beauty (SB) transposon mutagenesis screen to discover novel drivers of HCC. This
approach identied recurrent mutations within the Dlk1-Dio3 imprinted domain, indicating that alteration of one or more
elements within the domain provides a selective advantage to cells during the process of hepatocarcinogenesis. For the
current study, we performed transcriptome and small RNA sequencing to prole gene expression in SB–induced HCCs in an
attempt to clarify the genetic element(s) contributing to tumorigenesis. We identied strong induction of Retrotransposon-
like 1 (Rtl1) expression as the only consistent alteration detected in all SB–induced tumors with Dlk1-Dio3 integrations,
suggesting that Rtl1 activation serves as a driver of HCC. While previous studies have identied correlations between
disrupted expression of multiple Dlk1-Dio3 domain members and HCC, we show here that direct modulation of a single
domain member, Rtl1, can promote hepatocarcinogenesis in vivo. Overexpression of Rtl1 in the livers of adult mice using a
hydrodynamic gene delivery technique resulted in highly penetrant (86%) tumor formation. Additionally, we detected
overexpression of RTL1 in 30% of analyzed human HCC samples, indicating the potential relevance of this locus as a
therapeutic target for patients. The Rtl1 locus is evolutionarily derived from the domestication of a retrotransposon. In
addition to identifying Rtl1 as a novel driver of HCC, our study represents one of the rst direct in vivo demonstrations of a
role for such a co-opted genetic element in promoting carcinogenesis.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of
cancer-related deaths worldwide [1]. In contrast to the downward
trends in incidence observed for most cancer types, that of HCC
continues to rise, particularly in the United States [2]. This is due
in part to increases in obesity and hepatitis C viral infection, both
of which have been implicated in HCC pathogenesis. Treatment
options for patients are limited, particularly for those with
advanced disease, and the ve-year survival rate remains low at
, 10%.
A major goal of HCC research is to develop therapies targeted
at the molecular mechanisms underlying tumor development and
progression. This type of approach is expected to be much more
ecacious, increasing survival rates for HCC patients. Consistent
with this idea, treatment with sorafenib, a multi-kinase inhibitor,
has shown survival benets for late-stage patients [3] – a rare
achievement in HCC treatment. Nevertheless, sorafenib treatment
is only able to extend median survival by three months, underlying
the need for improved targeted therapies. Unfortunately, the
molecular drivers of HCC remain poorly characterized, preclud-
ing the development of such therapeutics. Large-scale sequencing
eorts currently being undertaken by The Cancer Genome Atlas
(TCGA) project will likely characterize the recurrent genetic
alterations present in human liver tumors and may identify novel
therapeutic targets. However, it is becoming increasingly clear that
human tumors are incredibly complex, and identifying molecular
drivers of carcinogenesis among the larger number of background
events has proven dicult. Comparative analysis of the informa-
tion gained from human tumor proling with data from animal
1443001e|4eussI|9emuloV|3102lirpA1gro.scitenegsolp.www|sciteneGSOLP
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Creative Commons Legal Code
Attribution 4.0 International
Official translations of this license are available in other languages.
Creative Commons Corporation (“Creative Commons”) is not a law firm and does not provide legal
services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-
client or other relationship. Creative Commons makes its licenses and related information available on
an “as-is” basis. Creative Commons gives no warranties regarding its licenses, any material licensed
under their terms and conditions, or any related information. Creative Commons disclaims all liability
for damages resulting from their use to the fullest extent possible.
Using Creative Commons Public Licenses
Creative Commons public licenses provide a standard set of terms and conditions that creators and
other rights holders may use to share original works of authorship and other material subject to
copyright and certain other rights specified in the public license below. The following considerations are
for informational purposes only, are not exhaustive, and do not form part of our licenses.
Considerations for licensors: Our public licenses are intended for use by those authorized to give
the public permission to use material in ways otherwise restricted by copyright and certain other
rights. Our licenses are irrevocable. Licensors should read and understand the terms and
conditions of the license they choose before applying it. Licensors should also secure all rights
necessary before applying our licenses so that the public can reuse the material as expected.
Licensors should clearly mark any material not subject to the license. This includes other
CC-licensed material, or material used under an exception or limitation to copyright. More
considerations for licensors.
Considerations for the public: By using one of our public licenses, a licensor grants the public
permission to use the licensed material under specified terms and conditions. If the licensor’s
permission is not necessary for any reason–for example, because of any applicable exception or
limitation to copyright–then that use is not regulated by the license. Our licenses grant only
permissions under copyright and certain other rights that a licensor has authority to grant. Use of
the licensed material may still be restricted for other reasons, including because others have
copyright or other rights in the material. A licensor may make special requests, such as asking that
all changes be marked or described. Although not required by our licenses, you are encouraged to
respect those requests where reasonable. More considerations for the public.
Creative Commons Attribution 4.0 International Public License
By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and
conditions of this Creative Commons Attribution 4.0 International Public License ("Public License"). To the
extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in
consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights
in consideration of benefits the Licensor receives from making the Licensed Material available under
these terms and conditions.
Section 1 – Definitions.
Adapted Material means material subject to Copyright and Similar Rights that is derived from or
based upon the Licensed Material and in which the Licensed Material is translated, altered,
arranged, transformed, or otherwise modified in a manner requiring permission under the
Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the
Licensed Material is a musical work, performance, or sound recording, Adapted Material is always
produced where the Licensed Material is synched in timed relation with a moving image.
a. 
Adapter's License means the license You apply to Your Copyright and Similar Rights in Your
contributions to Adapted Material in accordance with the terms and conditions of this Public
License.
b. 
Copyright and Similar Rights means copyright and/or similar rights closely related to copyright
including, without limitation, performance, broadcast, sound recording, and Sui Generis Database
Rights, without regard to how the rights are labeled or categorized. For purposes of this Public
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License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.
Effective Technological Measures means those measures that, in the absence of proper
authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO
Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.
d. 
Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation
to Copyright and Similar Rights that applies to Your use of the Licensed Material.
e. 
Licensed Material means the artistic or literary work, database, or other material to which the
Licensor applied this Public License.
f. 
Licensed Rights means the rights granted to You subject to the terms and conditions of this
Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the
Licensed Material and that the Licensor has authority to license.
g. 
Licensor means the individual(s) or entity(ies) granting rights under this Public License.h. 
Share means to provide material to the public by any means or process that requires permission
under the Licensed Rights, such as reproduction, public display, public performance, distribution,
dissemination, communication, or importation, and to make material available to the public
including in ways that members of the public may access the material from a place and at a time
individually chosen by them.
i. 
Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC
of the European Parliament and of the Council of 11 March 1996 on the legal protection of
databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere
in the world.
j. 
You means the individual or entity exercising the Licensed Rights under this Public License. Your
has a corresponding meaning.
k. 
Section 2 – Scope.
License grant.
Subject to the terms and conditions of this Public License, the Licensor hereby grants You a
worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise
the Licensed Rights in the Licensed Material to:
reproduce and Share the Licensed Material, in whole or in part; andA. 
produce, reproduce, and Share Adapted Material.B. 
1. 
Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations
apply to Your use, this Public License does not apply, and You do not need to comply with
its terms and conditions.
2. 
Term. The term of this Public License is specified in Section 6(a).3. 
Media and formats; technical modifications allowed. The Licensor authorizes You to
exercise the Licensed Rights in all media and formats whether now known or hereafter
created, and to make technical modifications necessary to do so. The Licensor waives
and/or agrees not to assert any right or authority to forbid You from making technical
modifications necessary to exercise the Licensed Rights, including technical modifications
necessary to circumvent Effective Technological Measures. For purposes of this Public
License, simply making modifications authorized by this Section 2(a)(4) never produces
Adapted Material.
4. 
Downstream recipients.
Offer from the Licensor – Licensed Material. Every recipient of the Licensed Material
automatically receives an offer from the Licensor to exercise the Licensed Rights
under the terms and conditions of this Public License.
A. 
No downstream restrictions. You may not offer or impose any additional or different
terms or conditions on, or apply any Effective Technological Measures to, the
Licensed Material if doing so restricts exercise of the Licensed Rights by any
recipient of the Licensed Material.
B. 
5. 
No endorsement. Nothing in this Public License constitutes or may be construed as
permission to assert or imply that You are, or that Your use of the Licensed Material is,
connected with, or sponsored, endorsed, or granted official status by, the Licensor or others
designated to receive attribution as provided in Section 3(a)(1)(A)(i).
6. 
a. 
Other rights.
Moral rights, such as the right of integrity, are not licensed under this Public License, nor are
publicity, privacy, and/or other similar personality rights; however, to the extent possible, the
Licensor waives and/or agrees not to assert any such rights held by the Licensor to the
limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
1. 
Patent and trademark rights are not licensed under this Public License.2. 
To the extent possible, the Licensor waives any right to collect royalties from You for the
exercise of the Licensed Rights, whether directly or through a collecting society under any
voluntary or waivable statutory or compulsory licensing scheme. In all other cases the
Licensor expressly reserves any right to collect such royalties.
3. 
b. 
Section 3 – License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following conditions.
Attribution.
If You Share the Licensed Material (including in modified form), You must:1. 
a. 
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retain the following if it is supplied by the Licensor with the Licensed Material:
identification of the creator(s) of the Licensed Material and any others
designated to receive attribution, in any reasonable manner requested by the
Licensor (including by pseudonym if designated);
i. 
a copyright notice;ii. 
a notice that refers to this Public License;iii. 
a notice that refers to the disclaimer of warranties;iv. 
a URI or hyperlink to the Licensed Material to the extent reasonably
practicable;
v. 
A. 
indicate if You modified the Licensed Material and retain an indication of any previous
modifications; and
B. 
indicate the Licensed Material is licensed under this Public License, and include the
text of, or the URI or hyperlink to, this Public License.
C. 
You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the
medium, means, and context in which You Share the Licensed Material. For example, it may
be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that
includes the required information.
2. 
If requested by the Licensor, You must remove any of the information required by Section
3(a)(1)(A) to the extent reasonably practicable.
3. 
If You Share Adapted Material You produce, the Adapter's License You apply must not
prevent recipients of the Adapted Material from complying with this Public License.
4. 
Section 4 – Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed
Material:
for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and
Share all or a substantial portion of the contents of the database;
a. 
if You include all or a substantial portion of the database contents in a database in which You have
Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights
(but not its individual contents) is Adapted Material; and
b. 
You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the
contents of the database.
c. 
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this
Public License where the Licensed Rights include other Copyright and Similar Rights.
Section 5 – Disclaimer of Warranties and Limitation of Liability.
Unless otherwise separately undertaken by the Licensor, to the extent
possible, the Licensor offers the Licensed Material as-is and as-available, and
makes no representations or warranties of any kind concerning the Licensed
Material, whether express, implied, statutory, or other. This includes, without
limitation, warranties of title, merchantability, fitness for a particular purpose,
non-infringement, absence of latent or other defects, accuracy, or the presence
or absence of errors, whether or not known or discoverable. Where disclaimers
of warranties are not allowed in full or in part, this disclaimer may not apply to
You.
a. 
To the extent possible, in no event will the Licensor be liable to You on any
legal theory (including, without limitation, negligence) or otherwise for any
direct, special, indirect, incidental, consequential, punitive, exemplary, or other
losses, costs, expenses, or damages arising out of this Public License or use of
the Licensed Material, even if the Licensor has been advised of the possibility
of such losses, costs, expenses, or damages. Where a limitation of liability is
not allowed in full or in part, this limitation may not apply to You.
b. 
The disclaimer of warranties and limitation of liability provided above shall be interpreted in a
manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver
of all liability.
c. 
Section 6 – Term and Termination.
This Public License applies for the term of the Copyright and Similar Rights licensed here.
However, if You fail to comply with this Public License, then Your rights under this Public License
terminate automatically.
a. 
Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:
automatically as of the date the violation is cured, provided it is cured within 30 days of Your
discovery of the violation; or
1. 
upon express reinstatement by the Licensor.2. 
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to
seek remedies for Your violations of this Public License.
b. 
For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate
terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not
c. 
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terminate this Public License.
Sections 1, 5, 6, 7, and 8 survive termination of this Public License.d. 
Section 7 – Other Terms and Conditions.
The Licensor shall not be bound by any additional or different terms or conditions communicated
by You unless expressly agreed.
a. 
Any arrangements, understandings, or agreements regarding the Licensed Material not stated
herein are separate from and independent of the terms and conditions of this Public License.
b. 
Section 8 – Interpretation.
For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce,
limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made
without permission under this Public License.
a. 
To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be
automatically reformed to the minimum extent necessary to make it enforceable. If the provision
cannot be reformed, it shall be severed from this Public License without affecting the enforceability
of the remaining terms and conditions.
b. 
No term or condition of this Public License will be waived and no failure to comply consented to
unless expressly agreed to by the Licensor.
c. 
Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of,
any privileges and immunities that apply to the Licensor or You, including from the legal processes
of any jurisdiction or authority.
d. 
Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect
to apply one of its public licenses to material it publishes and in those instances will be considered the
“Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under
the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared
under a Creative Commons public license or as otherwise permitted by the Creative Commons policies
published at creativecommons.org/policies, Creative Commons does not authorize the use of the
trademark “Creative Commons” or any other trademark or logo of Creative Commons without its prior
written consent including, without limitation, in connection with any unauthorized modifications to any of
its public licenses or any other arrangements, understandings, or agreements concerning use of
licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.
Creative Commons may be contacted at creativecommons.org.
Additional languages available: Bahasa Indonesia, Deutsch, hrvatski, Nederlands, norsk, polski,
suomeksi, svenska, te reo Māori, українська, ﺔﻳﺑﺭﻌﻟﺍ, 日本語. Please read the FAQ for more information
about official translations.
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not be used in any other manner or for any other purpose, beyond what is granted in
the license. Permission is granted subject to an appropriate acknowledgement given to
the author, title of the material/book/journal and the publisher. You shall also duplicate
the copyright notice that appears in the Wiley publication in your use of the Wiley
Material. Permission is also granted on the understanding that nowhere in the text is a
previously published source acknowledged for all or part of this Wiley Material. Any
third party content is expressly excluded from this permission.
With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and no
derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only, the
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You may not alter, remove or suppress in any manner any copyright, trademark or
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basis, or any of the rights granted to you hereunder to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all times
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and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
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to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
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shall not assert any such right, license or interest with respect thereto
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EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
esneciL elbatnirP kniLsthgiR nirP/ppA/moc.thgirypoc.001s//:sptth tableLicenseFrame.jsp?publisherID...
2 of 4 4/12/2017 12:17 PM 165
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU.
WILEY shall have the right to terminate this Agreement immediately upon breach of
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You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
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